aspirin has been researched along with Diabetes Mellitus, Adult-Onset in 461 studies
Aspirin: The prototypical analgesic used in the treatment of mild to moderate pain. It has anti-inflammatory and antipyretic properties and acts as an inhibitor of cyclooxygenase which results in the inhibition of the biosynthesis of prostaglandins. Aspirin also inhibits platelet aggregation and is used in the prevention of arterial and venous thrombosis. (From Martindale, The Extra Pharmacopoeia, 30th ed, p5)
acetylsalicylate : A benzoate that is the conjugate base of acetylsalicylic acid, arising from deprotonation of the carboxy group.
acetylsalicylic acid : A member of the class of benzoic acids that is salicylic acid in which the hydrogen that is attached to the phenolic hydroxy group has been replaced by an acetoxy group. A non-steroidal anti-inflammatory drug with cyclooxygenase inhibitor activity.
| Excerpt | Relevance | Reference |
|---|---|---|
| "THEMIS is a double-blind, randomized trial of 19,220 patients with diabetes mellitus and stable coronary artery disease (CAD) comparing ticagrelor to placebo, in addition to aspirin." | 9.69 | External applicability of the Effect of ticagrelor on Health Outcomes in diabEtes Mellitus patients Intervention Study (THEMIS) trial: An analysis of patients with diabetes and coronary artery disease in the REduction of Atherothrombosis for Continued Hea ( Abtan, J; Bhatt, DL; Bueno, H; Ducrocq, G; Eagle, KA; Elbez, Y; Fox, K; Goto, S; Harrington, RA; Leiter, LA; Lev, E; Mehta, SR; Ohman, EM; Pais, P; Petrov, I; Simon, T; Sinnaeve, PR; Smith, SC; Steg, PG; Wilson, P, 2023) |
| " All participants had a documented history of coronary heart disease or high cardiovascular risk at screening and received aspirin (acetylsalicylic acid) 100 mg daily throughout the trial." | 9.51 | Efficacy and safety of alogliptin versus acarbose in Chinese type 2 diabetes patients with high cardiovascular risk or coronary heart disease treated with aspirin and inadequately controlled with metformin monotherapy or drug-naive: A multicentre, randomi ( Gao, B; Gao, W; Ji, Q; Wan, H; Xu, F; Zhang, X; Zhou, R, 2022) |
| "To conduct a health economic evaluation of ticagrelor in patients with type 2 diabetes and coronary artery disease (CAD) from a multinational payer perspective." | 9.51 | Cost-effectiveness of ticagrelor in patients with type 2 diabetes and coronary artery disease: a European economic evaluation of the THEMIS trial. ( Andersson, M; Bhatt, DL; Bueno, H; Darlington, O; De Luca, L; Fox, KM; Harrington, RA; Himmelmann, A; Hoskin, L; James, SK; Leiter, LA; McEwan, P; Mehta, SR; Mellström, C; Ridderstråle, W; Simon, T; Steg, PG; Tank, A, 2022) |
| " The aim of this narrative review is to investigate the role of blood pressure (BP) monitoring, physical activity, and prophylactic aspirin to reduce the prevalence of preeclampsia and to improve pregnancy outcome in women with preexisting diabetes." | 9.41 | Prediction and prevention of preeclampsia in women with preexisting diabetes: the role of home blood pressure, physical activity, and aspirin. ( Damm, P; Do, NC; Mathiesen, ER; Nørgaard, SK; Ringholm, L; Vestgaard, M, 2023) |
| "To evaluate and compare the efficacy of long-term use of low-dose aspirin for the prevention of dementia in men and women." | 9.34 | Sex Difference in Effects of Low-Dose Aspirin on Prevention of Dementia in Patients With Type 2 Diabetes: A Long-term Follow-up Study of a Randomized Clinical Trial. ( Doi, N; Jinnouchi, H; Masuda, I; Matsumoto, C; Morimoto, T; Nakayama, M; Ogawa, H; Okada, S; Saito, Y; Sakuma, M; Soejima, H; Waki, M, 2020) |
| "In patients with ischemic heart disease and type 2 diabetes mellitus in 4-6 weeks after acute coronary syndrome (ACS) on stable dual antiplatelet therapy (DAPT) with aspirin and clopidogrel co-adminstrated with rosuvastatin residual platelet reactivity on adenosine diphosphate was higher than in patients receiving atorvastatin." | 9.24 | [IMPACT OF ATORVASTATIN AND ROSUVASTATIN ON RESIDUAL ON-CLOPIDOGREL TREATMENT PLATELET REACTIVITY IN PATIENTS WITH ISCHEMIC HEART DISEASE AND TYPE 2 DIABETES MELLITUS AFTER ACUTE CORONARY SYNDROME]. ( Kochubiei, O; Ovrakh, T; Serik, S, 2017) |
| " None of the aspirin doses had a significant impact upon BMI, blood pressure, lipid parameters, insulin sensitivity (HOMA), FRAP, TAOS, GSH, endothelial function, glycaemic control (fructosamine) or inflammation (sVCAM-1 and HsCRP)." | 9.19 | Aspirin in type 2 diabetes, a randomised controlled study: effect of different doses on inflammation, oxidative stress, insulin resistance and endothelial function. ( Cummings, MH; Laight, DW; Raghavan, RP, 2014) |
| " In this study we verified the idea that plasma homocysteine (Hcy) contributes to 'aspirin-resistance' in patients with coronary artery disease (CAD) and with or without type 2 diabetes mellitus (T2DM)." | 9.17 | Homocysteine is a novel risk factor for suboptimal response of blood platelets to acetylsalicylic acid in coronary artery disease: a randomized multicenter study. ( Drzewoski, J; Kamysz, W; Karafova, A; Karolczak, K; Watala, C, 2013) |
| "In a population of diabetic patients with coronary artery disease and a high risk of time-dependent aspirin resistance, aspirin divided twice per day can significantly decrease the rate of biological loss of efficacy at trough level." | 9.16 | Biological efficacy of twice daily aspirin in type 2 diabetic patients with coronary artery disease. ( Bal dit Sollier, C; Dillinger, JG; Drissa, A; Drouet, L; Henry, P; Logeart, D; Manzo Silberman, S; Sideris, G; Voicu, S, 2012) |
| "Aspirin dosing regimens are associated with different pharmacodynamic effects in platelets from T2DM patients and stable coronary artery disease, with a twice-daily, low-dose aspirin administration resulting in greater platelet inhibition than once-daily administration as assessed by aspirin-sensitive assays and a dose-dependent effect on serum TXB(2) levels." | 9.15 | Pharmacodynamic effects of different aspirin dosing regimens in type 2 diabetes mellitus patients with coronary artery disease. ( Angiolillo, DJ; Bass, TA; Capodanno, D; Capranzano, P; Darlington, A; Desai, B; Dharmashankar, K; Ferreiro, JL; Kodali, M; Patel, A; Seecheran, N; Tello-Montoliu, A; Tomasello, SD; Ueno, M, 2011) |
| "Aspirin is widely used in the secondary prevention of coronary artery diseases, including myocardial infarction, stroke, and vascular related deaths." | 9.15 | Effect of polymorphism and type II diabetes on aspirin resistance in patients with unstable coronary artery disease. ( Gao, F; Men, JL; Ren, J; Wang, ZX; Wei, MX, 2011) |
| "Adjunctive treatment with pentoxifylline is not associated with increased platelet inhibitory effects in DM patients with coronary artery disease receiving DAPT." | 9.15 | Impact of pentoxifylline on platelet function profiles in patients with type 2 diabetes mellitus and coronary artery disease on dual antiplatelet therapy with aspirin and clopidogrel. ( Angiolillo, DJ; Bass, TA; Capodanno, D; Charlton, RK; Desai, B; Dharmashankar, K; Ferreiro, JL; Kodali, M; Seecheran, N; Tello-Montoliu, A; Tomasello, SD; Ueno, M, 2011) |
| "In a laboratory substudy of the PRAGUE-8 trial, the influences of nonmodifiable (age and sex) and modifiable (body mass index and tobacco smoke) factors, comorbidity (hypertension, hyperlipidemia, diabetes mellitus, and renal insufficiency) and cotherapy (statin, aspirin, and heparin), on the course of clopidogrel efficacy were investigated in 105 patients pretreated with clopidogrel >or=6 hours before coronary angiography +/- percutaneous coronary intervention." | 9.14 | Factors influencing clopidogrel efficacy in patients with stable coronary artery disease undergoing elective percutaneous coronary intervention: statin's advantage and the smoking "paradox". ( Bilkova, D; Kala, P; Marinov, I; Motovska, Z; Petr, R; Simek, S; Widimsky, P, 2009) |
| "The results of the Sarpogrelate-Aspirin Comparative Clinical Study for Efficacy and Safety in Secondary Prevention of Cerebral Infarction (S-ACCESS), a randomized double-blind study of sarpogrelate (selective 5-HT(2A) receptor antagonist) versus aspirin in 1510 Japanese patients, have been reported." | 9.14 | Sarpogrelate versus aspirin in secondary prevention of cerebral infarction: differential efficacy in diabetes? Subgroup analysis from S-ACCESS. ( Nishimaru, K; Shinohara, Y, 2009) |
| "These data suggest that glycemic control, obesity, and the dose of aspirin have influence on AR in diabetic subjects." | 9.14 | Aspirin resistance is associated with glycemic control, the dose of aspirin, and obesity in type 2 diabetes mellitus. ( Akin, O; Ata, N; Deveci, OS; Ertugrul, DT; Küçükazman, M; Tutal, E; Ure, OS; Yalçin, AA; Yavuz, B; Yildiz, M; Yilmaz, H, 2010) |
| "The aim of this study was to evaluate the effects of low-dose niacin extended-release (niacin-ER) combined with simvastatin (SV) in the treatment of patients with mixed dyslipidemia who have not normalized their lipid profile with statin therapy alone." | 9.14 | Effects of low-dose of niacin associated to simvastatin in the treatment of mixed dyslipidemia Salgad. ( Casulari, LA; Dos Santos, AM; Salgado, BJ; Salgado, JV, 2010) |
| "Forty patients who had diabetes with nephropathy and arteriosclerosis obliterans and had already been treated with angiotensin II receptor blocker (n = 40) were randomly assigned to sarpogrelate (300 mg/d; n = 20) or aspirin group (100 mg/d; n = 20)." | 9.13 | Reduced albuminuria with sarpogrelate is accompanied by a decrease in monocyte chemoattractant protein-1 levels in type 2 diabetes. ( Ishizuka, T; Ito, S; Mori, T; Nako, K; Ogawa, S, 2008) |
| ", aspirin alone (330 mg 3 times daily) or in combination with dipyridamole (75 mg 3 times daily), was tested versus placebo in 475 patients with early diabetic retinopathy." | 9.06 | Effect of aspirin alone and aspirin plus dipyridamole in early diabetic retinopathy. A multicenter randomized controlled clinical trial. The DAMAD Study Group. ( , 1989) |
| " Over the past three decades, studies have investigated the role of aspirin in preeclampsia prevention, yielding some promising results for certain at-risk groups, yet unconvincing evidence of benefit among women with pre-pregnancy diabetes." | 9.05 | The Role of Aspirin for Preeclampsia Prevention in Women with Diabetes. ( Breathnach, FM; Finnegan, C, 2020) |
| " A total of 477 patients receiving double antiaggregation therapy with aspirin and clopidogrel, after suffering a first event, were followed for 1 year to record relapse, as a surrogate end point to measure their therapeutic response, as defined by presenting with an acute coronary event (unstable angina, ST-segment-elevation myocardial infarction, or non-ST-segment-elevation myocardial infarction), stent thrombosis/restenosis, or cardiac mortality." | 8.12 | Clinical and Pharmacological Parameters Determine Relapse During Clopidogrel Treatment of Acute Coronary Syndrome. ( Martínez-Quintana, E; Medina-Gil, JM; Rodríguez-González, F; Saavedra-Santana, P; Santana-Mateos, M; Tugores, A, 2022) |
| "To evaluate the association between aspirin use during first pregnancy and later maternal cardiovascular risk." | 8.12 | Association between aspirin use during pregnancy and cardiovascular risk factors 2-7 years after delivery: The nuMoM2b Heart Health Study. ( Bairey Merz, N; Barnes, S; Catov, J; Chung, JH; Greenland, P; Grobman, W; Haas, D; Hoffman, M; Levine, LD; McNeil, R; Mercer, B; Parker, CB; Saade, G; Shanks, A; Silver, RM; Simhan, H; Theilen, LH; Thorsten, V; Varagic, J; Wapner, R, 2022) |
| "Patients taking low-dose aspirin to prevent cardiovascular disease (CVD) may also benefit from a reduced risk of colorectal cancer (CRC)." | 8.02 | Patient Preferences of Low-Dose Aspirin for Cardiovascular Disease and Colorectal Cancer Prevention in Italy: A Latent Class Analysis. ( De Caterina, R; Krucien, N; Marsh, K; Seo, J; Soriano Gabarró, M; Tervonen, T; Vora, P; Wissinger, U, 2021) |
| "Aspirin reduced the risks of MACCE and cancer without increasing the bleeding risk in elderly Koreans with hypertension, T2DM, or dyslipidemia." | 7.96 | Efficacy of Aspirin in the Primary Prevention of Cardiovascular Diseases and Cancer in the Elderly: A Population-Based Cohort Study in Korea. ( Jung, M; Lee, S, 2020) |
| "Whether metformin may reduce hepatocellular carcinoma (HCC) risk requires confirmation." | 7.88 | Metformin and risk of hepatocellular carcinoma in patients with type 2 diabetes. ( Tseng, CH, 2018) |
| "Our findings indicate a favorable effect of clopidogrel at discharge compared with aspirin in preventing death, recurrent stroke, and CVD events in diabetic patients with a first-ever noncardioembolic AIS." | 7.85 | Aspirin Versus Clopidogrel for Type 2 Diabetic Patients with First-Ever Noncardioembolic Acute Ischemic Stroke: Ten-Year Survival Data from the Athens Stroke Outcome Project. ( Elisaf, M; Manios, E; Milionis, H; Ntaios, G; Papavasileiou, V; Spengos, K; Vemmos, K, 2017) |
| "Aspirin is a cornerstone in management of coronary artery disease (CAD)." | 7.81 | Determinants of reduced antiplatelet effect of aspirin in patients with stable coronary artery disease. ( Grove, EL; Hvas, AM; Kristensen, SD; Larsen, SB; Neergaard-Petersen, S; Würtz, M, 2015) |
| "To elucidate the correlation between urinary 11-dehydro-thromboxane B2 (11dhTxB2) and clinical efficacy of aspirin treatment in patients with type 2 diabete and coronary artery disease (CAD)." | 7.81 | [Correlation between the level of the urinary 11-dehydrothromboxane B2 and the clinical efficacy of aspirin in patients with type 2 diabetes and coronary artery disease]. ( Bai, ZS; Chen, XH; Feng, XR; Liu, ML; Liu, TF; Zhang, JW, 2015) |
| "The benefit of aspirin in primary prevention of myocardial infarction and the associated gastro-intestinal bleeding risks have not been well established in the elderly population with diabetes." | 7.80 | Myocardial infarction and gastro-intestinal bleeding risks associated with aspirin use among elderly individuals with type 2 diabetes. ( Grégoire, JP; Moisan, J; Poirier, P; Sirois, C, 2014) |
| "Patients (DM, n = 30; non-DM, n = 30) with stable coronary artery disease taking aspirin 81 mg/day and P2Y12 antagonist naive were enrolled." | 7.80 | Impaired responsiveness to the platelet P2Y12 receptor antagonist clopidogrel in patients with type 2 diabetes and coronary artery disease. ( Angiolillo, DJ; Bass, TA; Darlington, A; Desai, B; Ferreiro, JL; Franchi, F; Guzman, LA; Jakubowski, JA; Moser, BA; Rollini, F; Sugidachi, A; Tello-Montoliu, A; Ueno, M, 2014) |
| "The aim of this study was to evaluate the relationship of obesity, leptin, insulin resistance and C-reactive protein (CRP) with coronary heart disease (CHD) risk factors in patients with Type 2 diabetes mellitus (DM) with CHD compared with those with Type 2 DM without CHD." | 7.73 | Plasma leptin concentration in patients with Type 2 diabetes: relationship to cardiovascular disease risk factors and insulin resistance. ( Abdella, NA; Al Jebely, S; Al Mohammedi, H; Al Ozairi, ES; Mojiminiyi, OA; Moussa, MA; Zaki, M, 2005) |
| "Patients with type 2 diabetes mellitus (T2DM) are at higher risk of thrombotic complications." | 6.87 | Comparison of pharmacodynamic effects of ticagrelor vs prasugrel in type 2 diabetes mellitus patients with coronary heart disease. ( Cao, PG; Guo, DD; Quan, AJ; Shang, LL; Zhao, HY, 2018) |
| "CAD patients with type 2 diabetes had higher platelet aggregation (all p-values <0." | 6.80 | The Influence of Haemoglobin A1c Levels on Platelet Aggregation and Platelet Turnover in Patients with Coronary Artery Disease Treated with Aspirin. ( Gregersen, S; Grove, EL; Hvas, AM; Kristensen, SD; Larsen, SB; Neergaard-Petersen, S, 2015) |
| " The aim of this study was to perform serial pharmacodynamic assessments of prasugrel with high-dose clopidogrel in patients with DM." | 6.76 | A pharmacodynamic comparison of prasugrel vs. high-dose clopidogrel in patients with type 2 diabetes mellitus and coronary artery disease: results of the Optimizing anti-Platelet Therapy In diabetes MellitUS (OPTIMUS)-3 Trial. ( Angiolillo, DJ; Badimon, JJ; Baker, BA; Effron, MB; Frelinger, AL; Jakubowski, JA; Michelson, AD; Ojeh, CK; Saucedo, JF; Zhu, B, 2011) |
| "Patients with type 2 diabetes mellitus (T2DM) have reduced platelet inhibition compared with non-diabetics following P2Y(12) receptor blockade." | 6.73 | A randomized study assessing the impact of cilostazol on platelet function profiles in patients with diabetes mellitus and coronary artery disease on dual antiplatelet therapy: results of the OPTIMUS-2 study. ( Angiolillo, DJ; Aslam, M; Bass, TA; Box, LC; Capranzano, P; Charlton, RK; Desai, B; Goto, S; Guzman, LA; Shoemaker, SB; Suzuki, Y; Zenni, MM, 2008) |
| "Paralleling the rise in obesity, the cardiometabolic syndrome is a rapidly growing health problem in the United States." | 6.45 | Utility of aspirin therapy in patients with the cardiometabolic syndrome and diabetes. ( Gardner, DW; Gardner, M; Lastra, G; Manrique, C; Palmer, J; Sowers, JR, 2009) |
| " The data reported in the literature do not however enable any evidenced-based decision on dosing for the diabetic population with numerous cardiovascular risks." | 6.41 | [Prevention of cardiovascular diseases in type 2 diabetes with aspirin]. ( Duly-Bouhanick, B; Guilloteau, G; Hadjadj, S; Menard, S; Plun-Favreau, J; Soares-Barbosa, S, 2001) |
| "Aspirin is an essential drug in the prevention of atherosclerotic cardiovascular disease (ASCVD)." | 5.91 | Appropriateness of aspirin use among diabetic patients in primary prevention of atherosclerotic cardiovascular diseases: an analysis of the ASSOS study. ( Basaran, O; Celik, O; Cil, C; Demirci, E; Dogan, V; Kaya, C; Kırıs, T; Memic Sancar, K; Orscelik, O; Resulzade, MM; Tanık, VO, 2023) |
| "A total of 5308 patients with type 2 diabetes were identified by the National Health Insurance from 1998 to 2000 and followed up until 2013." | 5.72 | Antiplatelet agents aspirin and dipyridamole, and the risk of different carcinoma in patients with type 2 diabetes mellitus: A Taiwan retrospective cohort study. ( Hsu, WH; Huang, HY; Lee, MY; Liang, HL; Lu, TW; Sung, YW, 2022) |
| "THEMIS is a double-blind, randomized trial of 19,220 patients with diabetes mellitus and stable coronary artery disease (CAD) comparing ticagrelor to placebo, in addition to aspirin." | 5.69 | External applicability of the Effect of ticagrelor on Health Outcomes in diabEtes Mellitus patients Intervention Study (THEMIS) trial: An analysis of patients with diabetes and coronary artery disease in the REduction of Atherothrombosis for Continued Hea ( Abtan, J; Bhatt, DL; Bueno, H; Ducrocq, G; Eagle, KA; Elbez, Y; Fox, K; Goto, S; Harrington, RA; Leiter, LA; Lev, E; Mehta, SR; Ohman, EM; Pais, P; Petrov, I; Simon, T; Sinnaeve, PR; Smith, SC; Steg, PG; Wilson, P, 2023) |
| " All participants had a documented history of coronary heart disease or high cardiovascular risk at screening and received aspirin (acetylsalicylic acid) 100 mg daily throughout the trial." | 5.51 | Efficacy and safety of alogliptin versus acarbose in Chinese type 2 diabetes patients with high cardiovascular risk or coronary heart disease treated with aspirin and inadequately controlled with metformin monotherapy or drug-naive: A multicentre, randomi ( Gao, B; Gao, W; Ji, Q; Wan, H; Xu, F; Zhang, X; Zhou, R, 2022) |
| "To conduct a health economic evaluation of ticagrelor in patients with type 2 diabetes and coronary artery disease (CAD) from a multinational payer perspective." | 5.51 | Cost-effectiveness of ticagrelor in patients with type 2 diabetes and coronary artery disease: a European economic evaluation of the THEMIS trial. ( Andersson, M; Bhatt, DL; Bueno, H; Darlington, O; De Luca, L; Fox, KM; Harrington, RA; Himmelmann, A; Hoskin, L; James, SK; Leiter, LA; McEwan, P; Mehta, SR; Mellström, C; Ridderstråle, W; Simon, T; Steg, PG; Tank, A, 2022) |
| "Previously, in the ESCAPE study, a randomized controlled trial, we found that 12 months of cilostazol administration significantly decreased coronary artery stenosis and the noncalcified plaque component compared with aspirin." | 5.51 | Cilostazol treatment for preventing adverse cardiovascular events in patients with type 2 diabetes and coronary atherosclerosis: Long-term follow-up of the ESCAPE study. ( Chun, EJ; Lim, S; Sohn, M, 2022) |
| "The cohort of women with a history of preeclampsia were divided into 2 groups, before and after the release of the US Preventive Services Task Force 2014 recommendations." | 5.46 | Impact of USPSTF recommendations for aspirin for prevention of recurrent preeclampsia. ( Aagaard, KM; Chu, DM; Hollier, LM; Mastrobattista, JM; Racusin, DA; Ramin, SM; Sangi-Haghpeykar, H; Tolcher, MC, 2017) |
| " We investigated if the effect of aspirin declined during the 24-hour dosing interval in patients with coronary artery disease and type 2 diabetes, and whether this correlated with increased platelet turnover." | 5.42 | Reduced antiplatelet effect of aspirin during 24 hours in patients with coronary artery disease and type 2 diabetes. ( Christensen, KH; Grove, EL; Hvas, AM; Kristensen, SD; Würtz, M, 2015) |
| "Metformin is the mainstay therapy for type 2 diabetes (T2D) and many patients also take salicylate-based drugs [i." | 5.42 | Metformin and salicylate synergistically activate liver AMPK, inhibit lipogenesis and improve insulin sensitivity. ( Blümer, RM; Bujak, AL; Crane, JD; Day, EA; Ford, RJ; Fullerton, MD; Gerstein, HC; Kemp, BE; Marcinko, K; Oakhill, JS; Pinkosky, SL; Scott, JW; Smith, BK; Steinberg, GR, 2015) |
| " The aim of this narrative review is to investigate the role of blood pressure (BP) monitoring, physical activity, and prophylactic aspirin to reduce the prevalence of preeclampsia and to improve pregnancy outcome in women with preexisting diabetes." | 5.41 | Prediction and prevention of preeclampsia in women with preexisting diabetes: the role of home blood pressure, physical activity, and aspirin. ( Damm, P; Do, NC; Mathiesen, ER; Nørgaard, SK; Ringholm, L; Vestgaard, M, 2023) |
| "Stent thrombosis is a morbid complication after percutaneous coronary intervention." | 5.40 | Clopidogrel resistance in diabetic patient with acute myocardial infarction due to stent thrombosis. ( Duraj, L; Fedor, M; Fedorová, J; Galajda, P; Kovář, F; Kubisz, P; Mokáň, M; Samoš, M; Šimonová, R; Staško, J, 2014) |
| "Fibrinogen levels were elevated in T2DM (p< 0." | 5.40 | The influence of type 2 diabetes on fibrin clot properties in patients with coronary artery disease. ( Ajjan, RA; Grant, PJ; Grove, EL; Hvas, AM; Kristensen, SD; Kurdee, Z; Larsen, SB; Neergaard-Petersen, S; Phoenix, F, 2014) |
| " If cigarette smoking is associated with a dose-response effect on pharmacodynamic measures in clopidogrel-treated patients is unknown." | 5.38 | Cigarette smoking is associated with a dose-response effect in clopidogrel-treated patients with diabetes mellitus and coronary artery disease: results of a pharmacodynamic study. ( Angiolillo, DJ; Bass, TA; Capodanno, D; Capranzano, P; Charlton, RK; Desai, B; Dharmashankar, K; Ferreiro, JL; Kodali, M; Tello-Montoliu, A; Tomasello, SD; Ueno, M, 2012) |
| "Diabetic patients with CAD had significantly higher levels of both platelet aggregation and activation compared to non-diabetic patients with CAD despite treatment with the same dosage of aspirin." | 5.36 | Reduced platelet response to aspirin in patients with coronary artery disease and type 2 diabetes mellitus. ( Grove, EL; Hvas, AM; Kristensen, SD; Larsen, SB; Mortensen, SB, 2010) |
| "To evaluate and compare the efficacy of long-term use of low-dose aspirin for the prevention of dementia in men and women." | 5.34 | Sex Difference in Effects of Low-Dose Aspirin on Prevention of Dementia in Patients With Type 2 Diabetes: A Long-term Follow-up Study of a Randomized Clinical Trial. ( Doi, N; Jinnouchi, H; Masuda, I; Matsumoto, C; Morimoto, T; Nakayama, M; Ogawa, H; Okada, S; Saito, Y; Sakuma, M; Soejima, H; Waki, M, 2020) |
| "In patients with stable coronary artery disease and diabetes without a history of myocardial infarction or stroke, those who received ticagrelor plus aspirin had a lower incidence of ischemic cardiovascular events but a higher incidence of major bleeding than those who received placebo plus aspirin." | 5.30 | Ticagrelor in Patients with Stable Coronary Disease and Diabetes. ( Andersson, M; Bhatt, DL; Corbalán, R; Cornel, JH; Fox, K; Ge, J; Harrington, RA; Held, C; Himmelmann, A; Leiter, LA; Leonsson-Zachrisson, M; Liu, Y; Mehta, SR; Nicolau, JC; Opolski, G; Ridderstråle, W; Simon, T; Steg, PG; Widimský, P; Zateyshchikov, D, 2019) |
| "In the setting of prior myocardial infarction, the oral antiplatelet ticagrelor added to aspirin reduced the risk of recurrent ischemic events, especially, in those with diabetes mellitus." | 5.30 | Rationale, design and baseline characteristics of the effect of ticagrelor on health outcomes in diabetes mellitus patients Intervention study. ( Andersson, M; Bhatt, DL; Fox, K; Harrington, RA; Held, C; Himmelmann, A; Leiter, LA; Mehta, SR; Ridderstråle, W; Simon, T; Steg, PG, 2019) |
| "In patients with ischemic heart disease and type 2 diabetes mellitus in 4-6 weeks after acute coronary syndrome (ACS) on stable dual antiplatelet therapy (DAPT) with aspirin and clopidogrel co-adminstrated with rosuvastatin residual platelet reactivity on adenosine diphosphate was higher than in patients receiving atorvastatin." | 5.24 | [IMPACT OF ATORVASTATIN AND ROSUVASTATIN ON RESIDUAL ON-CLOPIDOGREL TREATMENT PLATELET REACTIVITY IN PATIENTS WITH ISCHEMIC HEART DISEASE AND TYPE 2 DIABETES MELLITUS AFTER ACUTE CORONARY SYNDROME]. ( Kochubiei, O; Ovrakh, T; Serik, S, 2017) |
| "8 years with 10-75% coronary artery stenosis, as assessed by coronary computed tomography angiography, were randomly assigned to sarpogrelate 300 mg/day plus aspirin 100 mg/day (SPG + ASA group) or aspirin 100 mg/day alone (ASA group) for 6 months." | 5.24 | Effect of sarpogrelate, a selective 5-HT ( Chun, EJ; Han, SJ; Hur, JH; Jang, HC; Kang, DK; Kim, HJ; Kim, KM; Lee, DH; Lee, JE; Lim, S; Min, SH; Oh, TJ, 2017) |
| "213 patients with type 2 diabetes mellitus and hypertension were randomized to amlodipine 5 mg, or amlodipine 5 mg + ASA 100 mg for 3 months (Phase A); then, if adequate blood pressure control was reached patients terminated the study; otherwise, amlodipine was up-titrated to 10 mg/day for further 3 months and compared to amlodipine 10 mg + ASA 100 mg (Phase B)." | 5.20 | A study about the relevance of adding acetylsalicylic acid in primary prevention in subjects with type 2 diabetes mellitus: effects on some new emerging biomarkers of cardiovascular risk. ( D'Angelo, A; Derosa, G; Maffioli, P; Mugellini, A; Pesce, RM, 2015) |
| " None of the aspirin doses had a significant impact upon BMI, blood pressure, lipid parameters, insulin sensitivity (HOMA), FRAP, TAOS, GSH, endothelial function, glycaemic control (fructosamine) or inflammation (sVCAM-1 and HsCRP)." | 5.19 | Aspirin in type 2 diabetes, a randomised controlled study: effect of different doses on inflammation, oxidative stress, insulin resistance and endothelial function. ( Cummings, MH; Laight, DW; Raghavan, RP, 2014) |
| " In this study we verified the idea that plasma homocysteine (Hcy) contributes to 'aspirin-resistance' in patients with coronary artery disease (CAD) and with or without type 2 diabetes mellitus (T2DM)." | 5.17 | Homocysteine is a novel risk factor for suboptimal response of blood platelets to acetylsalicylic acid in coronary artery disease: a randomized multicenter study. ( Drzewoski, J; Kamysz, W; Karafova, A; Karolczak, K; Watala, C, 2013) |
| " Thrombus area was measured in T2DM and non-diabetic patients receiving aspirin and clopidogrel 7-10 days after troponin positive Non ST-elevation acute coronary syndrome (NSTE-ACS)." | 5.16 | Thrombus and antiplatelet therapy in type 2 diabetes mellitus. A prospective study after non-ST elevation acute coronary syndrome and a randomised, blinded, placebo-controlled study in stable angina. ( Badimon, JJ; Balasubramaniam, K; Marshall, SM; Schechter, CB; Viswanathan, GN; Zaman, AG, 2012) |
| "In a population of diabetic patients with coronary artery disease and a high risk of time-dependent aspirin resistance, aspirin divided twice per day can significantly decrease the rate of biological loss of efficacy at trough level." | 5.16 | Biological efficacy of twice daily aspirin in type 2 diabetic patients with coronary artery disease. ( Bal dit Sollier, C; Dillinger, JG; Drissa, A; Drouet, L; Henry, P; Logeart, D; Manzo Silberman, S; Sideris, G; Voicu, S, 2012) |
| "The Japanese Primary Prevention of Atherosclerosis With Aspirin for Diabetes (JPAD) trial was a prospective, randomized, open-label trial conducted throughout Japan that enrolled 2,539 type 2 diabetic patients without a history of atherosclerotic diseases." | 5.15 | Low-dose aspirin therapy in patients with type 2 diabetes and reduced glomerular filtration rate: subanalysis from the JPAD trial. ( Akai, Y; Doi, N; Jinnouchi, H; Morimoto, T; Nakayama, M; Ogawa, H; Okada, S; Saito, Y; Soejima, H; Sugiyama, S; Uemura, S; Waki, M, 2011) |
| "Aspirin dosing regimens are associated with different pharmacodynamic effects in platelets from T2DM patients and stable coronary artery disease, with a twice-daily, low-dose aspirin administration resulting in greater platelet inhibition than once-daily administration as assessed by aspirin-sensitive assays and a dose-dependent effect on serum TXB(2) levels." | 5.15 | Pharmacodynamic effects of different aspirin dosing regimens in type 2 diabetes mellitus patients with coronary artery disease. ( Angiolillo, DJ; Bass, TA; Capodanno, D; Capranzano, P; Darlington, A; Desai, B; Dharmashankar, K; Ferreiro, JL; Kodali, M; Patel, A; Seecheran, N; Tello-Montoliu, A; Tomasello, SD; Ueno, M, 2011) |
| "This study is a subanalysis of the Japanese Primary Prevention of Atherosclerosis With Aspirin for Diabetes (JPAD) trial-a randomized, controlled, open-label trial." | 5.15 | Differential effect of low-dose aspirin for primary prevention of atherosclerotic events in diabetes management: a subanalysis of the JPAD trial. ( Doi, N; Jinnouchi, H; Kanauchi, M; Morimoto, T; Nakayama, M; Ogawa, H; Okada, S; Saito, Y; Sakuma, M; Soejima, H; Uemura, S; Waki, M, 2011) |
| "Aspirin is widely used in the secondary prevention of coronary artery diseases, including myocardial infarction, stroke, and vascular related deaths." | 5.15 | Effect of polymorphism and type II diabetes on aspirin resistance in patients with unstable coronary artery disease. ( Gao, F; Men, JL; Ren, J; Wang, ZX; Wei, MX, 2011) |
| "Adjunctive treatment with pentoxifylline is not associated with increased platelet inhibitory effects in DM patients with coronary artery disease receiving DAPT." | 5.15 | Impact of pentoxifylline on platelet function profiles in patients with type 2 diabetes mellitus and coronary artery disease on dual antiplatelet therapy with aspirin and clopidogrel. ( Angiolillo, DJ; Bass, TA; Capodanno, D; Charlton, RK; Desai, B; Dharmashankar, K; Ferreiro, JL; Kodali, M; Seecheran, N; Tello-Montoliu, A; Tomasello, SD; Ueno, M, 2011) |
| "In a laboratory substudy of the PRAGUE-8 trial, the influences of nonmodifiable (age and sex) and modifiable (body mass index and tobacco smoke) factors, comorbidity (hypertension, hyperlipidemia, diabetes mellitus, and renal insufficiency) and cotherapy (statin, aspirin, and heparin), on the course of clopidogrel efficacy were investigated in 105 patients pretreated with clopidogrel >or=6 hours before coronary angiography +/- percutaneous coronary intervention." | 5.14 | Factors influencing clopidogrel efficacy in patients with stable coronary artery disease undergoing elective percutaneous coronary intervention: statin's advantage and the smoking "paradox". ( Bilkova, D; Kala, P; Marinov, I; Motovska, Z; Petr, R; Simek, S; Widimsky, P, 2009) |
| "The results of the Sarpogrelate-Aspirin Comparative Clinical Study for Efficacy and Safety in Secondary Prevention of Cerebral Infarction (S-ACCESS), a randomized double-blind study of sarpogrelate (selective 5-HT(2A) receptor antagonist) versus aspirin in 1510 Japanese patients, have been reported." | 5.14 | Sarpogrelate versus aspirin in secondary prevention of cerebral infarction: differential efficacy in diabetes? Subgroup analysis from S-ACCESS. ( Nishimaru, K; Shinohara, Y, 2009) |
| "These data suggest that glycemic control, obesity, and the dose of aspirin have influence on AR in diabetic subjects." | 5.14 | Aspirin resistance is associated with glycemic control, the dose of aspirin, and obesity in type 2 diabetes mellitus. ( Akin, O; Ata, N; Deveci, OS; Ertugrul, DT; Küçükazman, M; Tutal, E; Ure, OS; Yalçin, AA; Yavuz, B; Yildiz, M; Yilmaz, H, 2010) |
| "The aim of this study was to evaluate the effects of low-dose niacin extended-release (niacin-ER) combined with simvastatin (SV) in the treatment of patients with mixed dyslipidemia who have not normalized their lipid profile with statin therapy alone." | 5.14 | Effects of low-dose of niacin associated to simvastatin in the treatment of mixed dyslipidemia Salgad. ( Casulari, LA; Dos Santos, AM; Salgado, BJ; Salgado, JV, 2010) |
| "The effects of therapy with aspirin 300 mg/day and with combined aspirin 100 mg/day plus clopidogrel 75 mg/day on platelet function were compared in patients with diabetes mellitus and coronary artery disease and impaired antiplatelet responses to aspirin 100 mg/day." | 5.13 | Comparison of increased aspirin dose versus combined aspirin plus clopidogrel therapy in patients with diabetes mellitus and coronary heart disease and impaired antiplatelet response to low-dose aspirin. ( Aygul, N; Duzenli, MA; Ozdemir, K; Soylu, A; Tokac, M, 2008) |
| "To investigate the effect of low-dose aspirin administered in the morning or evening on the rate of discontinuation of prolonged-release nicotinic acid (Niaspan) due to flushing in patients at elevated cardiovascular risk." | 5.13 | Influence of the timing of low-dose aspirin on tolerability of prolonged-release nicotinic acid in patients at elevated cardiovascular risk. ( Alves, JD; Darioli, R; Hostalek, U; Steinhagen-Thiessen, E; Vogt, A, 2008) |
| "Forty patients who had diabetes with nephropathy and arteriosclerosis obliterans and had already been treated with angiotensin II receptor blocker (n = 40) were randomly assigned to sarpogrelate (300 mg/d; n = 20) or aspirin group (100 mg/d; n = 20)." | 5.13 | Reduced albuminuria with sarpogrelate is accompanied by a decrease in monocyte chemoattractant protein-1 levels in type 2 diabetes. ( Ishizuka, T; Ito, S; Mori, T; Nako, K; Ogawa, S, 2008) |
| "Urinary 11-dehydro-TXB2, plasma sCD40 L, and sP-selectin were measured, together with indices of low-grade inflammation, glycemic control, and lipid profile, in 82 patients with type-2 diabetes and 39 without diabetes, treated with low doses of aspirin." | 5.12 | Persistent platelet activation in patients with type 2 diabetes treated with low doses of aspirin. ( Amore, C; Avanzini, F; Brero, L; de Berardis, G; de Simone, G; Dell'Elba, G; di Summa, P; Evangelista, V; Giorda, CB; Iacuitti, G; Levantesi, G; Maione, A; Manarini, S; Marelli, G; Nada, E; Nicolucci, A; Pecce, R; Pozzoli, G; Pupillo, M; Tognoni, G; Totani, L, 2007) |
| "This was a prospective observation of pregnancy outcomes among 462 women with pregestational diabetes mellitus (White classes B-F) and singleton pregnancies who were enrolled in a multicenter trial to compare low-dose aspirin with placebo for preeclampsia prevention." | 5.09 | Risks of preeclampsia and adverse neonatal outcomes among women with pregestational diabetes mellitus. National Institute of Child Health and Human Development Network of Maternal-Fetal Medicine Units. ( Caritis, S; Dombrowski, M; Hauth, J; Klebanoff, M; Landon, M; Lindheimer, M; MacPherson, C; McNellis, D; Meis, P; Miodovnik, M; Paul, R; Roberts, J; Sibai, BM; Thurnau, G; VanDorsten, JP, 2000) |
| ", aspirin alone (330 mg 3 times daily) or in combination with dipyridamole (75 mg 3 times daily), was tested versus placebo in 475 patients with early diabetic retinopathy." | 5.06 | Effect of aspirin alone and aspirin plus dipyridamole in early diabetic retinopathy. A multicenter randomized controlled clinical trial. The DAMAD Study Group. ( , 1989) |
| " Over the past three decades, studies have investigated the role of aspirin in preeclampsia prevention, yielding some promising results for certain at-risk groups, yet unconvincing evidence of benefit among women with pre-pregnancy diabetes." | 5.05 | The Role of Aspirin for Preeclampsia Prevention in Women with Diabetes. ( Breathnach, FM; Finnegan, C, 2020) |
| " Over the 10 to 15 years after clinical diagnosis, tight glycemic control probably reduces the risk for blindness and end-stage renal disease, and aggressive control of hypertension, lipid therapy, and aspirin use reduce cardiovascular events." | 4.82 | Screening adults for type 2 diabetes: a review of the evidence for the U.S. Preventive Services Task Force. ( Donahue, K; Frame, P; Harris, R; Lohr, KN; Rathore, SS; Woolf, SH, 2003) |
| "Platelets are key contributors to allergic asthma and aspirin-exacerbated respiratory disease (AERD), an asthma phenotype involving platelet activation and IL-33-dependent mast cell activation." | 4.31 | Glucagon-like Peptide-1 Receptor Pathway Attenuates Platelet Activation in Aspirin-Exacerbated Respiratory Disease. ( Amin, T; Boyce, JA; Cahill, KN; Feng, C; Foer, D; Hayashi, H; Lai, J; Laidlaw, TM; Lin, A; Liu, T; McGill, A; Nagai, J; Newcomb, DC; Niswender, KD; Snyder, WE; Tani, Y, 2023) |
| " A total of 477 patients receiving double antiaggregation therapy with aspirin and clopidogrel, after suffering a first event, were followed for 1 year to record relapse, as a surrogate end point to measure their therapeutic response, as defined by presenting with an acute coronary event (unstable angina, ST-segment-elevation myocardial infarction, or non-ST-segment-elevation myocardial infarction), stent thrombosis/restenosis, or cardiac mortality." | 4.12 | Clinical and Pharmacological Parameters Determine Relapse During Clopidogrel Treatment of Acute Coronary Syndrome. ( Martínez-Quintana, E; Medina-Gil, JM; Rodríguez-González, F; Saavedra-Santana, P; Santana-Mateos, M; Tugores, A, 2022) |
| "To evaluate the association between aspirin use during first pregnancy and later maternal cardiovascular risk." | 4.12 | Association between aspirin use during pregnancy and cardiovascular risk factors 2-7 years after delivery: The nuMoM2b Heart Health Study. ( Bairey Merz, N; Barnes, S; Catov, J; Chung, JH; Greenland, P; Grobman, W; Haas, D; Hoffman, M; Levine, LD; McNeil, R; Mercer, B; Parker, CB; Saade, G; Shanks, A; Silver, RM; Simhan, H; Theilen, LH; Thorsten, V; Varagic, J; Wapner, R, 2022) |
| " Univariate analysis showed that a family history of CHD, history of type 2 diabetes, hypertension, smoking, and drinking, discontinuation of aspirin, use of conventional dose statins, calcified lesions, ≥ 3 implanted stents, stent length ≥ 30 mm, stent diameter < 3 mm, and tandem stent increased the risk of restenosis." | 4.12 | Risk factors for in-stent restenosis after coronary stent implantation in patients with coronary artery disease: A retrospective observational study. ( Bian, YJ; Liu, Y; Xue, YT; Zhang, J; Zhang, Q; Zhao, K, 2022) |
| "Patients taking low-dose aspirin to prevent cardiovascular disease (CVD) may also benefit from a reduced risk of colorectal cancer (CRC)." | 4.02 | Patient Preferences of Low-Dose Aspirin for Cardiovascular Disease and Colorectal Cancer Prevention in Italy: A Latent Class Analysis. ( De Caterina, R; Krucien, N; Marsh, K; Seo, J; Soriano Gabarró, M; Tervonen, T; Vora, P; Wissinger, U, 2021) |
| "Aspirin reduced the risks of MACCE and cancer without increasing the bleeding risk in elderly Koreans with hypertension, T2DM, or dyslipidemia." | 3.96 | Efficacy of Aspirin in the Primary Prevention of Cardiovascular Diseases and Cancer in the Elderly: A Population-Based Cohort Study in Korea. ( Jung, M; Lee, S, 2020) |
| "It was concluded that simultaneous inhibition of the JAK-STAT and NF-κB signalling pathways with tofacitinib and aspirin respectively, could mitigate insulin resistance and hyperglycemia in T2D." | 3.91 | Inhibition of JAK-STAT and NF-κB signalling systems could be a novel therapeutic target against insulin resistance and type 2 diabetes. ( Bako, HY; Ibrahim, MA; Ibrahim, S; Isah, MS, 2019) |
| "We conducted a prospective cohort study on patients enrolled in the Japanese primary prevention of atherosclerosis with aspirin for diabetes (JPAD) trial which was started in 2002." | 3.91 | One quarter of total myocardial infarctions are silent manifestation in patients with type 2 diabetes mellitus. ( Doi, N; Jinnouchi, H; Masuda, I; Morimoto, T; Nakayama, M; Ogawa, H; Okada, S; Saito, Y; Sakuma, M; Soejima, H; Sugiyama, S; Uemura, S; Waki, M, 2019) |
| "Whether metformin may reduce hepatocellular carcinoma (HCC) risk requires confirmation." | 3.88 | Metformin and risk of hepatocellular carcinoma in patients with type 2 diabetes. ( Tseng, CH, 2018) |
| "Our findings indicate a favorable effect of clopidogrel at discharge compared with aspirin in preventing death, recurrent stroke, and CVD events in diabetic patients with a first-ever noncardioembolic AIS." | 3.85 | Aspirin Versus Clopidogrel for Type 2 Diabetic Patients with First-Ever Noncardioembolic Acute Ischemic Stroke: Ten-Year Survival Data from the Athens Stroke Outcome Project. ( Elisaf, M; Manios, E; Milionis, H; Ntaios, G; Papavasileiou, V; Spengos, K; Vemmos, K, 2017) |
| "The aim of this study was to investigate whether aspirin use can reduce the incidence of gastric cancer in patients with hypertension or type 2 diabetes." | 3.83 | Long-Term Low-Dose Aspirin Use Reduces Gastric Cancer Incidence: A Nationwide Cohort Study. ( Choi, IJ; Kim, JH; Kim, SY; Kim, YI; Kim, YW; Lee, JH; Park, JH; Ryu, KW, 2016) |
| "Aspirin use for primary prevention in patients at high risk with diabetes mellitus (DM) is often recommended under the assumption that most patients with DM have coronary artery disease (CAD)." | 3.83 | Value of Coronary Computed Tomography Angiography in Tailoring Aspirin Therapy for Primary Prevention of Atherosclerotic Events in Patients at High Risk With Diabetes Mellitus. ( Bax, JJ; de Graaf, MA; Delgado, V; Dimitriu-Leen, AC; Jukema, JW; Kharagjitsingh, AV; Knuuti, J; Kroft, LJ; Scholte, AJ; van den Hoogen, IJ; van Rosendael, AR; Wolterbeek, R, 2016) |
| "Aspirin is a cornerstone in management of coronary artery disease (CAD)." | 3.81 | Determinants of reduced antiplatelet effect of aspirin in patients with stable coronary artery disease. ( Grove, EL; Hvas, AM; Kristensen, SD; Larsen, SB; Neergaard-Petersen, S; Würtz, M, 2015) |
| " Two subgroups of GK and Wistar control rats were injected intraperitoneally with 100 mg aspirin/kg body weight/ day for 5 weeks." | 3.81 | Enhanced Glucose Tolerance and Pancreatic Beta Cell Function by Low Dose Aspirin in Hyperglycemic Insulin-Resistant Type 2 Diabetic Goto-Kakizaki (GK) Rats. ( Adeghate, E; Amiri, L; Howarth, FC; Jayaprakash, P; John, A; Raza, H; Shafarin, J; Yasin, J, 2015) |
| "To elucidate the correlation between urinary 11-dehydro-thromboxane B2 (11dhTxB2) and clinical efficacy of aspirin treatment in patients with type 2 diabete and coronary artery disease (CAD)." | 3.81 | [Correlation between the level of the urinary 11-dehydrothromboxane B2 and the clinical efficacy of aspirin in patients with type 2 diabetes and coronary artery disease]. ( Bai, ZS; Chen, XH; Feng, XR; Liu, ML; Liu, TF; Zhang, JW, 2015) |
| "The benefit of aspirin in primary prevention of myocardial infarction and the associated gastro-intestinal bleeding risks have not been well established in the elderly population with diabetes." | 3.80 | Myocardial infarction and gastro-intestinal bleeding risks associated with aspirin use among elderly individuals with type 2 diabetes. ( Grégoire, JP; Moisan, J; Poirier, P; Sirois, C, 2014) |
| "Patients (DM, n = 30; non-DM, n = 30) with stable coronary artery disease taking aspirin 81 mg/day and P2Y12 antagonist naive were enrolled." | 3.80 | Impaired responsiveness to the platelet P2Y12 receptor antagonist clopidogrel in patients with type 2 diabetes and coronary artery disease. ( Angiolillo, DJ; Bass, TA; Darlington, A; Desai, B; Ferreiro, JL; Franchi, F; Guzman, LA; Jakubowski, JA; Moser, BA; Rollini, F; Sugidachi, A; Tello-Montoliu, A; Ueno, M, 2014) |
| "This study aimed to characterize the in vitro effect of EV-077, a compound that antagonises the binding of prostanoids and isoprostanes to the thromboxane receptor (TP) and inhibits the thromboxane synthase (TS), on platelet aggregation of patients with type-2 diabetes and coronary artery disease (CAD) on chronic aspirin treatment." | 3.78 | EV-077 in vitro inhibits platelet aggregation in type-2 diabetics on aspirin. ( Alberts, P; Armesto, AR; Cattaneo, M; Daray, FM; Errasti, AE; Femia, EA; Meyer, JP; Nowak, W; Podda, GM; Pugliano, M; Razzari, C; Rothlin, RP; Sakariassen, KS; Sorensen, AS, 2012) |
| "To investigate the impact of platelet turnover on the antiplatelet effect of aspirin in patients with stable coronary artery disease (CAD) and to identify determinants of platelet turnover." | 3.77 | Effect of platelet turnover on whole blood platelet aggregation in patients with coronary artery disease. ( Grove, EL; Hvas, AM; Kristensen, SD; Larsen, SB; Mortensen, SB, 2011) |
| " Data were analysed from three community-dwelling populations of older persons (>50 years) in central Scotland: the Aspirin for Asymptomatic Atherosclerosis (AAA) Trial (n = 2,091), the Edinburgh Type 2 Diabetes Study (ET2DS, n = 1,066), and the Lothian Birth Cohort 1936 (LBC1936, n = 1,091)." | 3.77 | Genetic associations between fibrinogen and cognitive performance in three Scottish cohorts. ( Deary, IJ; Fowkes, FG; Gow, AJ; Harris, SE; Houlihan, LM; Lowe, GD; Luciano, M; Marioni, RE; Murray, GD; Price, JF; Rumley, A; Stewart, MC; Strachan, MW, 2011) |
| "Diabetes and heart failure commonly coexist, and prior studies have suggested better outcomes with metformin than other antidiabetic agents." | 3.76 | Treatment of type 2 diabetes and outcomes in patients with heart failure: a nested case-control study from the U.K. General Practice Research Database. ( Bhagra, S; Eurich, DT; Jhund, PS; Lewsey, JD; MacDonald, MR; Majumdar, SR; McAlister, FA; McMurray, JJ; Petrie, JR; Petrie, MC, 2010) |
| " The quality of control of diabetes, hypertension or hyperlipidemia and the use of aspirin were assessed in 2914 patients at baseline and after 3,7 years." | 3.75 | ["Diabetes in Germany"(DIG) study. A prospective 4-year-follow-up study on the quality of treatment for type 2 diabetes in daily practice]. ( Benke, I; Hanefeld, M; Köhler, C; Ott, P; Stelzer, J, 2009) |
| "Aspirin is currently known to give inadequate protection against coronary artery disease in diabetes compared to person without it." | 3.74 | A study of aspirin resistance in type 2 diabetes. ( Chaudhuri, U; Chowdhury, S; Lahiri, P; Mukhopadhyay, P; Pandit, K; Singla, MK, 2008) |
| "Platelet function analyses, which included measures of platelet aggregation and activation, were performed in 173 T2DM patients with coronary artery disease on chronic treatment with aspirin and clopidogrel." | 3.74 | Impact of platelet reactivity on cardiovascular outcomes in patients with type 2 diabetes mellitus and coronary artery disease. ( Alfonso, F; Angiolillo, DJ; Bañuelos, C; Bass, TA; Bernardo, E; Costa, MA; Escaned, J; Fernandez-Ortiz, A; Guzman, LA; Hernández-Antolin, R; Jimenez-Quevedo, P; Macaya, C; Moreno, R; Palazuelos, J; Sabaté, M, 2007) |
| "The aim of this study was to evaluate the relationship of obesity, leptin, insulin resistance and C-reactive protein (CRP) with coronary heart disease (CHD) risk factors in patients with Type 2 diabetes mellitus (DM) with CHD compared with those with Type 2 DM without CHD." | 3.73 | Plasma leptin concentration in patients with Type 2 diabetes: relationship to cardiovascular disease risk factors and insulin resistance. ( Abdella, NA; Al Jebely, S; Al Mohammedi, H; Al Ozairi, ES; Mojiminiyi, OA; Moussa, MA; Zaki, M, 2005) |
| "Our results conclude that 10% decrease in body mass index (BMI) among overweight patients, smoking cessation, initiation to undertake a preventive treatment with low-dose aspirin, initiation to undertake or intensify blood pressure control, initiation to undertake or intensify lipidic control, and shift to biguanides among overweight patients are factors associated with significant benefits (avoided costs) which compensate for the increase in treatment costs." | 3.73 | [Assessment of the budgetary impact of treatment guidelines in type II diabetes mellitus in France]. ( Crainich, D; Lebrun, T; Marissal, JP; Sailly, JC, 2005) |
| "Gastric ulcers were induced in normal/NIDDM rats by various physical (2 hr cold restraint stress and 4 hr pylorus ligation) and chemical agents (ethanol, 1 ml/200 g, oral, 1 hr before; aspirin, 200 mg/kg, oral, 4 hr) and duodenal ulcers were induced by cysteamine (40 mg/200 g)." | 3.72 | Effect of Bacopa monniera and Azadirachta indica on gastric ulceration and healing in experimental NIDDM rats. ( Agrawal, VK; Aryya, NC; Dorababu, M; Goel, RK; Prabha, T; Priyambada, S, 2004) |
| "Metformin was associated with a reduced cancer incidence risk (adjusted hazard ratio [HR] = 0." | 3.30 | Association of metformin, aspirin, and cancer incidence with mortality risk in adults with diabetes. ( Broder, JC; Ernst, ME; Espinoza, S; Gibbs, P; Lockery, JE; Loomans-Kropp, HA; Orchard, SG; Polekhina, G; Wolfe, R; Woods, RL; Zoungas, S, 2023) |
| "Patients with type 2 diabetes mellitus (T2DM) are susceptible to developing symptomatic peripheral arterial disease (PAD)." | 3.11 | Ultrasonography evaluation on the protective effect of combination therapy of beraprost sodium and aspirin on arteries occlusion and stiffness in patients with type 2 diabetes mellitus - a prospective, randomized study. ( Chen, Y; Fu, L; Li, J; Lin, X; Lu, W; Ren, M; Yan, L; Yang, C; Yin, J, 2022) |
| "We randomly assigned 116 patients with type 2 diabetes and cardiovascular risk factors but no evident cardiovascular disease to receive aspirin at a dose of 100 mg or cilostazol at a dose of 200 mg daily for 14 days." | 3.11 | Comparative Study of Ex Vivo Antiplatelet Activity of Aspirin and Cilostazol in Patients with Diabetes and High Risk of Cardiovascular Disease. ( Hong, S; Lee, WJ; Park, CY, 2022) |
| "Rivaroxaban treatment for 20 weeks (n = 89) resulted in a significant improvement of post-ischaemic forearm blood flow (3." | 3.01 | Rivaroxaban compared with low-dose aspirin in individuals with type 2 diabetes and high cardiovascular risk: a randomised trial to assess effects on endothelial function, platelet activation and vascular biomarkers. ( Birkenfeld, AL; Bornstein, SR; Hanefeld, M; Henkel, E; Matschke, JB; Pistrosch, F; Schipp, B; Schipp, D; Sradnick, J; Weigmann, I, 2021) |
| "Type 2 Diabetes mellitus is associated with aging and shortened telomere length." | 2.94 | The effects of aspirin and N-3 fatty acids on telomerase activity in adults with diabetes mellitus. ( Abdolahi, A; Block, RC; Brenna, JT; Godugu, K; Holub, A; Mousa, S; Tu, XM, 2020) |
| " We examined acute and chronic effects, and effects over the 24h dosing interval." | 2.90 | Differential vascular effects of aspirin in people with Type 2 diabetes without cardiovascular disease and matched controls without diabetes. ( Baier, JM; Funck, KL; Grove, EL; Gullaksen, S; Hvas, AM; Laugesen, E; Poulsen, PL; Vernstrøm, L, 2019) |
| "Cilostazol treatment was associated with significantly lowered IMT in T2D patients compared to aspirin, independent of conventional cardiovascular risk factors." | 2.90 | Randomized control trial comparing the effect of cilostazol and aspirin on changes in carotid intima-medial thickness. ( Chun, M; Hong, S; Kang, J; Kim, D; Lee, K; Little, BB; Nam, M; Paik, S; Park, Y; Woo, J, 2019) |
| "Aspirin was used by 56." | 2.90 | Antithrombotic treatment gap among patients with atrial fibrillation and type 2 diabetes. ( Green, JB; Guimarães, PO; Holman, RR; Lokhnygina, Y; Lopes, RD; McGuire, DK; Peterson, ED; Stevens, SR, 2019) |
| "Patients with type 2 diabetes mellitus (T2DM) are at higher risk of thrombotic complications." | 2.87 | Comparison of pharmacodynamic effects of ticagrelor vs prasugrel in type 2 diabetes mellitus patients with coronary heart disease. ( Cao, PG; Guo, DD; Quan, AJ; Shang, LL; Zhao, HY, 2018) |
| "The primary end point was total cancer incidence." | 2.87 | Effect of Aspirin on Cancer Chemoprevention in Japanese Patients With Type 2 Diabetes: 10-Year Observational Follow-up of a Randomized Controlled Trial. ( Doi, N; Jinnouchi, H; Masuda, I; Matsumoto, C; Morimoto, T; Nakayama, M; Ogawa, H; Okada, S; Saito, Y; Sakuma, M; Soejima, H; Waki, M, 2018) |
| "Ticagrelor is a P2Y12 receptor antagonist with evidence of cardiovascular event reduction in patients with acute coronary syndromes and those with a previous myocardial infarction." | 2.87 | Ticagrelor and the Prevention of Microvascular Complications in Diabetes Patients with Lower Extremity Arterial Disease; Rationale and Design of the Hema-Kinesis Trial. ( Chen, Q; Cho, DJ; Lee, ML; Najera, SD; Rosenson, RS, 2018) |
| " Because increased platelet reactivity and/or turnover are postulated mechanisms, we examined whether higher and/or more frequent aspirin dosing might reduce platelet reactivity more effectively." | 2.82 | Randomized controlled trial comparing impact on platelet reactivity of twice-daily with once-daily aspirin in people with Type 2 diabetes. ( Bethel, MA; Coleman, RL; Harrison, P; Hill, L; Holman, RR; Kennedy, I; Oulhaj, A; Sourij, H; Sun, Y; Tucker, L; White, S, 2016) |
| "Thirty adults with type 2 diabetes mellitus ingested aspirin (81 mg/day) for 7 days, then EPA+DHA (2." | 2.80 | The effects of aspirin on platelet function and lysophosphatidic acids depend on plasma concentrations of EPA and DHA. ( Abdolahi, A; Block, RC; Brenna, JT; Georas, SN; Lawrence, P; Mousa, SA; Phipps, RP; Tu, X, 2015) |
| "Forty patients with chronic periodontitis and type 2 DM were equally divided into groups 1 (patients received ω3 plus low-dose aspirin for 6 mo) and 2 (patients received placebo during the same period)." | 2.80 | Effect of omega 3 fatty acids plus low-dose aspirin on both clinical and biochemical profiles of patients with chronic periodontitis and type 2 diabetes: a randomized double blind placebo-controlled study. ( Elwakeel, NM; Hazaa, HH, 2015) |
| "Intensified multifactorial treatment in type 2 diabetes results in an enhanced decrease in hs-CRP." | 2.80 | Effect of six years intensified multifactorial treatment on levels of hs-CRP and adiponectin in patients with screen detected type 2 diabetes: the ADDITION-Netherlands randomized trial. ( Berends, J; Beulens, JW; den Ouden, H; Rutten, GE; Stellato, RK, 2015) |
| "CAD patients with type 2 diabetes had higher platelet aggregation (all p-values <0." | 2.80 | The Influence of Haemoglobin A1c Levels on Platelet Aggregation and Platelet Turnover in Patients with Coronary Artery Disease Treated with Aspirin. ( Gregersen, S; Grove, EL; Hvas, AM; Kristensen, SD; Larsen, SB; Neergaard-Petersen, S, 2015) |
| " The present study attempts to study the pharmacodynamic interactions of P." | 2.79 | Study of pharmacodynamic interaction of Phyllanthus emblica extract with clopidogrel and ecosprin in patients with type II diabetes mellitus. ( Fatima, N; Muralidhar, N; Pingali, U, 2014) |
| "Thirty adults with type 2 diabetes mellitus were treated with aspirin 81 mg/d for 7 days, then with fish oil 4 g/day for 28 days, then the combination of fish oil and aspirin for another 7 days." | 2.78 | Effects of low-dose aspirin and fish oil on platelet function and NF-kappaB in adults with diabetes mellitus. ( Abdolahi, A; Block, RC; Brenna, JT; Cai, X; Cui, H; Georas, S; Meednu, N; Mousa, S; Smith, B; Thevenet-Morrison, K, 2013) |
| " The anti-platelet effect may be diminished by poor glycemic control or inadequate dosing of aspirin." | 2.77 | The influence of aspirin dose and glycemic control on platelet inhibition in patients with type 2 diabetes mellitus. ( Bähler, L; Gerdes, VE; Hoekstra, JB; Holleman, F; Kamphuisen, PW; Lemkes, BA; Nieuwland, R; Stroobants, AK; Van Den Dool, EJ, 2012) |
| " We hypothesized that faster recovery of platelet cyclooxygenase-1 activity may explain incomplete thromboxane (TX) inhibition during the 24-h dosing interval." | 2.77 | The recovery of platelet cyclooxygenase activity explains interindividual variability in responsiveness to low-dose aspirin in patients with and without diabetes. ( Cardillo, C; Davì, G; Del Ponte, A; Ferrante, E; Ghirlanda, G; Lattanzio, S; Liani, R; Martini, F; Mattoscio, D; Mirabella, M; Morosetti, R; Mucci, L; Patrono, C; Petrucci, G; Pitocco, D; Rocca, B; Santilli, F; Vazzana, N; Vitacolonna, E; Zaccardi, F, 2012) |
| "Patients with type 2 diabetes mellitus (T2DM) have impaired clopidogrel-induced antiplatelet effects, which may be in part attributed to their reduced sensitivity to insulin and consequently, results in upregulation of the P2Y12 signalling pathway." | 2.77 | Effects of pioglitazone on platelet P2Y12-mediated signalling in clopidogrel-treated patients with type 2 diabetes mellitus. ( Angiolillo, DJ; Bass, TA; Box, LC; Desai, B; Ferreiro, JL; Guzman, LA; Rollini, F; Suryadevara, S; Tello-Montoliu, A; Ueno, M; Zenni, M, 2012) |
| " The aim of this study was to perform serial pharmacodynamic assessments of prasugrel with high-dose clopidogrel in patients with DM." | 2.76 | A pharmacodynamic comparison of prasugrel vs. high-dose clopidogrel in patients with type 2 diabetes mellitus and coronary artery disease: results of the Optimizing anti-Platelet Therapy In diabetes MellitUS (OPTIMUS)-3 Trial. ( Angiolillo, DJ; Badimon, JJ; Baker, BA; Effron, MB; Frelinger, AL; Jakubowski, JA; Michelson, AD; Ojeh, CK; Saucedo, JF; Zhu, B, 2011) |
| " We tested if twice daily dosing of aspirin would be more effective in T2DM, possibly due to increased platelet turnover." | 2.76 | Twice daily dosing of aspirin improves platelet inhibition in whole blood in patients with type 2 diabetes mellitus and micro- or macrovascular complications. ( Arnetz, L; Brismar, K; Hjemdahl, P; Li, N; Östenson, CG; Spectre, G, 2011) |
| "Hemodialysis patients with type 2 diabetes exhibit an excessive cardiovascular risk and regularly receive heparin." | 2.75 | Antibodies to platelet factor 4-heparin complex and outcome in hemodialysis patients with diabetes. ( Berger, M; Krane, V; Lilienthal, J; Schambeck, C; Wanner, C; Winkler, K, 2010) |
| " Long-term use of aspirin reduced the incidence of recurrent AMI (p = 0." | 2.75 | [Investigation of the effects of low dose aspirin therapy on primary and secondary prevention of cardiovascular disease]. ( Ogawa, H; Soejima, H, 2010) |
| "Women who had ever reported asthma or COPD were associated with an increased diabetes risk; the multivariate RRs were 1." | 2.75 | Asthma, chronic obstructive pulmonary disease, and type 2 diabetes in the Women's Health Study. ( Buring, JE; Klevak, A; Liu, S; Manson, JE; Song, Y, 2010) |
| "For the patients with newly diagnosed type 2 diabetes, additional administration of CDDP to the conventional treatment could exert beneficial effects on blood glucose controling, and lipid profile improvement and delay of arterial intima-media proliferation." | 2.75 | [Effect of compound danshen dripping pill on arterial intima-media thickness in patients with newly diagnosed type 2 diabetes mellitus]. ( Liu, D; Tang, JY; Yan, L, 2010) |
| "Documented clinical type 2 diabetes was prospectively evaluated throughout the trial." | 2.74 | A randomized trial of low-dose aspirin in the prevention of clinical type 2 diabetes in women. ( Buring, JE; Cook, NR; Manson, JE; Pradhan, AD; Ridker, PM, 2009) |
| "Decreased risk of type 2 diabetes may be added to the list of the clinical benefits of aspirin." | 2.74 | Aspirin use and risk of type 2 diabetes in apparently healthy men. ( Hayashino, Y; Hennekens, CH; Kurth, T, 2009) |
| "The increasing prevalence of type 2 diabetes poses a major public health challenge." | 2.74 | The ADDITION-Cambridge trial protocol: a cluster -- randomised controlled trial of screening for type 2 diabetes and intensive treatment for screen-detected patients. ( Barling, RS; Echouffo-Tcheugui, JB; Griffin, SJ; Kinmonth, AL; Prevost, AT; Simmons, RK; Wareham, NJ; Williams, KM, 2009) |
| "Patients with type 2 diabetes mellitus (T2DM) have reduced platelet inhibition compared with non-diabetics following P2Y(12) receptor blockade." | 2.73 | A randomized study assessing the impact of cilostazol on platelet function profiles in patients with diabetes mellitus and coronary artery disease on dual antiplatelet therapy: results of the OPTIMUS-2 study. ( Angiolillo, DJ; Aslam, M; Bass, TA; Box, LC; Capranzano, P; Charlton, RK; Desai, B; Goto, S; Guzman, LA; Shoemaker, SB; Suzuki, Y; Zenni, MM, 2008) |
| "In this study of patients with type 2 diabetes, low-dose aspirin as primary prevention did not reduce the risk of cardiovascular events." | 2.73 | Low-dose aspirin for primary prevention of atherosclerotic events in patients with type 2 diabetes: a randomized controlled trial. ( Doi, N; Jinnouchi, H; Kanauchi, M; Morimoto, T; Nakayama, M; Ogawa, H; Saito, Y; Sugiyama, S; Uemura, S, 2008) |
| "Anaemia in diabetes mellitus (DM) and/or chronic renal failure (CRF) may be caused by a decreased production of erythropoietin (EPO), EPO resistance, and by the lysis of the young circulating red blood cells (neocytolysis) induced by subclinical inflammation and low EPO level." | 2.73 | Single dose of acetylsalicylic acid in patients with Type 2 diabetes mellitus and/or chronic renal failure ameliorates anaemia by decreasing the rate of neocytolysis. ( Köszegi, T; Laczy, B; Markó, L; Mohás, M; Molnár, GA; Nagy, J; Tamaskó, M; Wagner, L; Wagner, Z; Wittmann, I, 2007) |
| "In at-risk patients with type 2 diabetes, intensive intervention with multiple drug combinations and behavior modification had sustained beneficial effects with respect to vascular complications and on rates of death from any cause and from cardiovascular causes." | 2.73 | Effect of a multifactorial intervention on mortality in type 2 diabetes. ( Gaede, P; Lund-Andersen, H; Parving, HH; Pedersen, O, 2008) |
| "In these patients with type 2 diabetes and a history of TIA, patterns of platelet inhibition differed significantly according to whether treatment was with ER-DP+ASA or clopidogrel with or without ASA." | 2.73 | Antiplatelet profiles of the fixed-dose combination of extended-release dipyridamole and low-dose aspirin compared with clopidogrel with or without aspirin in patients with type 2 diabetes and a history of transient ischemic attack: a randomized, single-b ( Hanley, DF; Malinin, AI; Pokov, AN; Serebruany, VL, 2008) |
| "Inhibiting thrombosis is a cornerstone of vascular protection." | 2.72 | Life and limb protection with dual anti-thrombotic pathway inhibition: COMPASS ushers in a new day in atherothrombotic risk reduction. ( Al-Omran, M; Bhatt, DL; Choi, R; Eikelboom, JW; Heffernan, M; Teoh, H; Verma, S, 2021) |
| "Type 2 diabetes is characterised by reduced monocyte TIMP-1 mRNA levels, and a lower plasma MMP-9 to TIMP-1 protein ratio compared to controls, a pattern that would promote coronary plaque instability if reproduced within vascular plaque." | 2.72 | Monocyte matrix and ADAM metalloproteinase expression in type 2 diabetes after aspirin therapy. ( Baugh, M; Davies, I; Gavrilovic, J; Hughes, D; Sampson, M; Wall, S; Worley, J, 2006) |
| "Aspirin sensitivity was defined as inhibition (i." | 2.71 | Aspirin sensitivity of platelet aggregation in diabetes mellitus. ( Albert, SG; Hasnain, BI; Joist, JH; Mooradian, AD; Ritter, DG, 2005) |
| "Triflusal is an antiplatelet drug related to aspirin, with different pharmacological properties and a lower haemorrhagic risk." | 2.71 | Inhibition of thromboxane biosynthesis by triflusal in type 2 diabetes mellitus. ( Avellone, G; Ballone, E; Ciabattoni, G; Davì, G; Di Febbo, C; Di Nicola, M; Falco, A; Pinto, A; Salvati, F; Vitacolonna, E, 2005) |
| "Seventy-six patients with type-2 diabetic nephropathy, who had normal renal function tests were randomized into the 4 groups; each group (n = 19) received one of the following treatments: aspirin (1000 mg), dipyridamole (750 mg), their combination or placebo daily for 2 months." | 2.70 | A comparative randomized and placebo-controlled short-term trial of aspirin and dipyridamole for overt type-2 diabetic nephropathy. ( Khajehdehi, P; Mostafavi, H; Roozbeh, J, 2002) |
| "Accommodative amplitudes in Early Treatment Diabetic Retinopathy Study patients were lower than normal accommodative amplitudes." | 2.68 | Accommodative amplitudes in the Early Treatment Diabetic Retinopathy Study. ( Benson, WE; Braun, CI; Chew, EY; Ferris, FL; Remaley, NA, 1995) |
| "Pentosidine levels were significantly correlated with severity of retinopathy and neuropathy, but not nephropathy." | 2.68 | Effects of aspirin or basic amino acids on collagen cross-links and complications in NIDDM. ( Blanco, MC; Camejo, M; Contreras, I; Giansante, E; Gonzalez, F; Lopez, T; Martinez, N; Molina, M; Postalian, S; Reiser, KM; Sanchez, MR; Suarez, N, 1997) |
| "This review presents prevalence of type 2 diabetes mellitus (DM) in patients with ischemic heart disease (IHD), risk factors in common, and a considerable worsening of prognosis in their combination." | 2.66 | [Choosing Antithrombotic Therapy in Patients with Coronary Heart Disease and Type 2 Diabetes Mellitus: How to Reduce the Risk of Death]. ( Karavaev, PG; Koziolova, NA; Veklich, AS, 2020) |
| "Aspirin resistance has been often considered a guilty actor, although many mechanisms have been mistaken for true aspirin resistance, such as patient poor compliance, inadequate dosing, drug interactions, and high-platelet turnover." | 2.58 | Aspirin in primary prevention for patients with diabetes: Still a matter of debate. ( Bonaventura, A; Liberale, L; Montecucco, F, 2018) |
| "Type 2 diabetes mellitus is characterised by persistent thromboxane (TX)-dependent platelet activation, regardless of disease duration." | 2.52 | Aspirin for primary prevention in diabetes mellitus: from the calculation of cardiovascular risk and risk/benefit profile to personalised treatment. ( Davì, G; Pignatelli, P; Santilli, F; Violi, F, 2015) |
| " Endpoints included major adverse cardiac effects (MACEs), target lesion revascularization (TLR), target vessel revascularization (TVR), death, stent thrombosis, bleeding and adverse drug reactions during a 9-12 months period, as well as platelet activities." | 2.52 | Comparing the effectiveness and safety between triple antiplatelet therapy and dual antiplatelet therapy in type 2 diabetes mellitus patients after coronary stents implantation: a systematic review and meta-analysis of randomized controlled trials. ( Bundhun, PK; Chen, MH; Qin, T, 2015) |
| "Obesity is a substantial cardiovascular risk factor, and recently, large trials of lifestyle and surgical (e." | 2.50 | Type 2 diabetes and cardiovascular disease: what next? ( Golden, SH; Joseph, JJ, 2014) |
| "Avoiding hypoglycemia is most important for elderly patients with long history of diabetes and atherosclerosis." | 2.49 | [Cardiovascular event in elderly patients with diabetes mellitus]. ( Nomura, K, 2013) |
| " Therefore, several new antiplatelet treatment strategies have been developed in order to optimize platelet inhibition: a) modification of dosing of commonly used agents; b) use of new agents; and c) addition of a third antiplatelet drug (triple therapy)." | 2.48 | Challenges and perspectives of antiplatelet therapy in patients with diabetes mellitus and coronary artery disease. ( Angiolillo, DJ; Ferreiro, JL, 2012) |
| "Patients with type 2 diabetes mellitus are at 2 to 4 times increased risk of cardiovascular events compared with those without diabetes, both among patients with multiple risk factors only and those with established atherothrombosis." | 2.48 | Statin and aspirin therapy for the prevention of cardiovascular events in patients with type 2 diabetes mellitus. ( Bhatt, DL; Braunwald, E; Davidson, J; Hirshberg, B; Raz, I; Scirica, BM; Steg, PG; Udell, JA, 2012) |
| "Careful counseling of women with diabetic nephropathy before pregnancy with estimation of the risk for the mother and fetus is important." | 2.48 | Obstetric nephrology: pregnancy in women with diabetic nephropathy--the role of antihypertensive treatment. ( Clausen, P; Damm, P; Feldt-Rasmussen, B; Mathiesen, ER; Ringholm, L, 2012) |
| "Patients with type 2 diabetes mellitus are characterized by increased incidence of cardiovascular events and enhanced thromboxane-dependent platelet activation." | 2.47 | TP receptor activation and inhibition in atherothrombosis: the paradigm of diabetes mellitus. ( Davì, G; Mucci, L; Santilli, F, 2011) |
| "Patients with Type 2 diabetes carry an equivalent cardiovascular risk to that of a non-diabetic individual who has already experienced a coronary event." | 2.47 | Management of type-2 diabetes with anti-platelet therapies: special reference to aspirin. ( Rao, GH, 2011) |
| "Aspirin therapy was not associated with a statistically significant reduction in major cardiovascular events (relative risk [RR] 0." | 2.46 | Aspirin for primary prevention of cardiovascular events in patients with diabetes: A meta-analysis. ( Fu, M; Ge, J; Sun, A; Wang, K; Wu, C; Zhang, C; Zhang, P; Zhang, S; Zou, Y, 2010) |
| "Psoriasis is highly prevalent and is associated with skin-associated complaints as well as arthritis, depression and a lower quality of life." | 2.45 | Psoriasis: an opportunity to identify cardiovascular risk. ( Federman, DG; Gunderson, CG; Kirsner, RS; Prodanovich, S; Shelling, M, 2009) |
| "The prevalence of Type 2 diabetes mellitus (DM) continues to increase globally and brings with it a parallel increase in the associated cardiovascular disease complications." | 2.45 | Platelet perturbations in diabetes: implications for cardiovascular disease risk and treatment. ( Mathewkutty, S; McGuire, DK, 2009) |
| "Paralleling the rise in obesity, the cardiometabolic syndrome is a rapidly growing health problem in the United States." | 2.45 | Utility of aspirin therapy in patients with the cardiometabolic syndrome and diabetes. ( Gardner, DW; Gardner, M; Lastra, G; Manrique, C; Palmer, J; Sowers, JR, 2009) |
| "Patients with type 2 diabetes mellitus are at increased risk for macrovascular disease complications." | 2.44 | Preventing macrovascular complications in type 2 diabetes mellitus: glucose control and beyond. ( McGuire, DK; Stancoven, A, 2007) |
| "Aspirin non-response was more frequently associated with the use of "home-established" cut-offs or when closure time was only assessed after aspirin (rather than both before and after)." | 2.44 | Response variability to aspirin as assessed by the platelet function analyzer (PFA)-100. A systematic review. ( Cerletti, C; Crescente, M; de Gaetano, G; Di Castelnuovo, A; Iacoviello, L; Vermylen, J, 2008) |
| " Long-term use of high-dose aspirin and NSAIDs is associated with significant gastrointestinal side effects." | 2.44 | Diabetes, colorectal cancer and cyclooxygenase 2 inhibition. ( Fisher, M; McKay, GA; Smith, CJ, 2008) |
| "The Metabolic syndrome is a widely prevalent and multi-factorial disorder." | 2.43 | Metabolic syndrome. ( Agarwal, PK; Gogia, A, 2006) |
| "Pharmacologic and clinical studies focusing on the dose-response relationship of aspirin therapy were reviewed." | 2.42 | Aspirin dose for prevention of cardiovascular disease in diabetics. ( Jaber, LA; Nowak, SN, 2003) |
| "Type 2 diabetes has now reached epidemic proportions across the world and is the cause of substantial morbidity and mortality." | 2.42 | Intense management of diabetes mellitus: role of glucose control and antiplatelet agents. ( Mudaliar, S, 2004) |
| "Patients with type 2 diabetes have a high risk of morbidity and premature mortality from cardiovascular disease." | 2.41 | [Prevention of cardiovascular disease in type 2 diabetes]. ( Birkeland, KI; Claudi, T; Hanssen, KF; Hansteen, V; Hjermann, I; Jenssen, T; Jervell, J; Os, I, 2000) |
| " The data reported in the literature do not however enable any evidenced-based decision on dosing for the diabetic population with numerous cardiovascular risks." | 2.41 | [Prevention of cardiovascular diseases in type 2 diabetes with aspirin]. ( Duly-Bouhanick, B; Guilloteau, G; Hadjadj, S; Menard, S; Plun-Favreau, J; Soares-Barbosa, S, 2001) |
| "The phenomenal growth in the rate of type 2 diabetes presents an enormous burden to society." | 2.41 | Glycemic control and beyond: the ABCs of standards of care for type 2 diabetes and cardiovascular disease. ( Cunningham, M; Kernan-Schroeder, D, 2002) |
| "Chronic hyperglycemia is then added to these risk markers." | 2.40 | Multifactorial aspects of the treatment of the type II diabetic patient. ( Colwell, JA, 1997) |
| "Cardiovascular (CV) disease prevention with low-dose aspirin can be less effective in patients with a faster recovery of platelet (PLT) cyclooxygenase (COX)-1 activity during the 24-hour dosing interval." | 1.91 | Reduced platelet glycoprotein Ibα shedding accelerates thrombopoiesis and COX-1 recovery: implications for aspirin dosing regimen. ( Abbonante, V; Auciello, R; Balduini, A; Bologna, G; Camera, M; Ciotti, S; Cipollone, F; Cufaro, MC; Del Boccio, P; Di Castelnuovo, A; Hoffmeister, KM; Lanuti, P; Lee-Sundlov, M; Liani, R; Luongo, M; Pieragostino, D; Porro, B; Recchiuti, A; Santilli, F; Simeone, P; Tremoli, E; Tripaldi, R, 2023) |
| "Aspirin is an essential drug in the prevention of atherosclerotic cardiovascular disease (ASCVD)." | 1.91 | Appropriateness of aspirin use among diabetic patients in primary prevention of atherosclerotic cardiovascular diseases: an analysis of the ASSOS study. ( Basaran, O; Celik, O; Cil, C; Demirci, E; Dogan, V; Kaya, C; Kırıs, T; Memic Sancar, K; Orscelik, O; Resulzade, MM; Tanık, VO, 2023) |
| "Treatment with hydroxychloroquine might not be enough to lower the cardiovascular risk significantly in diabetes patients with Sjögren syndrome." | 1.72 | Sjögren syndrome is a hidden contributor of macrovascular and microvascular complications in patients with type 2 diabetes. ( Leong, PY; Su, YJ; Wang, YH; Wei, JC, 2022) |
| "A total of 5308 patients with type 2 diabetes were identified by the National Health Insurance from 1998 to 2000 and followed up until 2013." | 1.72 | Antiplatelet agents aspirin and dipyridamole, and the risk of different carcinoma in patients with type 2 diabetes mellitus: A Taiwan retrospective cohort study. ( Hsu, WH; Huang, HY; Lee, MY; Liang, HL; Lu, TW; Sung, YW, 2022) |
| "Aspirin was found to be irrationally prescribed to patients with DM (15." | 1.72 | Pharmacist-led medication therapy management of diabetes club patients at a primary healthcare clinic in Cape Town, South Africa: A retrospective and prospective audit. ( Bheekie, A; Sonday, F; Van Huyssteen, M, 2022) |
| "Aspirin was used significantly more in people attending shared care (p < 0." | 1.72 | Appropriateness of aspirin prescribing for primary and secondary prevention of cardiovascular disease in type 2 diabetes in different care settings. ( Byrne, S; Cronin, H; O'Donovan, A; Tan, SY; Tuthill, A, 2022) |
| "Treatment with aspirin did not aggravate the impairment of intestinal barrier in T2DM patients." | 1.62 | Impaired intestinal barrier function in type 2 diabetic patients measured by serum LPS, Zonulin, and IFABP. ( Chen, GC; Chen, QK; Huang, CL; Li, JY; Xie, QS; Yu, T; Yuan, JH, 2021) |
| "Acetylsalicylic acid (ASA) and type 2 diabetes mellitus (T2DM) affect fibrin clot properties through fibrinogen acetylation or glycation." | 1.62 | Glycation and acetylation sites on fibrinogen in plasma fibrin clot of patients with type 2 diabetes: Effects of low-dose acetylsalicylic acid. ( Bryk, AH; Undas, A; Wiśniewski, JR; Zettl, K, 2021) |
| "The best treatment for coronary artery disease (CAD) in patients with type 2 diabetes (DM2) and chronic kidney disease is unknown." | 1.62 | Effect of diabetic kidney disease on therapeutic strategies for coronary artery disease: ten year follow-up. ( Batista, DV; Filho, JPPL; Filho, RK; Garcia, RMR; Garzillo, CL; Hueb, W; Junior, CVS; Lima, EG; Martins, EB; Ramires, JAF; Rezende, PC, 2021) |
| "Type 2 diabetes mellitus is a complex metabolic disorder requiring polypharmacology approaches for effective treatment." | 1.51 | Towards multi-target antidiabetic agents: Discovery of biphenyl-benzimidazole conjugates as AMPK activators. ( Babkov, DA; Babkova, VA; Borisov, AV; Borodkin, GS; Brigadirova, AA; Kolodina, AA; Litvinov, RA; Morkovnik, AS; Sochnev, VS; Sokolova, EV; Spasov, AA; Zhukowskaya, ON, 2019) |
| " As the best ex vivo method of measuring ASA efficacy remains uncertain, we compared nine platelet function tests to assess responsiveness to three ASA dosing regimens in 24 T2D patients randomized in a three-treatment crossover design to ASA 100 mg/day, 200 mg/day, or 100 mg twice daily for 2-week treatment periods." | 1.51 | Comparison of nine platelet function tests used to determine responses to different aspirin dosages in people with type 2 diabetes. ( Bethel, MA; Coleman, R; Dinsdale, R; Harrison, P; Holman, RR; Kennedy, I, 2019) |
| ": The prevalence of hypertension, type 2 diabetes mellitus (DM2) and the metabolic syndrome continues to increase in Latin America, while the rates of diagnosis, treatment and control of these disorders remain low." | 1.51 | Latin American Consensus on the management of hypertension in the patient with diabetes and the metabolic syndrome. ( Accini, JL; Alcocer, L; Barbosa, E; Camacho, PA; Cobos, L; Coca, A; Diaz, M; Lanas, F; López-Jaramillo, P; Molina, DI; Pasquel, M; Ponte-Negretti, CI; Sanchez, R; Sebba-Barroso, W; Wyss, F; Zanchetti, A, 2019) |
| "Five patients (5." | 1.51 | [The Pathways to Increase the Efficacy of Drug Therapy in Patients with Ischemic Heart Disease after Coronary Artery Bypass Grafting]. ( Barbarash, OL; Hryachkova, ON; Kashtalap, VV; Shibanova, IA; Zykov, MV, 2019) |
| " We investigated if platelet aggregation increased during the standard 24-hour aspirin dosing interval in patients with T2DM compared to non-diabetic controls." | 1.48 | Antiplatelet effect of aspirin during 24h in patients with type 2 diabetes without cardiovascular disease. ( Baier, JM; Funck, KL; Grove, EL; Hvas, AM; Laugesen, E; Poulsen, PL; Vernstrøm, L, 2018) |
| "The cohort of women with a history of preeclampsia were divided into 2 groups, before and after the release of the US Preventive Services Task Force 2014 recommendations." | 1.46 | Impact of USPSTF recommendations for aspirin for prevention of recurrent preeclampsia. ( Aagaard, KM; Chu, DM; Hollier, LM; Mastrobattista, JM; Racusin, DA; Ramin, SM; Sangi-Haghpeykar, H; Tolcher, MC, 2017) |
| " Personalized dosing of DHA in those who take aspirin may be a beneficial option for patients with type 2 diabetes mellitus." | 1.46 | Effects of aspirin in combination with EPA and DHA on HDL-C cholesterol and ApoA1 exchange in individuals with type 2 diabetes mellitus. ( Abdolahi, A; Block, RC; Holub, A; Mousa, SA; Oda, MN; Tu, XM, 2017) |
| "Aspirin resistance was observed in 33 (18%) patients." | 1.46 | Prevalence of aspirin resistance in patients with type II diabetes: a descriptive-analytical study . ( Eskandarian, R; Fattah, A; Forozeshfard, M; Ghods, K; Razavi, M, 2017) |
| " The time interval from ADP receptor blocker loading dosing to the blood sampling was similar in T2D and ND patients in both examinations." | 1.43 | The Impact of Type 2 Diabetes on the Efficacy of ADP Receptor Blockers in Patients with Acute ST Elevation Myocardial Infarction: A Pilot Prospective Study. ( Bolek, T; Fedor, M; Fedorová, J; Galajda, P; Kovář, F; Kubisz, P; Mokáň, M; Samoš, M; Stančiaková, L; Staško, J, 2016) |
| " We investigated if the effect of aspirin declined during the 24-hour dosing interval in patients with coronary artery disease and type 2 diabetes, and whether this correlated with increased platelet turnover." | 1.42 | Reduced antiplatelet effect of aspirin during 24 hours in patients with coronary artery disease and type 2 diabetes. ( Christensen, KH; Grove, EL; Hvas, AM; Kristensen, SD; Würtz, M, 2015) |
| "Metformin is the mainstay therapy for type 2 diabetes (T2D) and many patients also take salicylate-based drugs [i." | 1.42 | Metformin and salicylate synergistically activate liver AMPK, inhibit lipogenesis and improve insulin sensitivity. ( Blümer, RM; Bujak, AL; Crane, JD; Day, EA; Ford, RJ; Fullerton, MD; Gerstein, HC; Kemp, BE; Marcinko, K; Oakhill, JS; Pinkosky, SL; Scott, JW; Smith, BK; Steinberg, GR, 2015) |
| "目的：研究西格列汀对2型糖尿病(Type 2 diabetes mellitus，T2DM)患者阿司匹林抵抗(aspirin resistance，AR)的影响及其机制。方法：从136例T2DM患者选取68例AR患者，随机分成西格列汀组及二甲双胍组，入组前及治疗过程中检测空腹血糖(fasting plasma glucose，FPG)、糖化血红蛋白(glycated hemoglobin，HbAlc)、高敏C反应蛋白(high-sensitivity C reactive protein，hs-CRP)，治疗的第1，3，6，12个月分别检测二磷酸腺苷(adenosine diphosphate，ADP)及花生四烯酸(arachidonic acid，AA)诱导的血小板聚集率(platelet aggregation，PAG)，评价西格列汀对AR的影响。结果：经降糖治疗6个月后，两组患者FPG和HbAlc基本达标，降糖效果差异无统计学意义(P>0." | 1.42 | [Impact of sitagliptin on aspirin resistance in patients with Type 2 diabetes mellitus]. ( Chen, C; Li, L; Li, M; Li, Y; Ou, M; Xu, X, 2015) |
| "Aspirin resistance was measured with a whole-blood desktop platelet function analyzer (PFA-100) with an epinephrine agonist." | 1.40 | Aspirin resistance in patients with type II diabetes mellitus. ( Atmaca, M; Demir, C; Esen, R; Tasdemir, E; Toptas, T, 2014) |
| "Stent thrombosis is a morbid complication after percutaneous coronary intervention." | 1.40 | Clopidogrel resistance in diabetic patient with acute myocardial infarction due to stent thrombosis. ( Duraj, L; Fedor, M; Fedorová, J; Galajda, P; Kovář, F; Kubisz, P; Mokáň, M; Samoš, M; Šimonová, R; Staško, J, 2014) |
| "T2DM was associated with increased thrombus [14861 (8003 to 30161) vs 8908 (6812 to 11996), μ(2)/mm, median (IQR), p=0." | 1.40 | Differences in thrombus structure and kinetics in patients with type 2 diabetes mellitus after non ST elevation acute coronary syndrome. ( Badimon, JJ; Balasubramaniam, K; Marshall, SM; Viswanathan, GN; Zaman, AG, 2014) |
| "Aspirin resistance was measured in aspirin reaction units using VerifyNow(®)." | 1.40 | Non-HDL cholesterol is an independent risk factor for aspirin resistance in obese patients with type 2 diabetes. ( Ahn, KJ; Cho, JH; Choi, KM; Kang, JG; Kim, JD; Kim, JH; Lee, BW; Lee, KY; Mok, JO; Moon, MK; Park, CY; Park, JY; Park, SW, 2014) |
| "Bleeding was assessed using the Bleeding Academic Research Consortium criteria." | 1.40 | Prognostic value of bleeding after percutaneous coronary intervention in patients with diabetes. ( Byrne, RA; Kastrati, A; Laugwitz, KL; Ndrepepa, G; Neumann, FJ; Pache, J; Pöhler, A; Richardt, G; Schulz, S, 2014) |
| "Fibrinogen levels were elevated in T2DM (p< 0." | 1.40 | The influence of type 2 diabetes on fibrin clot properties in patients with coronary artery disease. ( Ajjan, RA; Grant, PJ; Grove, EL; Hvas, AM; Kristensen, SD; Kurdee, Z; Larsen, SB; Neergaard-Petersen, S; Phoenix, F, 2014) |
| "Inflammation is postulated to link obesity and benign prostatic hyperplasia (BPH)." | 1.39 | Body mass index predicts failure of surgical management in benign prostatic hyperplasia. ( Dick, CP; Edwards, J; Halbert, GL; Horgan, PG; Orange, C; Qayyum, T; Underwood, MA; Walker, VC; Willder, JM, 2013) |
| "Aspirin insensitivity was more common in type 2 diabetes (15% vs." | 1.38 | Platelet reactivity in type 2 diabetes mellitus: a comparative analysis with survivors of myocardial infarction and the role of glycaemic control. ( Agha, A; Carmody, D; Foley, DP; Kavanagh, GF; Kenny, D; Mylotte, D; O'Reilly, M; Peace, AJ; Smith, D; Tedesco, AF; Thompson, CJ, 2012) |
| " If cigarette smoking is associated with a dose-response effect on pharmacodynamic measures in clopidogrel-treated patients is unknown." | 1.38 | Cigarette smoking is associated with a dose-response effect in clopidogrel-treated patients with diabetes mellitus and coronary artery disease: results of a pharmacodynamic study. ( Angiolillo, DJ; Bass, TA; Capodanno, D; Capranzano, P; Charlton, RK; Desai, B; Dharmashankar, K; Ferreiro, JL; Kodali, M; Tello-Montoliu, A; Tomasello, SD; Ueno, M, 2012) |
| "Aspirin resistance has been described in some patient populations such as those with an acute coronary syndrome, ischemic stroke, percutaneous coronary intervention with drug-eluting stent, stent re-stenosis, and diabetes mellitus (DM)." | 1.38 | Effect of hypoglycemic drugs on aspirin resistance in patients with diabetes mellitus. ( Ariturk, Z; Cil, H; Elbey, MA; Gündüz, E; Islamoglu, Y; Kaya, H; Soydinc, S; Tekbas, E; Yavuz, C, 2012) |
| "When treated with aspirin, the patients showed a 49% reduction in the generation of CD34+/KDR+ cells, indicating that the level of circulating CD34+/KDR+ cells also relates to in vivo platelet activation." | 1.37 | Human CD34+/KDR+ cells are generated from circulating CD34+ cells after immobilization on activated platelets. ( de Boer, HC; de Koning, EJ; Hovens, MM; Huisman, MV; Rabelink, AJ; Snoep, JD; Tamsma, JT; van Oeveren-Rietdijk, AM; van Zonneveld, AJ, 2011) |
| "The model predicts the outcomes of type 2 diabetes along five disease paths (nephropathy, neuropathy, retinopathy, coronary heart disease, and stroke) from the time of diagnosis until age 94 years or until death." | 1.36 | Cost-effectiveness of aspirin use among persons with newly diagnosed type 2 diabetes. ( Barker, LE; Hoerger, TJ; Li, R; Zhang, P, 2010) |
| "Diabetic patients with CAD had significantly higher levels of both platelet aggregation and activation compared to non-diabetic patients with CAD despite treatment with the same dosage of aspirin." | 1.36 | Reduced platelet response to aspirin in patients with coronary artery disease and type 2 diabetes mellitus. ( Grove, EL; Hvas, AM; Kristensen, SD; Larsen, SB; Mortensen, SB, 2010) |
| "Patients with type 2 diabetes have reduced EPC and increased risk of cardiovascular disease (CVD), which is reduced by multifactorial intervention." | 1.36 | Multifactorial treatment increases endothelial progenitor cells in patients with type 2 diabetes. ( Billestrup, N; Jacobsen, PK; Lajer, M; Mandrup-Poulsen, T; Parving, HH; Pedersen, N; Reinhard, H; Rossing, P, 2010) |
| "The text of EMRs for 499 patients with type 2 diabetes was searched using NLP for evidence of aspirin use and its contraindications." | 1.36 | Automated processing of electronic medical records is a reliable method of determining aspirin use in populations at risk for cardiovascular events. ( Balasubramaniam, SC; Hanson, P; Pakhomov, SV; Shah, ND; Smith, SA, 2010) |
| "Women with CHD also had a higher rate of cerebral ischemia than did men (27." | 1.36 | Sex-specific differences in metabolic control, cardiovascular risk, and interventions in patients with type 2 diabetes mellitus. ( Gerhat, D; Handisurya, A; Hudson, S; Kamyar, MR; Kautzky-Willer, A; Lemmens-Gruber, R; Luger, A; Stemer, G, 2010) |
| "Diabetes and more specially type 2 diabetes are a major cardiovascular risk factor." | 1.36 | [Antiplatelet agents and diabetes mellitus]. ( Bal dit Sollier, C; Drouet, L; Henry, P, 2010) |
| "To evaluate the association between type 2 diabetes and newly reported Parkinson's disease." | 1.35 | Prospective cohort study of type 2 diabetes and the risk of Parkinson's disease. ( Buring, JE; Driver, JA; Gaziano, JM; Kurth, T; Logroscino, G; Smith, A, 2008) |
| "Obesity is associated with inflammation." | 1.35 | The effect of anti-inflammatory (aspirin and/or statin) therapy on body weight in Type 2 diabetic individuals: EAT, a retrospective study. ( Boaz, M; Lisy, L; Wainstein, J; Zandman-Goddard, G, 2009) |
| "A sample of 208 from 463 patients with type 2 diabetes aged 20-75 years with or without a history of ischaemic heart disease (IHD)." | 1.35 | Adherence to clinical guidelines in the prevention of coronary heart disease in type II diabetes mellitus. ( Hudson, SA; Johnson, BJ; Kamyar, M; Lemmens-Gruber, R; McAnaw, JJ, 2008) |
| "Aspirin was used in 64% of patients with CAD and in 28." | 1.35 | Control of cardiovascular risk factors and use of aspirin in diabetic patients remain elusive. ( Garg, P; Jeevanantham, V; Khan, A; Nautiyal, A; Reddy, PC; Shrivastava, R, 2008) |
| "328 patients with type 2 diabetes mellitus (mean age, 58." | 1.34 | Management outcomes of patients with type 2 diabetes: targeting the 10-year absolute risk of coronary heart disease. ( Phillipov, G; Phillips, PJ; Yong, TY, 2007) |
| "Aspirin treatment is effective in diabetic patients with cardiovascular disease and it does not significantly increase the risk of retinal haemorrhage, gastrointestinal bleeding or hemorrhagic stroke." | 1.33 | Use of antiplatelet therapy in a diabetic outpatient service of a large urban public hospital. ( Bruno, A; Dani, F; Degiovanni, M; Grassi, G; Maghenzani, G; Pagano, G, 2005) |
| "Aspirin responders were defined when closure time was > or =300 s." | 1.33 | Prevalence of aspirin resistance in patients with type 2 diabetes. ( Bocksch, W; Cabeza, N; Dietz, R; Ersel, S; Fateh-Moghadam, S; Gawaz, M; Htun, P; Plöckinger, U; Reuter, T, 2005) |
| "We report a case of type 2 diabetes mellitus presenting hypothyroidism due to overeating of seaweed that was noticed as a result of a discrepancy between glycated albumin (GA) and glycated hemoglobin (GHb)." | 1.33 | A case of type 2 diabetes mellitus developing hypothyroidism discovered as a result of a discrepancy between glycated hemoglobin and glycated albumin values. ( Arai, H; Hataya, Y; Hosoda, K; Kanamoto, N; Moriyama, K; Nakao, K; Nanbu, T, 2006) |
| " Thirty-eight healthy volunteers and 38 type 2 diabetic patients were enrolled to test the hypothesis that the enhanced plasma degradation and lowered bioavailability of ASA in diabetic patients is associated with the attenuation of platelet response." | 1.33 | Increased blood plasma hydrolysis of acetylsalicylic acid in type 2 diabetic patients: a role of plasma esterases. ( Bryszewska, M; Dolník, M; Gresner, P; Sikurová, L; Waczulíková, I; Watala, C, 2006) |
| "Aspirin resistance was not related to age, glycohemoglobin, total cholesterol, or a history of cardiovascular disease." | 1.33 | Comparison of aspirin resistance in type 1 versus type 2 diabetes mellitus. ( Aaronson, A; Abrahamson, M; Goldfine, AB; Mehta, SS; Silver, RJ, 2006) |
| " An independent endpoint review committee adjudicated all reported major adverse cardiovascular events, stent thromboses, and target-vessel revascularizations." | 1.33 | Safety of coronary sirolimus-eluting stents in daily clinical practice: one-year follow-up of the e-Cypher registry. ( Berge, C; Deme, M; Gershlick, AH; Guagliumi, G; Guyon, P; Lotan, C; Schofer, J; Seth, A; Sousa, JE; Stoll, HP; Urban, P; Wijns, W, 2006) |
| "But aspirin therapy was used in only 35 cases (32." | 1.33 | The rate of checking urine microalbumin and aspirin primary prevention in type 2 DM. ( Limpawattana, P; Mahankkanukrauh, A; Sawanyawisuth, K; Wongvipaporn, C, 2006) |
| "During follow-up 56 recurrences occurred, making a total of 110 episodes of vitreous haemorrhage in 79 eyes of 54 patients." | 1.32 | Does cardiovascular therapy affect the onset and recurrence of preretinal and vitreous haemorrhage in diabetic eye disease? ( Banerjee, S; Denniston, AK; Dodson, PM; Gibson, JM, 2004) |
| "This is the first study to show that type 2 diabetes in elderly men is related to COX-mediated inflammation, reflected by enhanced prostaglandin formation." | 1.32 | Association of type 2 diabetes with cyclooxygenase-mediated inflammation and oxidative stress in an elderly population. ( Basu, S; Helmersson, J; Larsson, A; Vessby, B, 2004) |
| "Aspirin is a safe, inexpensive, and readily available therapy that is effective for preventing cardiovascular disease, and patients with type 2 DM are particularly likely to benefit from such preventive therapy." | 1.32 | Underuse of aspirin in type 2 diabetes mellitus: prevalence and correlates of therapy in rural Canada. ( Guirguis, LM; Johnson, JA; Klinke, JA; Lee, TK; Lewanczuk, RZ; Majumdar, SR; Toth, EL, 2004) |
| "Aspirin was prescribed (18%) primarily by the cardiologist." | 1.32 | [Practical prevention and treatment of cardiovascular diseases in patients with diabetes mellitus type 2 in an endocrinological department]. ( Abirova, ES; Daurbekova, LV; Giliarevskiĭ, SR; Murzabekova, LI; Orlov, VA, 2004) |
| "Aspirin treatment also resulted in a approximately 20% reduction in basal rates of hepatic glucose production and a approximately 20% improvement in insulin-stimulated peripheral glucose uptake under matched plasma insulin concentrations during the clamp." | 1.31 | Mechanism by which high-dose aspirin improves glucose metabolism in type 2 diabetes. ( Hundal, RS; Inzucchi, S; Mayerson, AB; Petersen, KF; Randhawa, PS; Shoelson, SE; Shulman, GI, 2002) |
| "Treatment with aspirin was associated with a significant reduction in cardiac and total mortality among non-insulin-dependent diabetic patients with coronary artery disease." | 1.30 | Effects of aspirin treatment on survival in non-insulin-dependent diabetic patients with coronary artery disease. Israeli Bezafibrate Infarction Prevention Study Group. ( Behar, S; Boyko, V; Gottlieb, S; Graff, E; Harpaz, D; Kishon, Y, 1998) |
| "These data indicate that NIDDM is associated with increased plasma lipid peroxidation." | 1.29 | Plasma 8-epi-PGF2 alpha levels are elevated in individuals with non-insulin dependent diabetes mellitus. ( Anggård, EE; Betteridge, DJ; Gopaul, NK; Mallet, AI; Nourooz-Zadeh, J; Wolff, SP, 1995) |
| "PDS from patients with NIDDM showed less PSA prior to the clinical onset of diabetic vascular complications, such as retinopathy and proteinuria." | 1.28 | Abnormality in prostacyclin-stimulatory activity in sera from diabetics. ( Inoguchi, T; Kunisaki, M; Nawata, H; Ono, H; Umeda, F; Watanabe, J, 1989) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 10 (2.17) | 18.7374 |
| 1990's | 23 (4.99) | 18.2507 |
| 2000's | 156 (33.84) | 29.6817 |
| 2010's | 219 (47.51) | 24.3611 |
| 2020's | 53 (11.50) | 2.80 |
| Authors | Studies |
|---|---|
| Yelovitch, S | 1 |
| Barr, HM | 1 |
| Camden, J | 1 |
| Weisman, GA | 1 |
| Shai, E | 1 |
| Varon, D | 1 |
| Fischer, B | 1 |
| Babkov, DA | 1 |
| Zhukowskaya, ON | 1 |
| Borisov, AV | 1 |
| Babkova, VA | 1 |
| Sokolova, EV | 1 |
| Brigadirova, AA | 1 |
| Litvinov, RA | 1 |
| Kolodina, AA | 1 |
| Morkovnik, AS | 1 |
| Sochnev, VS | 1 |
| Borodkin, GS | 1 |
| Spasov, AA | 1 |
| Pistrosch, F | 1 |
| Matschke, JB | 1 |
| Schipp, D | 1 |
| Schipp, B | 1 |
| Henkel, E | 1 |
| Weigmann, I | 1 |
| Sradnick, J | 1 |
| Bornstein, SR | 1 |
| Birkenfeld, AL | 1 |
| Hanefeld, M | 2 |
| Santana-Mateos, M | 1 |
| Medina-Gil, JM | 1 |
| Saavedra-Santana, P | 1 |
| Martínez-Quintana, E | 1 |
| Rodríguez-González, F | 1 |
| Tugores, A | 1 |
| Baumann, R | 1 |
| Retnam, R | 1 |
| Hernandez, CM | 1 |
| Edwards, V | 1 |
| Ryan, M | 2 |
| Gao, B | 1 |
| Gao, W | 1 |
| Wan, H | 1 |
| Xu, F | 1 |
| Zhou, R | 1 |
| Zhang, X | 2 |
| Ji, Q | 1 |
| Theilen, LH | 1 |
| Greenland, P | 1 |
| Varagic, J | 1 |
| Catov, J | 1 |
| Shanks, A | 1 |
| Thorsten, V | 1 |
| Parker, CB | 1 |
| McNeil, R | 1 |
| Mercer, B | 1 |
| Hoffman, M | 1 |
| Wapner, R | 1 |
| Haas, D | 1 |
| Simhan, H | 1 |
| Grobman, W | 1 |
| Chung, JH | 1 |
| Levine, LD | 1 |
| Barnes, S | 1 |
| Bairey Merz, N | 1 |
| Saade, G | 1 |
| Silver, RM | 1 |
| Matsumoto, C | 4 |
| Ogawa, H | 14 |
| Saito, Y | 12 |
| Okada, S | 9 |
| Soejima, H | 11 |
| Sakuma, M | 8 |
| Masuda, I | 4 |
| Nakayama, M | 10 |
| Doi, N | 9 |
| Jinnouchi, H | 10 |
| Waki, M | 9 |
| Morimoto, T | 12 |
| Lin, X | 1 |
| Chen, Y | 1 |
| Lu, W | 1 |
| Li, J | 2 |
| Fu, L | 1 |
| Yin, J | 1 |
| Ren, M | 1 |
| Yan, L | 2 |
| Yang, C | 1 |
| Hong, S | 2 |
| Lee, WJ | 1 |
| Park, CY | 2 |
| Steg, PG | 7 |
| Bhatt, DL | 8 |
| James, SK | 1 |
| Darlington, O | 1 |
| Hoskin, L | 1 |
| Simon, T | 5 |
| Fox, KM | 1 |
| Leiter, LA | 6 |
| Mehta, SR | 5 |
| Harrington, RA | 5 |
| Himmelmann, A | 4 |
| Ridderstråle, W | 4 |
| Andersson, M | 3 |
| Bueno, H | 3 |
| De Luca, L | 1 |
| Tank, A | 1 |
| Mellström, C | 2 |
| McEwan, P | 1 |
| Verma, S | 1 |
| Eikelboom, JW | 1 |
| Al-Omran, M | 1 |
| Choi, R | 1 |
| Heffernan, M | 1 |
| Teoh, H | 3 |
| Su, YJ | 1 |
| Leong, PY | 1 |
| Wang, YH | 1 |
| Wei, JC | 1 |
| Sohn, M | 1 |
| Chun, EJ | 2 |
| Lim, S | 2 |
| Reamy, BV | 1 |
| Viera, AJ | 1 |
| Chaudhary, R | 1 |
| Sharma, T | 1 |
| Tantry, US | 3 |
| Asgar, JA | 1 |
| Kundan, P | 1 |
| Duhan, S | 1 |
| Gill, H | 1 |
| Singh, A | 1 |
| Alasadi, Y | 1 |
| Gurbel, PA | 3 |
| Bliden, KP | 3 |
| Huang, HY | 1 |
| Lu, TW | 1 |
| Liang, HL | 1 |
| Hsu, WH | 1 |
| Sung, YW | 1 |
| Lee, MY | 1 |
| Sonday, F | 1 |
| Bheekie, A | 1 |
| Van Huyssteen, M | 1 |
| Abtan, J | 1 |
| Elbez, Y | 1 |
| Ducrocq, G | 1 |
| Goto, S | 2 |
| Smith, SC | 1 |
| Ohman, EM | 2 |
| Eagle, KA | 1 |
| Fox, K | 4 |
| Petrov, I | 1 |
| Sinnaeve, PR | 1 |
| Pais, P | 1 |
| Lev, E | 1 |
| Wilson, P | 1 |
| Shami, JJP | 3 |
| Yan, VKC | 3 |
| Wei, Y | 3 |
| Alwafi, H | 3 |
| Blais, JE | 3 |
| Wan, E | 3 |
| Wong, CKH | 3 |
| Cheung, KS | 3 |
| Leung, WK | 3 |
| Wong, MCS | 3 |
| Wong, ICK | 3 |
| Chan, EW | 3 |
| Zhang, J | 3 |
| Zhang, Q | 3 |
| Zhao, K | 3 |
| Bian, YJ | 3 |
| Liu, Y | 5 |
| Xue, YT | 3 |
| Simeone, P | 1 |
| Liani, R | 3 |
| Tripaldi, R | 1 |
| Ciotti, S | 1 |
| Recchiuti, A | 1 |
| Abbonante, V | 1 |
| Porro, B | 1 |
| Del Boccio, P | 1 |
| Di Castelnuovo, A | 2 |
| Lanuti, P | 1 |
| Camera, M | 1 |
| Pieragostino, D | 1 |
| Lee-Sundlov, M | 1 |
| Luongo, M | 1 |
| Auciello, R | 1 |
| Bologna, G | 1 |
| Cufaro, MC | 1 |
| Tremoli, E | 1 |
| Hoffmeister, KM | 1 |
| Cipollone, F | 3 |
| Balduini, A | 1 |
| Santilli, F | 7 |
| Demirci, E | 1 |
| Celik, O | 1 |
| Cil, C | 1 |
| Tanık, VO | 1 |
| Memic Sancar, K | 1 |
| Orscelik, O | 1 |
| Resulzade, MM | 1 |
| Kaya, C | 1 |
| Kırıs, T | 1 |
| Dogan, V | 1 |
| Basaran, O | 1 |
| Orchard, SG | 1 |
| Lockery, JE | 1 |
| Broder, JC | 1 |
| Ernst, ME | 1 |
| Espinoza, S | 1 |
| Gibbs, P | 1 |
| Wolfe, R | 1 |
| Polekhina, G | 1 |
| Zoungas, S | 1 |
| Loomans-Kropp, HA | 1 |
| Woods, RL | 2 |
| Zhang, L | 1 |
| Ji, X | 1 |
| Chen, J | 2 |
| Zhu, Y | 2 |
| Wang, Z | 1 |
| Ma, Z | 1 |
| Wu, Y | 1 |
| Wu, F | 1 |
| Zheng, Z | 1 |
| Verma, SK | 1 |
| Kalra, S | 1 |
| Do, NC | 1 |
| Vestgaard, M | 1 |
| Nørgaard, SK | 1 |
| Damm, P | 2 |
| Mathiesen, ER | 2 |
| Ringholm, L | 2 |
| Foer, D | 1 |
| Amin, T | 1 |
| Nagai, J | 1 |
| Tani, Y | 1 |
| Feng, C | 1 |
| Liu, T | 2 |
| Newcomb, DC | 1 |
| Lai, J | 1 |
| Hayashi, H | 1 |
| Snyder, WE | 1 |
| McGill, A | 1 |
| Lin, A | 1 |
| Laidlaw, TM | 1 |
| Niswender, KD | 1 |
| Boyce, JA | 1 |
| Cahill, KN | 1 |
| Held, C | 2 |
| Leonsson-Zachrisson, M | 1 |
| Opolski, G | 13 |
| Zateyshchikov, D | 1 |
| Ge, J | 2 |
| Nicolau, JC | 1 |
| Corbalán, R | 1 |
| Cornel, JH | 2 |
| Widimský, P | 2 |
| Rosberg, V | 1 |
| Grove, EL | 11 |
| Bøtker, HE | 1 |
| Kristensen, SD | 8 |
| Pareek, M | 1 |
| Bako, HY | 1 |
| Ibrahim, MA | 1 |
| Isah, MS | 1 |
| Ibrahim, S | 1 |
| Jung, M | 1 |
| Lee, S | 1 |
| Paven, E | 1 |
| Dillinger, JG | 2 |
| Bal Dit Sollier, C | 3 |
| Vidal-Trecan, T | 1 |
| Berge, N | 1 |
| Dautry, R | 1 |
| Gautier, JF | 1 |
| Drouet, L | 3 |
| Riveline, JP | 1 |
| Henry, P | 3 |
| Jiang, M | 1 |
| Li, P | 1 |
| You, JH | 1 |
| Zheng, X | 1 |
| Deng, J | 1 |
| Zhao, M | 1 |
| Feng, L | 1 |
| Fang, Y | 1 |
| Luo, Y | 1 |
| Gao, X | 1 |
| Yang, W | 2 |
| Zou, X | 1 |
| Zhou, X | 1 |
| Ji, L | 1 |
| Kyyak, YH | 1 |
| Barnett, OY | 1 |
| Halkevych, MP | 1 |
| Labinska, OY | 1 |
| Kyyak, HY | 1 |
| Kysil, OY | 1 |
| Chabior, A | 1 |
| Pordzik, J | 2 |
| Mirowska-Guzel, D | 4 |
| Postuła, M | 3 |
| Parker, WAE | 1 |
| Schulte, C | 1 |
| Barwari, T | 1 |
| Phoenix, F | 2 |
| Pearson, SM | 1 |
| Mayr, M | 2 |
| Grant, PJ | 2 |
| Storey, RF | 1 |
| Ajjan, RA | 2 |
| Rocca, B | 3 |
| Patrono, C | 6 |
| Raco, DL | 1 |
| Castro Dos Santos, NC | 1 |
| Andere, NMRB | 1 |
| Araujo, CF | 1 |
| de Marco, AC | 1 |
| Kantarci, A | 1 |
| Van Dyke, TE | 1 |
| Santamaria, MP | 1 |
| Koziolova, NA | 1 |
| Karavaev, PG | 1 |
| Veklich, AS | 1 |
| Nyambuya, TM | 1 |
| Dludla, PV | 1 |
| Mxinwa, V | 1 |
| Mokgalaboni, K | 1 |
| Ngcobo, SR | 1 |
| Tiano, L | 1 |
| Nkambule, BB | 1 |
| Holub, A | 2 |
| Mousa, S | 2 |
| Abdolahi, A | 4 |
| Godugu, K | 1 |
| Tu, XM | 2 |
| Brenna, JT | 4 |
| Block, RC | 4 |
| Pafundi, PC | 1 |
| Galiero, R | 1 |
| Caturano, A | 1 |
| Acierno, C | 1 |
| de Sio, C | 1 |
| Vetrano, E | 1 |
| Nevola, R | 1 |
| Gelso, A | 1 |
| Bono, V | 1 |
| Costagliola, C | 1 |
| Marfella, R | 2 |
| Sardu, C | 1 |
| Rinaldi, L | 1 |
| Salvatore, T | 1 |
| Adinolfi, LE | 1 |
| Sasso, FC | 2 |
| Hameed, AB | 1 |
| Combs, CA | 1 |
| Batais, MA | 1 |
| Almutairi, KM | 1 |
| Almigbal, TH | 1 |
| Alodhayani, A | 1 |
| Alonazi, WB | 1 |
| Vinluan, JM | 1 |
| Asnar, JB | 1 |
| Salem, RE | 1 |
| Aljubab, RA | 1 |
| Simon, TG | 1 |
| Chan, AT | 1 |
| Yuan, JH | 1 |
| Xie, QS | 1 |
| Chen, GC | 1 |
| Huang, CL | 1 |
| Yu, T | 1 |
| Chen, QK | 1 |
| Li, JY | 1 |
| Finnegan, C | 1 |
| Breathnach, FM | 1 |
| Bryk, AH | 1 |
| Zettl, K | 1 |
| Wiśniewski, JR | 1 |
| Undas, A | 1 |
| Wittbrodt, E | 1 |
| Bhalla, N | 1 |
| Sundell, KA | 1 |
| Hunt, P | 1 |
| Wong, ND | 1 |
| Kuster, M | 1 |
| Liang, PS | 1 |
| Shaukat, A | 1 |
| Crockett, SD | 1 |
| Kalashnikov, VY | 1 |
| Michurova, MS | 1 |
| Tervonen, T | 1 |
| Vora, P | 1 |
| Seo, J | 1 |
| Krucien, N | 1 |
| Marsh, K | 1 |
| De Caterina, R | 1 |
| Wissinger, U | 1 |
| Soriano Gabarró, M | 1 |
| McGuire, DK | 6 |
| Lev, EI | 1 |
| Kiss, RG | 1 |
| Dalby, AJ | 1 |
| Prats, J | 1 |
| Lee, JJ | 1 |
| Amerena, J | 1 |
| Kosiborod, MN | 1 |
| de Lusignan, S | 1 |
| Hinton, W | 1 |
| Seidu, S | 1 |
| Mathew, M | 1 |
| Feher, MD | 1 |
| Munro, N | 1 |
| Joy, M | 1 |
| Carinci, F | 1 |
| Hobbs, FDR | 1 |
| Khunti, K | 2 |
| Tan, SY | 1 |
| Cronin, H | 1 |
| Byrne, S | 1 |
| O'Donovan, A | 1 |
| Tuthill, A | 2 |
| Guo, X | 1 |
| Li, X | 1 |
| Liao, W | 1 |
| Shen, JZ | 1 |
| Ai, W | 1 |
| Pan, Q | 1 |
| Sun, Y | 2 |
| Zhang, K | 1 |
| Zhang, R | 1 |
| Qiu, Y | 1 |
| Dai, Q | 1 |
| Zheng, H | 1 |
| Guo, S | 1 |
| Batista, DV | 1 |
| Hueb, W | 2 |
| Lima, EG | 2 |
| Rezende, PC | 2 |
| Garzillo, CL | 2 |
| Garcia, RMR | 1 |
| Filho, JPPL | 1 |
| Martins, EB | 1 |
| Junior, CVS | 1 |
| Ramires, JAF | 1 |
| Filho, RK | 1 |
| Korytkowski, MT | 1 |
| Forman, DE | 1 |
| Hsu, CH | 1 |
| Yu, SM | 1 |
| Lau, SC | 1 |
| Chen, YL | 1 |
| Pei, D | 1 |
| Liu, IC | 1 |
| Tolcher, MC | 1 |
| Chu, DM | 1 |
| Hollier, LM | 1 |
| Mastrobattista, JM | 1 |
| Racusin, DA | 1 |
| Ramin, SM | 1 |
| Sangi-Haghpeykar, H | 1 |
| Aagaard, KM | 1 |
| Skolnik, N | 1 |
| Jaffa, FM | 1 |
| Kalyani, RR | 2 |
| Johnson, E | 1 |
| Shubrook, JH | 1 |
| Ahmed, SB | 1 |
| Metcalfe, A | 1 |
| Nerenberg, K | 1 |
| Russo, I | 1 |
| Penna, C | 1 |
| Musso, T | 1 |
| Popara, J | 1 |
| Alloatti, G | 1 |
| Cavalot, F | 1 |
| Pagliaro, P | 1 |
| Ovrakh, T | 1 |
| Serik, S | 1 |
| Kochubiei, O | 1 |
| Li, R | 2 |
| Tang, X | 1 |
| Jing, Q | 1 |
| Wang, Q | 1 |
| Yang, M | 1 |
| Han, X | 1 |
| Zhao, J | 1 |
| Yu, X | 1 |
| Cerit, L | 1 |
| Duygu, H | 1 |
| Şen, S | 1 |
| Çelik, S | 1 |
| Violi, F | 4 |
| Targher, G | 1 |
| Vestri, A | 1 |
| Carnevale, R | 2 |
| Averna, M | 2 |
| Farcomeni, A | 1 |
| Lenzi, A | 1 |
| Angelico, F | 2 |
| Pastori, D | 1 |
| Pagidipati, NJ | 1 |
| Navar, AM | 1 |
| Pieper, KS | 1 |
| Green, JB | 2 |
| Bethel, MA | 3 |
| Armstrong, PW | 1 |
| Josse, RG | 1 |
| Lokhnygina, Y | 2 |
| Halvorsen, S | 1 |
| Strandberg, TE | 1 |
| Delibasi, T | 1 |
| Holman, RR | 5 |
| Peterson, ED | 3 |
| Lee, KY | 2 |
| Hwang, BH | 1 |
| Kim, TH | 1 |
| Kim, CJ | 1 |
| Kim, JJ | 1 |
| Choo, EH | 1 |
| Choi, IJ | 2 |
| Choi, Y | 1 |
| Park, HW | 1 |
| Koh, YS | 1 |
| Kim, PJ | 1 |
| Lee, JM | 1 |
| Kim, MJ | 1 |
| Jeon, DS | 1 |
| Cho, JH | 2 |
| Jung, JI | 1 |
| Seung, KB | 1 |
| Chang, K | 1 |
| Wiernek, SL | 1 |
| Cavender, MA | 1 |
| Milionis, H | 1 |
| Ntaios, G | 1 |
| Papavasileiou, V | 1 |
| Spengos, K | 1 |
| Manios, E | 1 |
| Elisaf, M | 1 |
| Vemmos, K | 1 |
| Gillani, SW | 1 |
| Sulaiman, SAS | 1 |
| Abdul, MIM | 1 |
| Baig, MR | 1 |
| Aboyans, V | 1 |
| Desormais, I | 1 |
| Jarlan, L | 1 |
| Teissier, MP | 1 |
| Lacroix, P | 1 |
| Mousa, SA | 2 |
| Oda, MN | 1 |
| Shang, LL | 1 |
| Guo, DD | 1 |
| Zhao, HY | 1 |
| Quan, AJ | 1 |
| Cao, PG | 1 |
| Vernstrøm, L | 2 |
| Funck, KL | 2 |
| Laugesen, E | 2 |
| Baier, JM | 2 |
| Hvas, AM | 9 |
| Poulsen, PL | 2 |
| Zuo, HJ | 1 |
| Wang, WH | 1 |
| Deng, LQ | 1 |
| Su, JL | 1 |
| Sultan, M | 1 |
| Twito, O | 1 |
| Tohami, T | 1 |
| Ramati, E | 1 |
| Neumark, E | 1 |
| Rashid, G | 1 |
| Schlögl, M | 1 |
| Hofmänner, D | 1 |
| Manka, R | 1 |
| Keller, DI | 1 |
| Grenier, J | 1 |
| Langer, A | 1 |
| Goldin, L | 1 |
| Connelly, KA | 1 |
| Cheng, AYY | 1 |
| Tan, MK | 1 |
| Fitchett, D | 1 |
| Goodman, SG | 1 |
| Yan, AT | 1 |
| Bouida, W | 1 |
| Beltaief, K | 1 |
| Baccouche, H | 1 |
| Sassi, M | 1 |
| Dridi, Z | 1 |
| Trabelsi, I | 1 |
| Laaouiti, K | 1 |
| Chakroun, T | 1 |
| Hellara, I | 1 |
| Boukef, R | 1 |
| Sakly, N | 1 |
| Hassine, M | 1 |
| Added, F | 1 |
| Razgallah, R | 1 |
| Najjar, F | 1 |
| Nouira, S | 1 |
| Tseng, CH | 1 |
| Foster, JG | 1 |
| Wood, SK | 1 |
| Pfeffer, MA | 1 |
| DeMets, DL | 1 |
| Garber, A | 1 |
| Hennekens, CH | 2 |
| Harrison, P | 3 |
| Kennedy, I | 2 |
| Dinsdale, R | 1 |
| Coleman, R | 1 |
| Bonaventura, A | 1 |
| Liberale, L | 1 |
| Montecucco, F | 1 |
| Rosenson, RS | 2 |
| Chen, Q | 1 |
| Najera, SD | 1 |
| Lee, ML | 1 |
| Cho, DJ | 1 |
| Zhang, XL | 1 |
| Fu, HJ | 1 |
| Yang, GR | 1 |
| Wan, G | 1 |
| Li, D | 1 |
| Zhu, LX | 1 |
| Xie, RR | 1 |
| Lv, YJ | 1 |
| Zhang, JD | 1 |
| Li, YL | 1 |
| Dai, QF | 1 |
| Ji, Y | 1 |
| Gao, DY | 1 |
| Cui, XL | 1 |
| Liu, DY | 1 |
| Yuan, SY | 1 |
| Yuan, MX | 1 |
| Al-Sofiani, ME | 1 |
| Yanek, LR | 1 |
| Faraday, N | 1 |
| Kral, BG | 1 |
| Mathias, R | 1 |
| Becker, LC | 1 |
| Becker, DM | 1 |
| Vaidya, D | 1 |
| Uemura, S | 6 |
| Sugiyama, S | 5 |
| Abi Khalil, C | 1 |
| Omar, OM | 1 |
| Al Suwaidi, J | 1 |
| Taheri, S | 1 |
| Berkelmans, GFN | 1 |
| Gudbjörnsdottir, S | 1 |
| Visseren, FLJ | 1 |
| Wild, SH | 1 |
| Franzen, S | 1 |
| Chalmers, J | 1 |
| Davis, BR | 1 |
| Poulter, NR | 1 |
| Spijkerman, AM | 1 |
| Woodward, M | 1 |
| Pressel, SL | 1 |
| Gupta, AK | 1 |
| van der Schouw, YT | 1 |
| Svensson, AM | 1 |
| van der Graaf, Y | 2 |
| Read, SH | 1 |
| Eliasson, B | 1 |
| Dorresteijn, JAN | 1 |
| Egan, AM | 1 |
| Brassill, MJ | 1 |
| Brosnan, E | 1 |
| Carmody, L | 1 |
| Clarke, H | 1 |
| Coogan Kelly, C | 1 |
| Culliney, L | 1 |
| Durkan, M | 1 |
| Fenlon, M | 1 |
| Ferry, P | 1 |
| Hanlon, G | 1 |
| Higgins, T | 1 |
| Hoashi, S | 1 |
| Khamis, A | 1 |
| Kinsley, B | 1 |
| Kinsley, T | 1 |
| Kirwan, B | 1 |
| Liew, A | 1 |
| McGurk, C | 2 |
| McHugh, C | 1 |
| Murphy, MS | 1 |
| Murphy, P | 1 |
| O'Halloran, D | 1 |
| O'Mahony, L | 1 |
| O'Sullivan, E | 1 |
| Nolan, M | 1 |
| Peter, M | 1 |
| Roberts, G | 1 |
| Smyth, A | 1 |
| Todd, M | 1 |
| Wan Mahmood, WA | 1 |
| Yousif, O | 1 |
| P Dunne, F | 1 |
| Çakır, H | 2 |
| Kaymaz, C | 1 |
| Tanboga, İH | 1 |
| Tokgöz, HC | 1 |
| Hakgör, A | 1 |
| Akbal, ÖY | 1 |
| Er, F | 1 |
| Topal, D | 1 |
| Mutluer, FO | 1 |
| Demir, M | 1 |
| Tenekecioglu, E | 1 |
| López-Jaramillo, P | 1 |
| Barbosa, E | 1 |
| Molina, DI | 1 |
| Sanchez, R | 1 |
| Diaz, M | 1 |
| Camacho, PA | 1 |
| Lanas, F | 1 |
| Pasquel, M | 1 |
| Accini, JL | 1 |
| Ponte-Negretti, CI | 1 |
| Alcocer, L | 1 |
| Cobos, L | 1 |
| Wyss, F | 1 |
| Sebba-Barroso, W | 1 |
| Coca, A | 1 |
| Zanchetti, A | 1 |
| Tsujimoto, T | 1 |
| Kajio, H | 1 |
| Gullaksen, S | 1 |
| Nam, M | 1 |
| Little, BB | 1 |
| Paik, S | 1 |
| Lee, K | 1 |
| Woo, J | 1 |
| Kim, D | 1 |
| Kang, J | 1 |
| Chun, M | 1 |
| Park, Y | 1 |
| Guimarães, PO | 1 |
| Stevens, SR | 1 |
| Lopes, RD | 1 |
| Barbarash, OL | 1 |
| Kashtalap, VV | 1 |
| Zykov, MV | 1 |
| Hryachkova, ON | 1 |
| Shibanova, IA | 1 |
| Sharma, AN | 1 |
| Deyell, JS | 1 |
| Sharma, SN | 1 |
| Barseghian, A | 1 |
| Cheng, F | 1 |
| Li, W | 1 |
| Zhou, Y | 1 |
| Shen, J | 1 |
| Lee, PW | 1 |
| Tang, Y | 1 |
| Postula, M | 10 |
| Janicki, PK | 8 |
| Rosiak, M | 12 |
| Przybylkowski, A | 1 |
| Kaplon-Cieslicka, A | 9 |
| Grygorowicz, T | 1 |
| Trzepla, E | 8 |
| Filipiak, KJ | 12 |
| Czlonkowski, A | 6 |
| Wieczorek, P | 1 |
| Parma, R | 1 |
| Tendera, M | 1 |
| Wojakowski, W | 1 |
| Smith, B | 1 |
| Meednu, N | 1 |
| Thevenet-Morrison, K | 1 |
| Cai, X | 1 |
| Cui, H | 1 |
| Georas, S | 2 |
| Karolczak, K | 1 |
| Kamysz, W | 1 |
| Karafova, A | 1 |
| Drzewoski, J | 4 |
| Watala, C | 6 |
| Kimura, Y | 1 |
| Takano, K | 1 |
| Satoh, K | 1 |
| Aida, K | 1 |
| Kobayashi, T | 1 |
| Ozaki, Y | 1 |
| Kondracka, A | 6 |
| Kosior, DA | 5 |
| Kanauchi, M | 4 |
| Kapłon-Cieślicka, A | 3 |
| Członkowski, A | 1 |
| Araki, S | 1 |
| Matsuno, H | 1 |
| Haneda, M | 1 |
| Koya, D | 1 |
| Kanno, Y | 1 |
| Kume, S | 1 |
| Isshiki, K | 1 |
| Araki, H | 1 |
| Ugi, S | 1 |
| Kawai, H | 1 |
| Kashiwagi, A | 1 |
| Uzu, T | 1 |
| Maegawa, H | 1 |
| Zaremba, M | 2 |
| Serafin, A | 2 |
| Tasdemir, E | 2 |
| Toptas, T | 2 |
| Demir, C | 2 |
| Esen, R | 2 |
| Atmaca, M | 2 |
| Fatima, N | 1 |
| Pingali, U | 1 |
| Muralidhar, N | 1 |
| Gonçalves, LH | 3 |
| Silva, MV | 1 |
| Duarte, RC | 2 |
| Dusse, LM | 3 |
| Fernandes, AP | 3 |
| Bosco, AA | 3 |
| Gomes, KB | 2 |
| Carvalho, Md | 2 |
| Raghavan, RP | 1 |
| Laight, DW | 1 |
| Cummings, MH | 1 |
| Nomura, K | 1 |
| Cubero Gómez, JM | 1 |
| Navarro Puerto, MA | 1 |
| Acosta Martínez, J | 1 |
| De Mier Barragán, MI | 1 |
| Pérez Santigosa, PL | 1 |
| Sánchez Burguillos, F | 1 |
| Molano Casimiro, F | 1 |
| Pastor Torres, L | 1 |
| Samoš, M | 2 |
| Šimonová, R | 1 |
| Kovář, F | 2 |
| Duraj, L | 1 |
| Fedorová, J | 2 |
| Galajda, P | 2 |
| Staško, J | 2 |
| Fedor, M | 2 |
| Kubisz, P | 2 |
| Mokáň, M | 2 |
| Joseph, JJ | 1 |
| Golden, SH | 1 |
| Viswanathan, GN | 2 |
| Marshall, SM | 3 |
| Balasubramaniam, K | 2 |
| Badimon, JJ | 4 |
| Zaman, AG | 3 |
| Kim, JD | 1 |
| Ahn, KJ | 1 |
| Choi, KM | 1 |
| Kang, JG | 1 |
| Kim, JH | 2 |
| Lee, BW | 1 |
| Mok, JO | 1 |
| Moon, MK | 1 |
| Park, JY | 1 |
| Park, SW | 1 |
| Łabuz-Roszak, B | 1 |
| Pierzchała, K | 1 |
| Tyrpień, K | 1 |
| Ndrepepa, G | 1 |
| Schulz, S | 1 |
| Neumann, FJ | 1 |
| Laugwitz, KL | 1 |
| Richardt, G | 1 |
| Byrne, RA | 1 |
| Pöhler, A | 1 |
| Kastrati, A | 1 |
| Pache, J | 1 |
| Christensen, KH | 1 |
| Würtz, M | 2 |
| Sirois, C | 2 |
| Moisan, J | 2 |
| Poirier, P | 2 |
| Grégoire, JP | 2 |
| Yalcinkaya, E | 1 |
| Celik, M | 1 |
| Grimaldi, R | 1 |
| Bisi, M | 1 |
| Lonni, E | 1 |
| Beggiato, E | 1 |
| Valpreda, A | 1 |
| Lococo, MF | 1 |
| Dosio, E | 1 |
| Presutti, DG | 1 |
| Tagliabue, M | 1 |
| Gaita, F | 1 |
| Lattanzio, S | 2 |
| Vazzana, N | 2 |
| Ueland, T | 1 |
| Di Fulvio, P | 1 |
| Formoso, G | 1 |
| Consoli, A | 2 |
| Aukrust, P | 1 |
| Davì, G | 9 |
| Tassone, EJ | 1 |
| Perticone, M | 1 |
| Sciacqua, A | 1 |
| Mafrici, SF | 1 |
| Settino, C | 1 |
| Malara, N | 1 |
| Mollace, V | 1 |
| Sesti, G | 1 |
| Perticone, F | 1 |
| Pagano, A | 1 |
| Porta, G | 1 |
| Signoriello, G | 1 |
| Lascar, N | 1 |
| Minutolo, R | 1 |
| Carbonara, O | 1 |
| Persico, M | 1 |
| Piscione, F | 1 |
| De Nicola, L | 1 |
| Torella, R | 1 |
| Paolisso, G | 2 |
| Peller, M | 2 |
| Neergaard-Petersen, S | 4 |
| Larsen, SB | 5 |
| Kurdee, Z | 1 |
| Angiolillo, DJ | 13 |
| Jakubowski, JA | 2 |
| Ferreiro, JL | 7 |
| Tello-Montoliu, A | 6 |
| Rollini, F | 2 |
| Franchi, F | 1 |
| Ueno, M | 6 |
| Darlington, A | 2 |
| Desai, B | 7 |
| Moser, BA | 1 |
| Sugidachi, A | 1 |
| Guzman, LA | 4 |
| Bass, TA | 9 |
| Fosmire Rundgren, EW | 2 |
| Anderson, SL | 2 |
| Marrs, JC | 2 |
| Campos, FM | 1 |
| Filho, OA | 1 |
| Alves, MT | 2 |
| Borges, KB | 1 |
| Faria, MC | 1 |
| Gonçalves, GS | 1 |
| Sandrim, VC | 1 |
| Carvalho, MG | 1 |
| Miyares, MA | 1 |
| Davis, KA | 1 |
| Lapenna, D | 1 |
| La Barba, S | 1 |
| Tu, X | 1 |
| Georas, SN | 1 |
| Phipps, RP | 1 |
| Lawrence, P | 1 |
| Elwakeel, NM | 1 |
| Hazaa, HH | 1 |
| Petrone, AB | 1 |
| Sesso, HD | 2 |
| Gaziano, JM | 3 |
| Djoussé, L | 1 |
| Yogarajah, M | 1 |
| Sivasambu, B | 1 |
| Jaffe, EA | 1 |
| Ford, RJ | 1 |
| Fullerton, MD | 1 |
| Pinkosky, SL | 1 |
| Day, EA | 1 |
| Scott, JW | 1 |
| Oakhill, JS | 1 |
| Bujak, AL | 1 |
| Smith, BK | 1 |
| Crane, JD | 1 |
| Blümer, RM | 1 |
| Marcinko, K | 1 |
| Kemp, BE | 1 |
| Gerstein, HC | 1 |
| Steinberg, GR | 1 |
| Barbieri, L | 1 |
| Verdoia, M | 1 |
| Schaffer, A | 1 |
| Marino, P | 1 |
| De Luca, G | 1 |
| Eliraqi, GM | 1 |
| Vistisen, D | 2 |
| Lauritzen, T | 2 |
| Sandbaek, A | 1 |
| Jørgensen, ME | 1 |
| Faerch, K | 1 |
| Parhofer, KG | 1 |
| Sourij, H | 1 |
| Tucker, L | 1 |
| White, S | 1 |
| Hill, L | 1 |
| Oulhaj, A | 1 |
| Coleman, RL | 1 |
| den Ouden, H | 1 |
| Berends, J | 1 |
| Stellato, RK | 1 |
| Beulens, JW | 1 |
| Rutten, GE | 1 |
| Gregersen, S | 2 |
| Kim, YI | 1 |
| Kim, SY | 1 |
| Lee, JH | 1 |
| Kim, YW | 1 |
| Ryu, KW | 1 |
| Park, JH | 1 |
| Amiri, L | 1 |
| John, A | 1 |
| Shafarin, J | 1 |
| Adeghate, E | 1 |
| Jayaprakash, P | 1 |
| Yasin, J | 1 |
| Howarth, FC | 1 |
| Raza, H | 1 |
| Derosa, G | 1 |
| Mugellini, A | 1 |
| Pesce, RM | 1 |
| D'Angelo, A | 1 |
| Maffioli, P | 1 |
| Pignatelli, P | 2 |
| Luo, G | 1 |
| He, J | 1 |
| Wu, T | 1 |
| Huang, Y | 1 |
| Miao, Z | 1 |
| Zhao, Z | 1 |
| Wang, X | 1 |
| Wang, Y | 1 |
| Bundhun, PK | 1 |
| Qin, T | 1 |
| Chen, MH | 1 |
| Eyileten, C | 2 |
| Sugino, S | 1 |
| Wilimski, R | 1 |
| Li, Y | 1 |
| Li, L | 1 |
| Ou, M | 1 |
| Xu, X | 1 |
| Li, M | 1 |
| Chen, C | 1 |
| Grimes, RT | 1 |
| Ensor, J | 1 |
| Bennett, K | 1 |
| Henman, MC | 1 |
| Liu, TF | 1 |
| Zhang, JW | 1 |
| Chen, XH | 1 |
| Feng, XR | 1 |
| Bai, ZS | 1 |
| Liu, ML | 1 |
| Cudna, A | 1 |
| Dimitriu-Leen, AC | 1 |
| Scholte, AJ | 1 |
| van Rosendael, AR | 1 |
| van den Hoogen, IJ | 1 |
| Kharagjitsingh, AV | 1 |
| Wolterbeek, R | 1 |
| Knuuti, J | 1 |
| Kroft, LJ | 1 |
| Delgado, V | 1 |
| Jukema, JW | 1 |
| de Graaf, MA | 1 |
| Bax, JJ | 1 |
| Akai, Y | 2 |
| Ishii, H | 1 |
| Zhang, D | 1 |
| Liu, D | 2 |
| Cai, W | 1 |
| Yan, C | 1 |
| Han, Y | 1 |
| Becerra, AZ | 1 |
| Hopke, PK | 1 |
| Kane, C | 1 |
| Chalupa, D | 1 |
| Frampton, MW | 1 |
| Block, R | 1 |
| Rich, DQ | 1 |
| Chiva-Blanch, G | 1 |
| Suades, R | 1 |
| Padró, T | 1 |
| Vilahur, G | 1 |
| Peña, E | 1 |
| Ybarra, J | 1 |
| Pou, JM | 1 |
| Badimon, L | 1 |
| Korkmaz-Icöz, S | 1 |
| Al Said, S | 1 |
| Radovits, T | 1 |
| Li, S | 1 |
| Brune, M | 1 |
| Hegedűs, P | 1 |
| Atmanli, A | 1 |
| Ruppert, M | 1 |
| Brlecic, P | 1 |
| Lehmann, LH | 1 |
| Lahrmann, B | 1 |
| Grabe, N | 1 |
| Yoshikawa, Y | 2 |
| Yasui, H | 2 |
| Most, P | 1 |
| Karck, M | 1 |
| Szabó, G | 1 |
| Soeiro, Ade M | 1 |
| Mansur, Ade P | 1 |
| Schaan, BD | 1 |
| Caramelli, B | 1 |
| Rochitte, CE | 1 |
| Serrano, CV | 1 |
| Calderaro, D | 1 |
| Gualandro, DM | 1 |
| Marcondes-Braga, FG | 1 |
| Lima, FG | 1 |
| Oliveira, FM | 1 |
| Azevedo, FR | 1 |
| Chauhan, H | 1 |
| Salles, JE | 1 |
| Soares, J | 1 |
| Cardoso, JN | 1 |
| Pellanda, LC | 1 |
| Sacilotto, L | 1 |
| Baracioli, L | 1 |
| Bortolotto, LA | 1 |
| César, LA | 2 |
| Ochiai, ME | 1 |
| Minami, MH | 1 |
| Pinheiro, MB | 1 |
| Moretti, MA | 1 |
| Oliveira, MT | 1 |
| Lemos, PA | 2 |
| Admoni, SN | 1 |
| Lottenberg, SA | 1 |
| Rocha, VZ | 1 |
| Mathias, W | 1 |
| Rubino, F | 1 |
| Bolek, T | 1 |
| Stančiaková, L | 1 |
| Chang, CW | 1 |
| Horng, JT | 1 |
| Hsu, CC | 1 |
| Chen, JM | 1 |
| Milanowski, L | 1 |
| Tyminska, A | 1 |
| Ozieranski, K | 1 |
| Eskandarian, R | 1 |
| Razavi, M | 1 |
| Fattah, A | 1 |
| Ghods, K | 1 |
| Forozeshfard, M | 1 |
| Lee, DH | 1 |
| Hur, JH | 1 |
| Min, SH | 1 |
| Lee, JE | 1 |
| Oh, TJ | 1 |
| Kim, KM | 1 |
| Jang, HC | 1 |
| Han, SJ | 1 |
| Kang, DK | 1 |
| Kim, HJ | 1 |
| Capranzano, P | 4 |
| Aslam, M | 1 |
| Charlton, RK | 3 |
| Suzuki, Y | 1 |
| Box, LC | 2 |
| Shoemaker, SB | 1 |
| Zenni, MM | 1 |
| Driver, JA | 1 |
| Smith, A | 1 |
| Buring, JE | 7 |
| Kurth, T | 2 |
| Logroscino, G | 1 |
| Schrier, RW | 1 |
| Bogaert, YE | 1 |
| Duzenli, MA | 1 |
| Ozdemir, K | 1 |
| Aygul, N | 1 |
| Soylu, A | 1 |
| Tokac, M | 1 |
| Alves, JD | 1 |
| Steinhagen-Thiessen, E | 1 |
| Darioli, R | 1 |
| Hostalek, U | 1 |
| Vogt, A | 1 |
| Pradhan, AD | 2 |
| Cook, NR | 1 |
| Manson, JE | 6 |
| Ridker, PM | 1 |
| Belch, J | 1 |
| MacCuish, A | 1 |
| Campbell, I | 1 |
| Cobbe, S | 1 |
| Taylor, R | 1 |
| Prescott, R | 1 |
| Lee, R | 1 |
| Bancroft, J | 1 |
| MacEwan, S | 1 |
| Shepherd, J | 1 |
| Macfarlane, P | 1 |
| Morris, A | 1 |
| Jung, R | 1 |
| Kelly, C | 1 |
| Connacher, A | 1 |
| Peden, N | 1 |
| Jamieson, A | 1 |
| Matthews, D | 1 |
| Leese, G | 1 |
| McKnight, J | 1 |
| O'Brien, I | 1 |
| Semple, C | 1 |
| Petrie, J | 1 |
| Gordon, D | 1 |
| Pringle, S | 1 |
| MacWalter, R | 1 |
| Walsh, M | 1 |
| Spurling, G | 1 |
| Natarajan, A | 1 |
| Worthley, SG | 1 |
| Nicolucci, A | 5 |
| Federman, DG | 1 |
| Shelling, M | 1 |
| Prodanovich, S | 1 |
| Gunderson, CG | 1 |
| Kirsner, RS | 1 |
| Colberg, SR | 1 |
| Azoury, KR | 1 |
| Parson, HK | 1 |
| Vinik, AI | 1 |
| Manrique, C | 2 |
| Lastra, G | 3 |
| Palmer, J | 2 |
| Gardner, M | 2 |
| Sowers, JR | 2 |
| Ott, P | 1 |
| Benke, I | 1 |
| Stelzer, J | 1 |
| Köhler, C | 1 |
| Hayashino, Y | 1 |
| Motovska, Z | 1 |
| Petr, R | 1 |
| Bilkova, D | 1 |
| Marinov, I | 1 |
| Simek, S | 1 |
| Kala, P | 1 |
| Kramer, MH | 1 |
| Stulman, J | 1 |
| McGinn, T | 1 |
| Korenstein, D | 1 |
| Patel, A | 2 |
| Joshi, R | 1 |
| de Galan, B | 1 |
| Pulcinelli, FM | 1 |
| Biasucci, LM | 1 |
| Riondino, S | 1 |
| Giubilato, S | 1 |
| Leo, A | 1 |
| Di Renzo, L | 1 |
| Trifirò, E | 1 |
| Mattiello, T | 1 |
| Pitocco, D | 2 |
| Liuzzo, G | 1 |
| Ghirlanda, G | 2 |
| Crea, F | 1 |
| Colwell, JA | 5 |
| Singla, MK | 1 |
| Lahiri, P | 1 |
| Mukhopadhyay, P | 1 |
| Pandit, K | 1 |
| Chaudhuri, U | 1 |
| Chowdhury, S | 1 |
| Mathewkutty, S | 1 |
| Echouffo-Tcheugui, JB | 1 |
| Simmons, RK | 1 |
| Williams, KM | 1 |
| Barling, RS | 1 |
| Prevost, AT | 1 |
| Kinmonth, AL | 1 |
| Wareham, NJ | 1 |
| Griffin, SJ | 1 |
| Cola, C | 1 |
| Brugaletta, S | 1 |
| Martín Yuste, V | 1 |
| Campos, B | 1 |
| Sabaté, M | 4 |
| Tonkin, AM | 1 |
| Nelson, MR | 1 |
| Britt, HC | 1 |
| Reid, CM | 1 |
| Jackson, G | 1 |
| Roffi, M | 1 |
| Eberli, FR | 1 |
| Shinohara, Y | 1 |
| Nishimaru, K | 1 |
| Whaley-Connell, A | 1 |
| Rousseau, P | 1 |
| Mahé, G | 1 |
| Fromy, B | 1 |
| Ducluzeau, PH | 1 |
| Saumet, JL | 1 |
| Abraham, P | 1 |
| Boaz, M | 1 |
| Lisy, L | 1 |
| Zandman-Goddard, G | 1 |
| Wainstein, J | 1 |
| Skowasch, D | 1 |
| Tuleta, I | 1 |
| Viktor, A | 1 |
| Bauriedel, G | 1 |
| Nickenig, G | 1 |
| Gardner, DW | 1 |
| Martha, S | 1 |
| Devarakonda, KR | 1 |
| Anreddy, RN | 1 |
| Pantam, N | 1 |
| Spain, M | 1 |
| Edlund, BJ | 1 |
| Benhamou, Y | 1 |
| Lévesque, H | 1 |
| Singla, A | 1 |
| Antonino, MJ | 1 |
| Zhang, C | 1 |
| Sun, A | 1 |
| Zhang, P | 2 |
| Wu, C | 1 |
| Zhang, S | 1 |
| Fu, M | 1 |
| Wang, K | 1 |
| Zou, Y | 1 |
| Leung, WY | 1 |
| So, WY | 1 |
| Stewart, D | 1 |
| Lui, A | 1 |
| Tong, PC | 1 |
| Ko, GT | 1 |
| Kong, AP | 1 |
| Ma, RC | 1 |
| Chan, FK | 1 |
| Yang, X | 1 |
| Chiang, SC | 1 |
| Chan, JC | 1 |
| Ong, G | 1 |
| Davis, TM | 1 |
| Davis, WA | 1 |
| LaMarr, B | 1 |
| Valdez, C | 1 |
| Driscoll, K | 1 |
| Krane, V | 1 |
| Berger, M | 1 |
| Lilienthal, J | 1 |
| Winkler, K | 1 |
| Schambeck, C | 1 |
| Wanner, C | 1 |
| MacDonald, MR | 1 |
| Eurich, DT | 1 |
| Majumdar, SR | 2 |
| Lewsey, JD | 1 |
| Bhagra, S | 1 |
| Jhund, PS | 1 |
| Petrie, MC | 1 |
| McMurray, JJ | 1 |
| Petrie, JR | 1 |
| McAlister, FA | 1 |
| Barker, LE | 1 |
| Hoerger, TJ | 1 |
| Ertugrul, DT | 1 |
| Tutal, E | 1 |
| Yildiz, M | 1 |
| Akin, O | 1 |
| Yalçin, AA | 1 |
| Ure, OS | 1 |
| Yilmaz, H | 1 |
| Yavuz, B | 1 |
| Deveci, OS | 1 |
| Ata, N | 1 |
| Küçükazman, M | 1 |
| Younis, N | 1 |
| Williams, S | 1 |
| Ammori, B | 1 |
| Soran, H | 1 |
| Mortensen, SB | 2 |
| Mannucci, PM | 1 |
| Geisler, T | 1 |
| Mueller, K | 1 |
| Aichele, S | 1 |
| Bigalke, B | 1 |
| Stellos, K | 1 |
| Htun, P | 2 |
| Ninci, E | 1 |
| Fateh-Moghadam, S | 2 |
| May, AE | 1 |
| Gawaz, M | 2 |
| Pignone, M | 1 |
| Alberts, MJ | 1 |
| Cushman, M | 1 |
| Inzucchi, SE | 1 |
| Mukherjee, D | 1 |
| Williams, CD | 1 |
| Wilson, PW | 1 |
| Kirkman, MS | 1 |
| Reinhard, H | 1 |
| Jacobsen, PK | 1 |
| Lajer, M | 1 |
| Pedersen, N | 1 |
| Billestrup, N | 1 |
| Mandrup-Poulsen, T | 1 |
| Parving, HH | 3 |
| Rossing, P | 1 |
| Allan, GM | 1 |
| Ivers, N | 1 |
| McCormack, J | 1 |
| Morgan, GP | 1 |
| Mucci, L | 2 |
| Song, Y | 4 |
| Klevak, A | 1 |
| Liu, S | 5 |
| Rhee, SY | 2 |
| Kim, YS | 2 |
| Chon, S | 1 |
| Oh, S | 2 |
| Woo, JT | 1 |
| Kim, SW | 1 |
| Kim, JW | 1 |
| Salgado, BJ | 1 |
| Salgado, JV | 1 |
| Dos Santos, AM | 1 |
| Casulari, LA | 1 |
| de Boer, HC | 2 |
| Hovens, MM | 4 |
| van Oeveren-Rietdijk, AM | 1 |
| Snoep, JD | 3 |
| de Koning, EJ | 1 |
| Tamsma, JT | 3 |
| Huisman, MV | 4 |
| Rabelink, AJ | 1 |
| van Zonneveld, AJ | 2 |
| Pakhomov, SV | 1 |
| Shah, ND | 2 |
| Hanson, P | 1 |
| Balasubramaniam, SC | 1 |
| Smith, SA | 1 |
| Kautzky-Willer, A | 1 |
| Kamyar, MR | 1 |
| Gerhat, D | 1 |
| Handisurya, A | 1 |
| Stemer, G | 1 |
| Hudson, S | 1 |
| Luger, A | 1 |
| Lemmens-Gruber, R | 2 |
| Rao, GH | 1 |
| Mangiacapra, F | 1 |
| Peace, AJ | 2 |
| Wijns, W | 2 |
| Barbato, E | 1 |
| Saucedo, JF | 1 |
| Frelinger, AL | 1 |
| Michelson, AD | 1 |
| Zhu, B | 1 |
| Ojeh, CK | 1 |
| Baker, BA | 1 |
| Effron, MB | 1 |
| Marioni, RE | 1 |
| Deary, IJ | 1 |
| Murray, GD | 1 |
| Lowe, GD | 1 |
| Strachan, MW | 1 |
| Luciano, M | 1 |
| Houlihan, LM | 1 |
| Gow, AJ | 1 |
| Harris, SE | 1 |
| Rumley, A | 1 |
| Stewart, MC | 1 |
| Fowkes, FG | 1 |
| Price, JF | 1 |
| Tang, JY | 1 |
| Capodanno, D | 4 |
| Dharmashankar, K | 3 |
| Kodali, M | 3 |
| Tomasello, SD | 3 |
| Seecheran, N | 2 |
| DiChiara, J | 1 |
| Sóter, MO | 1 |
| Rodrigues, KF | 1 |
| Freitas, FR | 1 |
| Komatsuzaki, F | 1 |
| Sousa, MO | 1 |
| Pianett, GA | 1 |
| Amoah, V | 1 |
| Smallwood, A | 1 |
| Worrall, AP | 1 |
| Lovatt, T | 1 |
| Armesilla, AL | 1 |
| Nevill, AM | 1 |
| Cotton, JM | 1 |
| Crasto, W | 1 |
| Jarvis, J | 1 |
| Skinner, TC | 1 |
| Gray, LJ | 1 |
| Brela, J | 1 |
| Troughton, J | 1 |
| Daly, H | 1 |
| Lawrence, IG | 1 |
| McNally, PG | 1 |
| Carey, ME | 1 |
| Davies, MJ | 1 |
| Yang, TH | 1 |
| Kim, DI | 1 |
| Kim, DK | 2 |
| Jang, JS | 1 |
| Kim, U | 1 |
| Seol, SH | 1 |
| Hong, GR | 1 |
| Park, JS | 1 |
| Shin, DG | 1 |
| Kim, YJ | 1 |
| Cho, YK | 1 |
| Nam, CW | 1 |
| Hur, SH | 1 |
| Kim, KB | 1 |
| Kim, DS | 1 |
| Gao, F | 1 |
| Wang, ZX | 1 |
| Men, JL | 1 |
| Ren, J | 1 |
| Wei, MX | 1 |
| Spectre, G | 1 |
| Arnetz, L | 1 |
| Östenson, CG | 1 |
| Brismar, K | 1 |
| Li, N | 1 |
| Hjemdahl, P | 1 |
| Adachi, Y | 1 |
| Hattori, M | 1 |
| Sakurai, H | 1 |
| Santos, MT | 1 |
| Moscardo, A | 1 |
| Vallés, J | 1 |
| Mylotte, D | 1 |
| Kavanagh, GF | 1 |
| Tedesco, AF | 1 |
| Carmody, D | 1 |
| O'Reilly, M | 1 |
| Foley, DP | 1 |
| Thompson, CJ | 1 |
| Agha, A | 1 |
| Smith, D | 1 |
| Kenny, D | 1 |
| Lemkes, BA | 1 |
| Bähler, L | 1 |
| Kamphuisen, PW | 1 |
| Stroobants, AK | 1 |
| Van Den Dool, EJ | 1 |
| Hoekstra, JB | 1 |
| Nieuwland, R | 1 |
| Gerdes, VE | 1 |
| Holleman, F | 1 |
| Irwig, MS | 1 |
| Sood, P | 1 |
| Ni, D | 1 |
| Amass, T | 1 |
| Khurana, PS | 1 |
| Jayanthi, VV | 1 |
| Wang, L | 2 |
| Adler, SM | 1 |
| Cangemi, R | 1 |
| Nigro, C | 1 |
| Proietti, M | 1 |
| Lauro, D | 1 |
| Basili, S | 3 |
| Macchia, A | 1 |
| Laffaye, N | 1 |
| Comignani, PD | 1 |
| Cornejo Pucci, E | 1 |
| Igarzabal, C | 1 |
| Scazziota, AS | 1 |
| Herrera, L | 1 |
| Mariani, JA | 1 |
| Bragagnolo, JC | 1 |
| Catalano, H | 1 |
| Tognoni, G | 4 |
| Petrucci, G | 1 |
| Vitacolonna, E | 2 |
| Mattoscio, D | 1 |
| Zaccardi, F | 1 |
| Del Ponte, A | 1 |
| Ferrante, E | 1 |
| Martini, F | 1 |
| Cardillo, C | 1 |
| Morosetti, R | 1 |
| Mirabella, M | 1 |
| Ames, PR | 1 |
| Batuca, JR | 1 |
| Muncy, IJ | 1 |
| De La Torre, IG | 1 |
| Pascoe-Gonzales, S | 1 |
| Guyer, K | 1 |
| Matsuura, E | 1 |
| Lopez, LR | 1 |
| Manzano-Fernández, S | 1 |
| Marín, F | 1 |
| Saint-Lary, O | 1 |
| Boisnault, P | 1 |
| Naiditch, M | 1 |
| Szidon, P | 1 |
| Duhot, D | 1 |
| Bourgueil, Y | 1 |
| Pelletier-Fleury, N | 1 |
| Lordkipanidzé, M | 1 |
| Wu, CS | 1 |
| Sung, SF | 1 |
| Tong, SH | 1 |
| Ong, CT | 1 |
| Azcona, L | 1 |
| López Farré, AJ | 1 |
| Jiménez Mateos-Cáceres, P | 1 |
| Segura, A | 1 |
| Rodríguez, P | 1 |
| Modrego, J | 1 |
| Zamorano-León, JJ | 1 |
| Macaya, C | 4 |
| LeBlanc, A | 1 |
| Ruud, KL | 1 |
| Branda, ME | 1 |
| Tiedje, K | 1 |
| Boehmer, KR | 1 |
| Pencille, LJ | 1 |
| Van Houten, H | 1 |
| Matthews, M | 1 |
| May, CR | 1 |
| Yawn, BP | 1 |
| Montori, VM | 1 |
| Lafeber, M | 1 |
| Grobbee, DE | 1 |
| Spiering, W | 1 |
| Bots, ML | 1 |
| Visseren, FL | 1 |
| Park, SY | 1 |
| Kwon, HS | 1 |
| Cha, BY | 1 |
| Lee, HJ | 1 |
| Lee, HC | 1 |
| Linares Vicente, JA | 1 |
| Pérez, JO | 1 |
| Lacasa, RC | 1 |
| Udell, JA | 1 |
| Scirica, BM | 1 |
| Braunwald, E | 1 |
| Raz, I | 1 |
| Davidson, J | 1 |
| Hirshberg, B | 1 |
| Ariturk, Z | 1 |
| Islamoglu, Y | 1 |
| Gündüz, E | 1 |
| Yavuz, C | 1 |
| Cil, H | 1 |
| Tekbas, E | 1 |
| Soydinc, S | 1 |
| Kaya, H | 1 |
| Elbey, MA | 1 |
| Suryadevara, S | 1 |
| Zenni, M | 1 |
| Johansen, NB | 1 |
| Charles, M | 1 |
| Rasmussen, SS | 1 |
| Wiinberg, N | 1 |
| Borch-Johnsen, K | 1 |
| Sandbæk, A | 1 |
| Witte, DR | 1 |
| Feldt-Rasmussen, B | 1 |
| Clausen, P | 1 |
| Sakariassen, KS | 1 |
| Femia, EA | 1 |
| Daray, FM | 1 |
| Podda, GM | 1 |
| Razzari, C | 1 |
| Pugliano, M | 1 |
| Errasti, AE | 1 |
| Armesto, AR | 1 |
| Nowak, W | 1 |
| Alberts, P | 1 |
| Meyer, JP | 1 |
| Sorensen, AS | 1 |
| Cattaneo, M | 1 |
| Rothlin, RP | 1 |
| Simard, JM | 1 |
| Geng, Z | 1 |
| Silver, FL | 1 |
| Sheth, KN | 1 |
| Kimberly, WT | 1 |
| Stern, BJ | 1 |
| Colucci, M | 1 |
| Gerzanich, V | 1 |
| Schechter, CB | 1 |
| Sharma, KK | 1 |
| Guptha, S | 1 |
| Gupta, R | 1 |
| Drissa, A | 1 |
| Sideris, G | 1 |
| Voicu, S | 1 |
| Manzo Silberman, S | 1 |
| Logeart, D | 1 |
| Valentine, N | 1 |
| Van de Laar, FA | 1 |
| van Driel, ML | 1 |
| Willder, JM | 1 |
| Walker, VC | 1 |
| Halbert, GL | 1 |
| Dick, CP | 1 |
| Orange, C | 1 |
| Qayyum, T | 1 |
| Horgan, PG | 1 |
| Underwood, MA | 1 |
| Edwards, J | 1 |
| Willeit, P | 1 |
| Zampetaki, A | 1 |
| Dudek, K | 1 |
| Kaudewitz, D | 1 |
| King, A | 1 |
| Kirkby, NS | 1 |
| Crosby-Nwaobi, R | 1 |
| Prokopi, M | 1 |
| Drozdov, I | 1 |
| Langley, SR | 1 |
| Sivaprasad, S | 1 |
| Markus, HS | 1 |
| Mitchell, JA | 1 |
| Warner, TD | 1 |
| Kiechl, S | 1 |
| van Solingen, C | 1 |
| Prins, J | 1 |
| Duijs, JM | 1 |
| Rabelink, TJ | 1 |
| Cavarretta, E | 1 |
| Chiariello, GA | 1 |
| Condorelli, G | 1 |
| Hall, M | 1 |
| McGettigan, M | 1 |
| O'Callaghan, P | 1 |
| Graham, I | 1 |
| Shelley, E | 1 |
| Feely, J | 2 |
| Nowak, SN | 1 |
| Jaber, LA | 1 |
| Levenson, D | 1 |
| Harris, R | 1 |
| Donahue, K | 1 |
| Rathore, SS | 1 |
| Frame, P | 1 |
| Woolf, SH | 1 |
| Lohr, KN | 1 |
| Gaede, P | 2 |
| Hansen, HP | 1 |
| Pedersen, O | 2 |
| Bennett, KE | 1 |
| Williams, D | 1 |
| Nattrass, M | 1 |
| Tracy, RP | 1 |
| Adler, AI | 1 |
| Stiefelhagen, P | 1 |
| McCall, AL | 1 |
| Cummings, DM | 1 |
| King, DE | 1 |
| Mainous, AG | 1 |
| Sacco, M | 1 |
| Pellegrini, F | 1 |
| Roncaglioni, MC | 1 |
| Avanzini, F | 2 |
| Fong, DS | 1 |
| Aiello, L | 1 |
| Gardner, TW | 1 |
| King, GL | 1 |
| Blankenship, G | 1 |
| Cavallerano, JD | 1 |
| Ferris, FL | 3 |
| Klein, R | 2 |
| Passamonti, M | 1 |
| Pigni, M | 1 |
| Testolin, E | 1 |
| Banerjee, S | 1 |
| Denniston, AK | 1 |
| Gibson, JM | 1 |
| Dodson, PM | 1 |
| Helmersson, J | 1 |
| Vessby, B | 1 |
| Larsson, A | 1 |
| Basu, S | 1 |
| Zácková, V | 1 |
| Mudaliar, S | 1 |
| Dorababu, M | 1 |
| Prabha, T | 1 |
| Priyambada, S | 1 |
| Agrawal, VK | 1 |
| Aryya, NC | 1 |
| Goel, RK | 1 |
| Gale, E | 1 |
| Klinke, JA | 1 |
| Johnson, JA | 1 |
| Guirguis, LM | 1 |
| Toth, EL | 1 |
| Lee, TK | 1 |
| Lewanczuk, RZ | 1 |
| de Gaetano, G | 2 |
| Golanski, J | 2 |
| Pluta, J | 2 |
| Boncler, M | 2 |
| Rozalski, M | 2 |
| Luzak, B | 1 |
| Kropiwnicka, A | 1 |
| Claudi, T | 2 |
| Cooper, JG | 1 |
| Hausken, MF | 1 |
| Michaelsen, T | 1 |
| Harboe, K | 1 |
| Ingskog, W | 1 |
| ØStrem, A | 1 |
| Mansfield, M | 1 |
| Cannegieter, SC | 1 |
| Gikas, A | 1 |
| Sotiropoulos, A | 1 |
| Löbner, K | 1 |
| Füchtenbusch, M | 1 |
| Cull, CA | 1 |
| Neil, HA | 1 |
| Evangelista, V | 2 |
| Totani, L | 2 |
| Rotondo, S | 1 |
| Lorenzet, R | 1 |
| De Berardis, G | 2 |
| Abdella, NA | 1 |
| Mojiminiyi, OA | 1 |
| Moussa, MA | 1 |
| Zaki, M | 1 |
| Al Mohammedi, H | 1 |
| Al Ozairi, ES | 1 |
| Al Jebely, S | 1 |
| Czyz, M | 1 |
| Trojanowski, Z | 1 |
| Daurbekova, LV | 1 |
| Orlov, VA | 1 |
| Giliarevskiĭ, SR | 1 |
| Abirova, ES | 1 |
| Murzabekova, LI | 1 |
| Gurevich, MA | 1 |
| Yan, Y | 1 |
| Phillips, DR | 1 |
| Lu, SZ | 1 |
| Ning, SQ | 1 |
| Bruno, A | 1 |
| Grassi, G | 1 |
| Dani, F | 1 |
| Degiovanni, M | 1 |
| Maghenzani, G | 1 |
| Pagano, G | 1 |
| Albert, SG | 1 |
| Hasnain, BI | 1 |
| Ritter, DG | 1 |
| Joist, JH | 1 |
| Mooradian, AD | 1 |
| Harris, M | 1 |
| Wan, Q | 1 |
| Plöckinger, U | 1 |
| Cabeza, N | 1 |
| Reuter, T | 1 |
| Ersel, S | 1 |
| Dietz, R | 1 |
| Bocksch, W | 1 |
| Sampson, M | 1 |
| Wall, S | 1 |
| Baugh, M | 1 |
| Worley, J | 1 |
| Davies, I | 1 |
| Hughes, D | 1 |
| Gavrilovic, J | 1 |
| Woodman, RJ | 1 |
| Playford, DA | 1 |
| Watts, GF | 1 |
| Fernandez-Ortiz, A | 3 |
| Bernardo, E | 3 |
| Ramírez, C | 2 |
| Jimenez-Quevedo, P | 3 |
| Hernández, R | 2 |
| Moreno, R | 3 |
| Escaned, J | 3 |
| Alfonso, F | 3 |
| Bañuelos, C | 3 |
| Costa, MA | 3 |
| Moriyama, K | 1 |
| Kanamoto, N | 1 |
| Hataya, Y | 1 |
| Nanbu, T | 1 |
| Hosoda, K | 1 |
| Arai, H | 1 |
| Nakao, K | 1 |
| Abaci, A | 1 |
| Yilmaz, Y | 1 |
| Caliskan, M | 1 |
| Bayram, F | 1 |
| Cetin, M | 1 |
| Unal, A | 1 |
| Cetin, S | 1 |
| Chen, WH | 1 |
| Kaul, U | 1 |
| Leung, SK | 1 |
| Lau, YK | 1 |
| Tan, HC | 1 |
| Leung, AW | 1 |
| Lee, MK | 1 |
| Li, SK | 1 |
| Ng, W | 1 |
| Lee, PY | 1 |
| Lam, KF | 1 |
| Tse, HF | 1 |
| Lau, CP | 1 |
| Charpentier, G | 1 |
| Puel, J | 1 |
| Falco, A | 2 |
| Salvati, F | 1 |
| Avellone, G | 1 |
| Pinto, A | 1 |
| Di Febbo, C | 1 |
| Ballone, E | 1 |
| Di Nicola, M | 1 |
| Ciabattoni, G | 4 |
| Marissal, JP | 1 |
| Sailly, JC | 1 |
| Crainich, D | 1 |
| Lebrun, T | 1 |
| Brogan, GX | 1 |
| Mulgund, J | 1 |
| Gibler, WB | 1 |
| Pollack, CV | 1 |
| Farkouh, ME | 1 |
| Roe, MT | 1 |
| Mezzetti, A | 1 |
| Taraborelli, T | 1 |
| Devangelio, E | 1 |
| Gresner, P | 2 |
| Dolník, M | 1 |
| Waczulíková, I | 1 |
| Bryszewska, M | 1 |
| Sikurová, L | 1 |
| Mehta, SS | 1 |
| Silver, RJ | 1 |
| Aaronson, A | 1 |
| Abrahamson, M | 1 |
| Goldfine, AB | 1 |
| Deans, KA | 1 |
| Sattar, N | 1 |
| Piepoli, MF | 1 |
| Gogia, A | 1 |
| Agarwal, PK | 1 |
| Urban, P | 1 |
| Gershlick, AH | 1 |
| Guagliumi, G | 1 |
| Guyon, P | 1 |
| Lotan, C | 1 |
| Schofer, J | 1 |
| Seth, A | 1 |
| Sousa, JE | 1 |
| Berge, C | 1 |
| Deme, M | 1 |
| Stoll, HP | 1 |
| Sawanyawisuth, K | 1 |
| Limpawattana, P | 1 |
| Mahankkanukrauh, A | 1 |
| Wongvipaporn, C | 1 |
| Ruiz, J | 1 |
| Egli, M | 1 |
| Soares, PR | 1 |
| Hueb, WA | 1 |
| Lopes, N | 1 |
| Martinez, EE | 1 |
| Oliveira, SA | 1 |
| Ramires, JA | 1 |
| Scheen, AJ | 1 |
| Legrand, D | 1 |
| Lorusso, R | 1 |
| De Cicco, G | 1 |
| Beghi, C | 1 |
| Gherli, T | 1 |
| Poli, E | 1 |
| Corradi, D | 1 |
| Maestri, R | 1 |
| Bonadonna, S | 1 |
| Mancini, T | 1 |
| Giustina, A | 1 |
| Blonde, L | 1 |
| Dempster, J | 1 |
| Gallivan, JM | 1 |
| Warren-Boulton, E | 1 |
| Raméntol Teys, S | 1 |
| Pujol Blaya, V | 1 |
| León de la Fuente, M | 1 |
| León-Sanromà, M | 1 |
| Kraiem, S | 1 |
| Abassi, C | 1 |
| Annabi, N | 1 |
| Smaali, I | 1 |
| Issaa, I | 1 |
| Wali, M | 1 |
| Malou, M | 1 |
| Hannachi, S | 1 |
| Longo, S | 1 |
| Battikh, K | 1 |
| Slimane, ML | 1 |
| De la Figuera von Wichmann, M | 1 |
| Llisterri Caro, JL | 1 |
| Leitão, CB | 1 |
| Krahe, AL | 1 |
| Nabinger, GB | 1 |
| Picon, PX | 1 |
| Pecis, M | 1 |
| Zaslavsky, LM | 1 |
| Gross, JL | 3 |
| Canani, LH | 1 |
| Chin, SP | 1 |
| Liew, CK | 1 |
| Tay, SP | 1 |
| Rapaee, A | 1 |
| Liew, HB | 1 |
| Ang, CK | 1 |
| Fong, YY | 1 |
| Ong, TK | 1 |
| Gudum, HR | 1 |
| Sim, KH | 1 |
| Berry, C | 1 |
| Tardif, JC | 1 |
| Bourassa, MG | 1 |
| Choudhury, A | 1 |
| Chung, I | 1 |
| Blann, AD | 1 |
| Lip, GYH | 1 |
| Maciá Bobes, C | 1 |
| Ronzón Fernández, A | 1 |
| Fernández García, E | 1 |
| Wittmann, I | 1 |
| Molnár, GA | 1 |
| Wagner, L | 1 |
| Köszegi, T | 1 |
| Wagner, Z | 1 |
| Laczy, B | 1 |
| Tamaskó, M | 1 |
| Markó, L | 1 |
| Mohás, M | 1 |
| Nagy, J | 1 |
| Groeneveld, Y | 2 |
| Eikenboom, JC | 1 |
| Krayenbuehl, PA | 1 |
| Wiesli, P | 1 |
| Schmid, M | 1 |
| Schmid, C | 1 |
| Ehses, JA | 1 |
| Hersberger, M | 1 |
| Vetter, W | 1 |
| Schulthess, G | 1 |
| Yong, TY | 1 |
| Phillipov, G | 1 |
| Phillips, PJ | 1 |
| Camargo, EG | 2 |
| Weinert, LS | 1 |
| Lavinsky, J | 1 |
| Silveiro, SP | 2 |
| Stancoven, A | 1 |
| Giorda, CB | 1 |
| Brero, L | 1 |
| Levantesi, G | 1 |
| Marelli, G | 1 |
| Pupillo, M | 1 |
| Iacuitti, G | 1 |
| Pozzoli, G | 1 |
| di Summa, P | 1 |
| Nada, E | 1 |
| de Simone, G | 1 |
| Dell'Elba, G | 1 |
| Amore, C | 1 |
| Manarini, S | 1 |
| Pecce, R | 1 |
| Maione, A | 1 |
| Ding, EL | 1 |
| Rifai, N | 1 |
| Kamyar, M | 1 |
| Johnson, BJ | 1 |
| McAnaw, JJ | 1 |
| Hudson, SA | 1 |
| Palazuelos, J | 1 |
| Hernández-Antolin, R | 1 |
| Simon, DI | 1 |
| Schmaier, AH | 1 |
| Yusuf, S | 1 |
| Fallen, E | 1 |
| Guyton, RA | 1 |
| Frölich, M | 1 |
| Serebruany, VL | 2 |
| Malinin, AI | 2 |
| Pokov, A | 1 |
| Barsness, G | 1 |
| Hanley, DF | 2 |
| Thomas, MC | 1 |
| Crescente, M | 1 |
| Iacoviello, L | 1 |
| Vermylen, J | 1 |
| Cerletti, C | 1 |
| Ogawa, S | 1 |
| Mori, T | 1 |
| Nako, K | 1 |
| Ishizuka, T | 1 |
| Ito, S | 2 |
| Lund-Andersen, H | 1 |
| Robles-Díaz, G | 1 |
| Fastag, D | 1 |
| Yee, J | 1 |
| Pedrini, RO | 1 |
| Camargo, JL | 1 |
| van Werkum, JW | 1 |
| Topcu, Y | 1 |
| Postma, S | 1 |
| Kelder, JC | 1 |
| Hackeng, CM | 1 |
| ten Berg, JM | 1 |
| Verheugt, FW | 1 |
| Pokov, AN | 1 |
| Smith, CJ | 1 |
| McKay, GA | 1 |
| Fisher, M | 1 |
| Shrivastava, R | 1 |
| Khan, A | 1 |
| Jeevanantham, V | 1 |
| Nautiyal, A | 1 |
| Garg, P | 1 |
| Reddy, PC | 1 |
| Gopaul, NK | 1 |
| Anggård, EE | 1 |
| Mallet, AI | 1 |
| Betteridge, DJ | 1 |
| Wolff, SP | 1 |
| Nourooz-Zadeh, J | 1 |
| Nightingale, SL | 1 |
| Tani, N | 1 |
| Hada, K | 1 |
| Kitami, A | 1 |
| Nakano, M | 1 |
| Takahashi, H | 1 |
| Sato, I | 1 |
| Shibata, A | 1 |
| Braun, CI | 1 |
| Benson, WE | 1 |
| Remaley, NA | 1 |
| Chew, EY | 2 |
| Ferris, F | 1 |
| Husstedt, IW | 1 |
| Grotemeyer, KH | 1 |
| Evers, S | 1 |
| Staschewski, F | 1 |
| Wertelewski, R | 1 |
| Contreras, I | 1 |
| Reiser, KM | 1 |
| Martinez, N | 1 |
| Giansante, E | 1 |
| Lopez, T | 1 |
| Suarez, N | 1 |
| Postalian, S | 1 |
| Molina, M | 1 |
| Gonzalez, F | 1 |
| Sanchez, MR | 1 |
| Camejo, M | 1 |
| Blanco, MC | 1 |
| Mubarak, AA | 1 |
| Gresele, P | 1 |
| Catalano, M | 1 |
| Giammarresi, C | 1 |
| Volpato, R | 1 |
| Nenci, GG | 1 |
| Davis, MD | 1 |
| Fisher, MR | 1 |
| Gangnon, RE | 1 |
| Barton, F | 1 |
| Aiello, LM | 1 |
| Knatterud, GL | 1 |
| Harper, R | 1 |
| McCance, DR | 1 |
| Harpaz, D | 1 |
| Gottlieb, S | 1 |
| Graff, E | 1 |
| Boyko, V | 1 |
| Kishon, Y | 1 |
| Behar, S | 1 |
| Moss, SE | 1 |
| Klein, BE | 1 |
| Wesseling, H | 1 |
| Hébert, M | 1 |
| Wood, DM | 1 |
| Plehwe, WE | 1 |
| Colman, PG | 1 |
| Kajubi, SK | 1 |
| Sibai, BM | 1 |
| Caritis, S | 1 |
| Hauth, J | 1 |
| Lindheimer, M | 1 |
| VanDorsten, JP | 1 |
| MacPherson, C | 1 |
| Klebanoff, M | 1 |
| Landon, M | 1 |
| Miodovnik, M | 1 |
| Paul, R | 1 |
| Meis, P | 1 |
| Dombrowski, M | 1 |
| Thurnau, G | 1 |
| Roberts, J | 1 |
| McNellis, D | 1 |
| Pedersen, OB | 1 |
| Gaede, PH | 1 |
| Birkeland, KI | 1 |
| Hansteen, V | 1 |
| Hanssen, KF | 1 |
| Hjermann, I | 1 |
| Jenssen, T | 1 |
| Jervell, J | 1 |
| Os, I | 1 |
| Nagai, T | 1 |
| Tomizawa, T | 1 |
| Tonooka, N | 1 |
| Mita, Y | 1 |
| Misumi, S | 1 |
| Mori, M | 1 |
| Cockcroft, JR | 1 |
| Wilkinson, IB | 1 |
| Yki-Järvinen, H | 1 |
| Duly-Bouhanick, B | 1 |
| Menard, S | 1 |
| Hadjadj, S | 1 |
| Soares-Barbosa, S | 1 |
| Plun-Favreau, J | 1 |
| Guilloteau, G | 1 |
| Syrbe, G | 1 |
| Redlich, H | 1 |
| Weidlich, B | 1 |
| Ludwig, J | 1 |
| Kopitzsch, S | 1 |
| Göckefitz, A | 1 |
| Herzog, T | 1 |
| Kernan-Schroeder, D | 1 |
| Cunningham, M | 1 |
| Chiquette, E | 1 |
| Chilton, R | 1 |
| Lassila, R | 1 |
| Syvänne, M | 1 |
| Hundal, RS | 1 |
| Petersen, KF | 1 |
| Mayerson, AB | 1 |
| Randhawa, PS | 1 |
| Inzucchi, S | 1 |
| Shoelson, SE | 1 |
| Shulman, GI | 1 |
| Khajehdehi, P | 1 |
| Roozbeh, J | 1 |
| Mostafavi, H | 1 |
| Catalano, I | 1 |
| Notarbartolo, A | 1 |
| Strano, A | 1 |
| Inoguchi, T | 1 |
| Umeda, F | 1 |
| Ono, H | 1 |
| Kunisaki, M | 1 |
| Watanabe, J | 1 |
| Nawata, H | 1 |
| Mata-Segreda, JF | 1 |
| Fernández-Azofeifa, E | 1 |
| Madrigal, X | 1 |
| Morales, AC | 1 |
| Skrha, J | 1 |
| Hilgertová, J | 1 |
| Svacina, S | 1 |
| Srámková, J | 1 |
| Páv, J | 1 |
| Bratusch-Marrain, P | 1 |
| Vierhapper, H | 2 |
| Komjati, M | 2 |
| Waldhäusl, W | 1 |
| Giugliano, D | 3 |
| Bratusch-Marrain, PR | 1 |
| Waldhäusl, WK | 1 |
| Hopper, AH | 1 |
| Tindall, H | 1 |
| Davies, JA | 1 |
| Ceriello, A | 2 |
| Saccomanno, F | 2 |
| Quatraro, A | 1 |
| D'Onofrio, F | 2 |
| Di Pinto, P | 1 |
| Passariello, N | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Microvascular and Antiinflammatory Effects of Rivaroxaban Compared to Low Dose Aspirin in Type-2 Diabetic Patients With Very High Cardiovascular Risk and Subclinical Inflammation[NCT02164578] | Phase 3 | 179 participants (Actual) | Interventional | 2015-04-30 | Completed | ||
| Efficacy and Safety of Alogliptin vs. Acarbose in Chinese T2DM Patients With High CV Risk or CHD Treated With Aspirin and Inadequately Controlled With Metformin Monotherapy or Drug Naive: A Multicenter, Randomized, Open Label, Prospective Study[NCT03794336] | Phase 4 | 1,293 participants (Actual) | Interventional | 2019-06-29 | Completed | ||
| Japanese Primary Prevention of Atherosclerosis With Aspirin for Diabetes (JPAD) Trial[NCT00110448] | Phase 4 | 2,539 participants (Actual) | Interventional | 2002-12-31 | Completed | ||
| Effect of aSpirin Versus CilOstazol for Inhibition of Antiplatelet aggRegaTion in Type 2 DM Patients[NCT02933788] | Phase 4 | 116 participants (Anticipated) | Interventional | 2016-10-31 | Not yet recruiting | ||
| A Multinational, Randomised, Double-Blind, Placebo-Controlled Trial to Evaluate the Effect of Ticagrelor Twice Daily on the Incidence of Cardiovascular Death, Myocardial Infarction or Stroke in Patients With Type 2 Diabetes Mellitus (THEMIS - Effect of Ti[NCT01991795] | Phase 3 | 19,271 participants (Actual) | Interventional | 2014-02-10 | Completed | ||
| Effect of Aspirin on Renal Disease Progression in Patients With Type 2 Diabetes: a Multicentre Double-blind, Placebo-controlled, Randomised Trial. The LEDA (renaL disEase Progression by Aspirin in Diabetic pAtients) Study.[NCT02895113] | Phase 3 | 418 participants (Anticipated) | Interventional | 2017-01-31 | Not yet recruiting | ||
| TECOS: A Randomized, Placebo Controlled Clinical Trial to Evaluate Cardiovascular Outcomes After Treatment With Sitagliptin in Patients With Type 2 Diabetes Mellitus and Inadequate Glycemic Control[NCT00790205] | Phase 3 | 14,671 participants (Actual) | Interventional | 2008-12-10 | Completed | ||
| Ramadan Fasting Effects in Patients With Cardiovascular Risk Factors[NCT02720133] | 500 participants (Actual) | Observational [Patient Registry] | 2013-07-31 | Completed | |||
| The Effects of Fish Oil and Aspirin on Cardiovascular Risk in Type 2 Diabetes[NCT01181882] | Phase 2 | 30 participants (Actual) | Interventional | 2010-08-31 | Completed | ||
| The Links Between Dysglycaemia, Insulin Resistance, Endothelial Function, Inflammation and Oxidative Stress: Effect of Different Doses of Aspirin in Subjects With Type-2 Diabetes and High Cardiovascular Risk[NCT00898950] | 21 participants (Actual) | Interventional | 2004-08-31 | Completed | |||
| Targeting Platelets in Chronic HIV Infection[NCT02578706] | Phase 2 | 27 participants (Actual) | Interventional | 2015-10-31 | Completed | ||
| Acetylsalicylic Acid Administered in Patients With Type 2 Diabetes Mellitus and Its Effect on the Antioxidant Enzyme System[NCT03341117] | Phase 3 | 21 participants (Actual) | Interventional | 2014-12-02 | Completed | ||
| Comparison of Effectiveness of Low Dose Aspirin Vs Omega 3 Fatty Acids as Adjuvants to Non-surgical Periodontal Therapy in Type II Diabetic Patients With Chronic Periodontitis[NCT03599401] | 42 participants (Actual) | Interventional | 2016-10-15 | Completed | |||
| The ADDITION Study. Anglo-Danish-Dutch Study of Intensive Treatment In PeOple With screeN Detected Diabetes in Primary Care[NCT00237549] | 3,057 participants (Actual) | Interventional | 2001-01-31 | Completed | |||
| Evaluation of Some Emerging Biomarkers of Cardiovascular Risk Stratification in Hypertensive Patients: a 5-years Follow-up[NCT02064218] | 0 participants | Observational | 2007-11-30 | Recruiting | |||
| Comparison of Platelet Inhibitory Effect With Adjunctive Cilostazol Versus High Maintenance-dose ClopidogrEL in Acute Myocardial Infarction Patients According to CYP2C19 Polymorphism[NCT00915733] | Phase 4 | 80 participants (Actual) | Interventional | 2009-05-31 | Completed | ||
| Women's Health Study of Low-dose Aspirin and Vitamin E in Apparently Healthy Women[NCT00000479] | Phase 3 | 39,876 participants (Actual) | Interventional | 1992-09-30 | Completed | ||
| The Impact of Aspirin Dose Modification on the Innate Immune Response - Will Lower Dose Aspirin Therapy Reduce the Response to Endotoxin[NCT03869268] | Phase 4 | 72 participants (Actual) | Interventional | 2019-04-24 | Completed | ||
| Assessment of Platelet-dependent Thrombosis in Patients With Acute Coronary Syndromes Using an ex Vivo Arterial Injury Model[NCT00728286] | 90 participants (Actual) | Observational | 2008-10-31 | Completed | |||
| Assessment of Platelet-dependent Thrombosis by an ex Vivo Arterial Injury Model: a Placebo Controlled Trial of Clopidogrel as Antiplatelet Therapy in Patients With Type 2 Diabetes Mellitus and Coronary Artery Disease[NCT00728156] | Phase 4 | 90 participants (Actual) | Interventional | 2009-08-31 | Completed | ||
| DPP-4 Inhibitors in Patients With Type 2 Diabetes and Acute Myocardial Infarction:Effects on Platelet Function[NCT02377388] | Phase 3 | 74 participants (Actual) | Interventional | 2017-02-07 | Completed | ||
| Is a Reduced Biochemical Response to Aspirin Associated With Increased Cardiovascular Morbidity and Mortality in High Risk Patients With Coronary Artery Disease?[NCT01383304] | 906 participants (Actual) | Observational | 2007-11-30 | Active, not recruiting | |||
| The Role of Multiple Electrode Aggregometry in Detection of Clopidogrel Resistance in Diabetic Patients With Coronary Artery Disease and Prediction of Clinical Outcomes. A Comparative-method, Non Interventional, Single Center Study.[NCT01991093] | 280 participants (Actual) | Observational | 2014-06-30 | Completed | |||
| A Pharmacodynamic Comparison of Prasugrel (LY640315) Versus High Dose Clopidogrel in Subjects With Type 2 Diabetes Mellitus and Coronary Artery Disease.[NCT00642174] | Phase 2 | 35 participants (Actual) | Interventional | 2008-04-30 | Completed | ||
| Pharmacodynamic Effects of Different Aspirin Dosing Regimens in Type 2 Diabetes Mellitus Patients With Coronary Artery Disease[NCT01201785] | Phase 4 | 20 participants (Actual) | Interventional | 2009-01-31 | Completed | ||
| Use of a Card to Improve Risk Factor Control in Patients With Type II Diabetes[NCT01339520] | 104 participants (Actual) | Interventional | 2008-11-30 | Completed | |||
| Type 2 Diabetes Mellitus: Role of Inflammation and Innate Immunity in The Pathogenesis of Endothelial Dysfunction and Atherosclerosis[NCT01250340] | Phase 4 | 80 participants (Anticipated) | Interventional | 2010-08-31 | Recruiting | ||
| Aspirin Statins Or Both For The Reduction Of Thrombin Generation In Diabetic People[NCT00793754] | Phase 4 | 30 participants (Actual) | Interventional | 2009-03-31 | Completed | ||
| WilL LOWer Dose Aspirin be More Effective Following ACS? (WILLOW-ACS)[NCT02741817] | Phase 4 | 20 participants (Actual) | Interventional | 2016-06-26 | Completed | ||
| Wiser Choices for Patients With Type II Diabetes: Diabetes Medication Choice[NCT00388050] | 85 participants (Actual) | Interventional | 2006-07-31 | Completed | |||
| The Characterisation of Vascular Biomarkers Before and After Cardiac Resynchronization Therapy in Patients With Chronic Heart Failure and Their Role in Predicting Response[NCT02541773] | 58 participants (Anticipated) | Observational | 2013-11-30 | Active, not recruiting | |||
| Testing the Effectiveness of Different Messaging Approaches to Increase Doctor Visits to Confirm or Exclude a Diagnosis of Prediabetes or Diabetes Amongst Individuals With Risk Factors for Diabetes: A Randomised, Controlled Trial[NCT05755555] | 5,000 participants (Actual) | Interventional | 2022-08-04 | Active, not recruiting | |||
| Prevalence of Aspirin Resistance in Ischemic Stroke Patients at Assiut University Hospital[NCT05151263] | 133 participants (Anticipated) | Observational | 2023-11-01 | Not yet recruiting | |||
| A Randomized, Open-label, Active-controlled, Parallel-group Study to Investigate the Platelet Inhibition of Ticagrelor Versus Clopidogrel in Patients With Stable Coronary Artery Disease and Type 2 Diabetes Mellitus After Recent Elective Percutaneous Coron[NCT02748330] | Phase 4 | 40 participants (Actual) | Interventional | 2016-06-30 | Completed | ||
| Prospective, Single-Arm, Multi-Centre, Observational Registry to Further Validate Safety and Efficacy of the Nobori DES in Real-World Patients[NCT01261273] | 18,000 participants (Actual) | Observational | 2010-08-25 | Completed | |||
| BIOTRONIK-Safety and Clinical PerFormance of the Drug ELuting Orsiro Stent in the Treatment of Subjects With de Novo Coronary Artery Lesions-VI[NCT02870985] | Phase 3 | 440 participants (Anticipated) | Interventional | 2015-07-31 | Recruiting | ||
| The Impact of Novel Strategies to Improve Cardiometabolic Status and Adherence to Exercise Regimens in Patients at High Risk for Cardiovascular Disease[NCT03103854] | 500 participants (Anticipated) | Interventional | 2014-01-01 | Recruiting | |||
| Intensified Multifactorial Intervention in Patients With Type 2 Diabetes and Microalbuminuria[NCT00320008] | 160 participants (Actual) | Interventional | 1992-01-31 | Active, not recruiting | |||
| A Randomised Controlled Trial of a Duodenal Sleeve Bypass Device (EndoBarrier)Compared With Standard Medical Therapy for the Management of Obese Subjects With Type 2 Diabetes[NCT02459561] | 170 participants (Actual) | Interventional | 2015-03-31 | Active, not recruiting | |||
| Aqueous Biomarker Levels in Diabetic Retinopathy and Diabetic Macular Edema[NCT05333055] | 150 participants (Anticipated) | Observational | 2022-04-11 | Not yet recruiting | |||
| [NCT00000151] | Phase 3 | 0 participants | Interventional | 1979-12-31 | Completed | ||
| Long-Term Efficacy and Safety of Intravitreal Aflibercept Injections for the Treatment of Diabetic Retinopathy for Subjects Who Completed the 2-Year PANORAMA Trial[NCT04708145] | Phase 4 | 150 participants (Anticipated) | Interventional | 2021-06-01 | Active, not recruiting | ||
| Intravitreal Aflibercept for Retinal Non-Perfusion in Proliferative Diabetic Retinopathy[NCT02863354] | Phase 2 | 43 participants (Actual) | Interventional | 2016-08-31 | Completed | ||
| Intravitreal Aflibercept as Indicated by Real-Time Objective Imaging to Achieve Diabetic Retinopathy Improvement[NCT03531294] | Phase 2 | 40 participants (Actual) | Interventional | 2018-05-23 | Completed | ||
| Prevention of Pre-eclampsia Using Metformin: a Randomized Control Trial[NCT04855513] | 414 participants (Anticipated) | Interventional | 2022-03-24 | Not yet recruiting | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
"Change of maximal postischemic forearm blood flow during reactive hyperaemia after 5 min of forearm ischemia (FBF max. ml/100ml).~Difference of change in post-ischemic forearm blood flow measured by venous occlusion plethysmography at baseline and after 20 weeks treatment with rivaroxaban or aspirin." (NCT02164578)
Timeframe: Baseline and week 20
| Intervention | ml/100ml (Mean) |
|---|---|
| Rivaroxaban | 3.60 |
| Aspirin | 1.00 |
Difference of change in post-ischemic forearm blood flow measured by venous occlusion plethysmography at baseline and after 52 weeks treatment with rivaroxaban or aspirin. (NCT02164578)
Timeframe: Baseline and week 52
| Intervention | ml/100ml (Mean) |
|---|---|
| Rivaroxaban | 6.11 |
| Aspirin | 1.56 |
Change in pulse wave velocity as a marker for arterial stiffness (measured by IEM Mobil-O-Graph) (NCT02164578)
Timeframe: Baseline to week 20
| Intervention | m/s (Mean) |
|---|---|
| Rivaroxaban | 0.02 |
| Aspirin | 0.14 |
Change in pulse wave velocity as a marker of arterial stiffness (measured by IEM Mobil-O-Graph) (NCT02164578)
Timeframe: Baseline and week 52
| Intervention | m/s (Mean) |
|---|---|
| Rivaroxaban | 0.24 |
| Aspirin | 0.51 |
Change in skin blood flow for assessment of peripheral skin microcirculatory function (measured by laserdopplerfluxmetry; LDF) (NCT02164578)
Timeframe: Baseline to week 20
| Intervention | arbitrary units (Mean) |
|---|---|
| Rivaroxaban | 3.47 |
| Aspirin | -6.01 |
Change in skin blood flow for assessment of peripheral skin microcirculatory function (measured by laserdopplerfluxmetry; LDF) (NCT02164578)
Timeframe: Baseline to week 52
| Intervention | arbitrary units (Mean) |
|---|---|
| Rivaroxaban | -7.3 |
| Aspirin | 5.8 |
"Clinically relevant non-major (CRNM) bleeding defined as at least one of the following:~spontaneous skin hematoma of at least 25 cm~spontaneous nose bleeding of more than 5 minutes duration~macroscopic hematuria, either spontaneous or, if associated with an intervention, lasting more than 24 hours~spontaneous rectal bleeding (more than spotting on toilet paper)~gingival bleeding for more than 5 minutes~bleeding leading to hospitalization and/or requiring surgical treatment~bleeding leading to a transfusion of less than 2 units of whole blood or red cells~any other bleeding event considered clinically relevant by the investigator" (NCT02164578)
Timeframe: Week 1 to week 20
| Intervention | events (Number) |
|---|---|
| Rivaroxaban | 11 |
| Aspirin | 1 |
"Clinically relevant non-major (CRNM) bleeding defined as at least one of the following:~spontaneous skin hematoma of at least 25 cm~spontaneous nose bleeding of more than 5 minutes duration~macroscopic hematuria, either spontaneous or, if associated with an intervention, lasting more than 24 hours~spontaneous rectal bleeding (more than spotting on toilet paper)~gingival bleeding for more than 5 minutes~bleeding leading to hospitalization and/or requiring surgical treatment~bleeding leading to a transfusion of less than 2 units of whole blood or red cells~any other bleeding event considered clinically relevant by the investigator" (NCT02164578)
Timeframe: Week 1 to week 52
| Intervention | events (Number) |
|---|---|
| Rivaroxaban | 6 |
| Aspirin | 1 |
Major bleeding defined as clinically overt and associated with one of the following: 1) reduction of hemoglobin level of 2 g/L or 2) required transfusion of at least 2 units of red cells or, involved a critical organ or was fatal, in accordance with the recommendation of the International Society on Thrombosis and Hemostasis (ISTH). (NCT02164578)
Timeframe: Week 1 to week 20
| Intervention | events (Number) |
|---|---|
| Rivaroxaban | 1 |
| Aspirin | 0 |
Major bleeding defined as clinically overt and associated with one of the following: 1) reduction of hemoglobin level of 2 g/L or 2) required transfusion of at least 2 units of red cells or, involved a critical organ or was fatal, in accordance with the recommendation of the International Society on Thrombosis and Hemostasis (ISTH). (NCT02164578)
Timeframe: Week 1 to week 52
| Intervention | events (Number) |
|---|---|
| Rivaroxaban | 0 |
| Aspirin | 0 |
Participants with all-cause death. If no event, censoring occurs at the earliest of PACD and last endpoint assessment date. Includes deaths based on publically available vital status data in patients who have withdrawn consent. (NCT01991795)
Timeframe: From randomisation to primary analysis censoring date (PACD). Median time in study until PACD was 40 months.
| Intervention | Number of participants with event (Number) |
|---|---|
| Ticagrelor 60 mg | 579 |
| Ticagrelor Placebo | 592 |
Participants with Cardiovascular (CV) death, myocardial infarction (MI) or stroke. If no event, censoring occurs at the earliest of PACD, last endpoint assessment date and non-CV death date. (NCT01991795)
Timeframe: From randomisation to primary analysis censoring date (PACD). Median time in study until PACD was 40 months.
| Intervention | Number of participants with event (Number) |
|---|---|
| Ticagrelor 60 mg | 736 |
| Ticagrelor Placebo | 818 |
Participants with Cardiovascular (CV) death. If no event, censoring occurs at the earliest of PACD, last endpoint assessment date and non-CV death date. (NCT01991795)
Timeframe: From randomisation to primary analysis censoring date (PACD). Median time in study until PACD was 40 months.
| Intervention | Number of participants with event (Number) |
|---|---|
| Ticagrelor 60 mg | 364 |
| Ticagrelor Placebo | 357 |
Participants with ischaemic stroke. If no event, censoring occurs at the earliest of PACD, last endpoint assessment date and death date. (NCT01991795)
Timeframe: From randomisation to primary analysis censoring date (PACD). Median time in study until PACD was 40 months.
| Intervention | Number of participants with event (Number) |
|---|---|
| Ticagrelor 60 mg | 152 |
| Ticagrelor Placebo | 191 |
Participants with myocardial infarction. If no event, censoring occurs at the earliest of primary analysis censoring date (PACD), last endpoint assessment date and death date (NCT01991795)
Timeframe: From randomisation to primary analysis censoring date (PACD). Median time in study until PACD was 40 months.
| Intervention | Number of participants with event (Number) |
|---|---|
| Ticagrelor 60 mg | 274 |
| Ticagrelor Placebo | 328 |
Participants with permanent discontinuation of study medication due to any bleeding event. If no event, censoring occurs at the earliest of last endpoint assessment date, death date and the date of last dose of study medication (NCT01991795)
Timeframe: From randomisation to 7 days following the date of last dose of study medication. Maximum duration of exposure was 59 months.
| Intervention | Number of participants with event (Number) |
|---|---|
| Ticagrelor 60 mg | 466 |
| Ticagrelor Placebo | 125 |
Participants with PLATO major bleeding event. If no event, censoring occurs at the earliest of last endpoint assessment date, death date and 7 days following the date of last dose of study medication (NCT01991795)
Timeframe: From randomisation to 7 days following the date of last dose of study medication. Maximum duration of exposure was 59 months.
| Intervention | Number of participants with event (Number) |
|---|---|
| Ticagrelor 60 mg | 310 |
| Ticagrelor Placebo | 145 |
Participants with TIMI major bleeding event. If no event, censoring occurs at the earliest of last endpoint assessment date, death date and 7 days following the date of last dose of study medication (NCT01991795)
Timeframe: From randomisation to 7 days following the date of last dose of study medication. Maximum duration of exposure was 59 months.
| Intervention | Number of participants with event (Number) |
|---|---|
| Ticagrelor 60 mg | 206 |
| Ticagrelor Placebo | 100 |
Participants with TIMI major or minor bleeding event. If no event, censoring occurs at the earliest of last endpoint assessment date, death date and 7 days following the date of last dose of study medication (NCT01991795)
Timeframe: From randomisation to 7 days following the date of last dose of study medication. Maximum duration of exposure was 59 months.
| Intervention | Number of participants with event (Number) |
|---|---|
| Ticagrelor 60 mg | 285 |
| Ticagrelor Placebo | 129 |
Percent incidence of all-cause mortality is reported as the percentage of participants who died due to any cause. (NCT00790205)
Timeframe: Up to 5 years
| Intervention | Percentage of participants (Number) |
|---|---|
| Sitagliptin | 7.5 |
| Placebo | 7.3 |
Percent incidence of all-cause mortality is reported as the percentage of participants who died due to any cause. (NCT00790205)
Timeframe: Up to 5 years
| Intervention | Percentage of participants (Number) |
|---|---|
| Sitagliptin | 4.7 |
| Placebo | 4.3 |
Percent incidence of CHF requiring hospitalization was reported as the percentage of participants who were admitted to the hospital for CHF. (NCT00790205)
Timeframe: Up to 5 years
| Intervention | Percentage of participants (Number) |
|---|---|
| Sitagliptin | 3.1 |
| Placebo | 3.1 |
Percent incidence of CHF requiring hospitalization was reported as the percentage of participants who were admitted to the hospital for CHF. (NCT00790205)
Timeframe: Up to 5 years
| Intervention | Percentage of participants (Number) |
|---|---|
| Sitagliptin | 2.8 |
| Placebo | 2.8 |
Chronic insulin therapy is defined as a continuous period of insulin use of more than 3 months. (NCT00790205)
Timeframe: Up to 5 years
| Intervention | Percentage of participants (Number) |
|---|---|
| Sitagliptin | 9.7 |
| Placebo | 13.2 |
Chronic insulin therapy is defined as a continuous period of insulin use of more than 3 months. (NCT00790205)
Timeframe: Up to 5 years
| Intervention | Percentage of participants (Number) |
|---|---|
| Sitagliptin | 8.6 |
| Placebo | 11.9 |
Primary composite CV endpoint of MACE plus which includes CV-related death, nonfatal MI, nonfatal stroke, or unstable angina requiring hospitalization. (NCT00790205)
Timeframe: Up to 5 years
| Intervention | Percentage of participants (Number) |
|---|---|
| Sitagliptin | 9.6 |
| Placebo | 9.6 |
CV composite endpoint of MACE which includes CV-related death, nonfatal MI, or nonfatal stroke. (NCT00790205)
Timeframe: Up to 5 years
| Intervention | Percentage of participants (Number) |
|---|---|
| Sitagliptin | 10.2 |
| Placebo | 10.2 |
CV composite endpoint of MACE which includes CV-related death, nonfatal MI, or nonfatal stroke. (NCT00790205)
Timeframe: Up to 5 years
| Intervention | Percentage of participants (Number) |
|---|---|
| Sitagliptin | 8.4 |
| Placebo | 8.3 |
Primary composite CV endpoint of MACE plus which includes CV-related death, nonfatal MI, nonfatal stroke, or unstable angina requiring hospitalization. (NCT00790205)
Timeframe: Up to 5 years
| Intervention | Percentage of participants (Number) |
|---|---|
| Sitagliptin | 11.4 |
| Placebo | 11.6 |
In participants not receiving insulin at baseline, time to addition of first co-interventional agent (i.e., next oral AHA or chronic insulin, where chronic insulin therapy is defined as a continuous period of insulin use of more than 3 months.) (NCT00790205)
Timeframe: Up to 5 years
| Intervention | Percentage of participants (Number) |
|---|---|
| Sitagliptin | 21.7 |
| Placebo | 27.9 |
In participants not receiving insulin at baseline, time to addition of first co-interventional agent (i.e., next oral antihyperglycemic agent [AHA] or chronic insulin, where chronic insulin therapy is defined as a continuous period of insulin use of more than 3 months.) (NCT00790205)
Timeframe: Up to 5 years
| Intervention | Percentage of participants (Number) |
|---|---|
| Sitagliptin | 18.9 |
| Placebo | 24.5 |
HbA1c is a measure of the percentage of glycated hemoglobin in the blood. Estimated mean difference between sitagliptin and placebo controlling for baseline HbA1c and region. (NCT00790205)
Timeframe: Baseline and up to 4 years
| Intervention | Percentage of HbA1c (Mean) | ||||||
|---|---|---|---|---|---|---|---|
| Month 4: Sitagliptin, n= 6772; Placebo, n= 6738 | Month 8: Sitagliptin, n= 6478; Placebo, n= 6414 | Month 12: Sitagliptin, n= 6448; Placebo, n= 6384 | Month 24: Sitagliptin, n= 6105; Placebo, n= 5975 | Month 36: Sitagliptin, n= 3521; Placebo, n= 3439 | Month 48: Sitagliptin, n= 1432; Placebo, n= 1383 | Month 60: Sitagliptin, n= 123; Placebo, n= 128 | |
| Placebo | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | 0.0 |
| Sitagliptin | -0.3 | -0.2 | -0.2 | -0.1 | -0.1 | 0.0 | 0.0 |
HbA1c is a measure of the percentage of glycated hemoglobin in the blood. Estimated mean difference between sitagliptin and placebo controlling for baseline HbA1c and region. (NCT00790205)
Timeframe: Baseline and up to 4 years
| Intervention | Percentage of HbA1c (Mean) | ||||||
|---|---|---|---|---|---|---|---|
| Month 4; Sitagliptin, n=6632, Placebo, n=6588 | Month 8; Sitagliptin, n=6294, Placebo, n=6197 | Month 12; Sitagliptin, n=6217, Placebo, n=6092 | Month 24; Sitagliptin, n=5668, Placebo, n=5475 | Month 36; Sitagliptin, n=3227, Placebo, n=3083 | Month 48; Sitagliptin, n=1271, Placebo, n=1224 | Month 60; Sitagliptin, n=106, Placebo, n=108 | |
| Placebo | 0.1 | 0.1 | 0.1 | 0.2 | 0.1 | 0.1 | 0.0 |
| Sitagliptin | -0.3 | -0.3 | -0.2 | -0.1 | -0.1 | 0.0 | -0.1 |
Change in renal function based on eGFR using the MDRD method. (NCT00790205)
Timeframe: Baseline and up to 5 years
| Intervention | mL/min/1.73 m^2 (Mean) | ||||||
|---|---|---|---|---|---|---|---|
| Month 4; Sitagliptin, n=3949; Placebo, n=3977 | Month 8; Sitagliptin, n=3687; Placebo, n=3648 | Month 12; Sitagliptin, n=5082; Placebo, n=5015 | Month 24; Sitagliptin, n=5157; Placebo, n=5071 | Month 36; Sitagliptin, n=3037; Placebo, n=2942 | Month 48; Sitagliptin, n=1237; Placebo, n=1210 | Month 60; Sitagliptin, n=93; Placebo, n=106 | |
| Placebo | -0.8 | -0.9 | -0.5 | -1.7 | -1.6 | -2.8 | -5.7 |
| Sitagliptin | -1.8 | -2.4 | -1.8 | -3.2 | -3.8 | -4.0 | -4.2 |
Change in renal function based on estimated glomerular filtration rate [eGFR] using the Modification of Diet in Renal Disease [MDRD] method. (NCT00790205)
Timeframe: Baseline and up to 5 years
| Intervention | mL/min/1.73 m^2 (Mean) | ||||||
|---|---|---|---|---|---|---|---|
| Month 4; Sitagliptin, n= 3859; Placebo, n= 3864 | Month 8; Sitagliptin, n= 3562; Placebo, n= 3501 | Month 12; Sitagliptin, n=4912, Placebo, n=4778 | Month 24; Sitagliptin, n=4782, Placebo, n=4637 | Month 36; Sitagliptin, n=2776, Placebo, n=2614 | Month 48; Sitagliptin, n=1096, Placebo, n=1056 | Month 60; Sitagliptin, n=79, Placebo, n=88 | |
| Placebo | -0.8 | -0.9 | -0.5 | -1.7 | -1.6 | -2.8 | -6.4 |
| Sitagliptin | -1.9 | -2.5 | -1.8 | -3.1 | -3.7 | -3.7 | -3.5 |
Change from baseline reflects the difference between the urine albumin:creatinine ratio reported time point and baseline value. (NCT00790205)
Timeframe: Baseline and up to 5 years
| Intervention | g/mol Creatinine (Mean) | ||||||
|---|---|---|---|---|---|---|---|
| Month 4; n=677, n=713 | Month 8; n=658, n=624 | Month 12; n=1167, n=1115 | Month 24; n=1011, n=964 | Month 36; n=537, n=553 | Month 48; n=265, n=256 | Month 60; n=14, n=18 | |
| Placebo | -1.4 | 0.5 | 1.2 | 3.1 | 3.9 | 1.6 | 6.4 |
| Sitagliptin | -2.1 | 2.1 | 1.3 | 0.5 | 2.6 | 1.9 | -2.5 |
Change from baseline reflects the difference between the urine albumin:creatinine ratio reported time point and baseline value. (NCT00790205)
Timeframe: Baseline and up to 5 years
| Intervention | g/mol Creatinine (Mean) | ||||||
|---|---|---|---|---|---|---|---|
| Month 4; Sitagliptin, n=664; Placebo, n=688 | Month 8; Sitagliptin, n=635; Placebo, n=597 | Month 12; Sitagliptin, n=1126; Placebo, n=1059 | Month 24; Sitagliptin, n=930; Placebo, n=892 | Month 36; Sitagliptin, n=488; Placebo, n=513 | Month 48; Sitagliptin, n=238; Placebo, n=233 | Month 60; Sitagliptin, n=13; Placebo, n=17 | |
| Placebo | -1.4 | 0.2 | 1.2 | 3.2 | 4.0 | 1.5 | 4.8 |
| Sitagliptin | -2.2 | 1.7 | 0.8 | 0.7 | 2.5 | 1.3 | -2.7 |
Alpha angle is measured using thromboelastography, measured by a tangent to the clotting curve through the 2mm point (NCT02578706)
Timeframe: baseline and 24 weeks
| Intervention | degree (Mean) |
|---|---|
| Aspirin and Placebo | 0.00 |
| Clopidogrel and Placebo | -0.60 |
| Placebo Only | -0.50 |
The classical monocyte is characterized by high level expression of the CD14 cell surface receptor (CD14++ CD16- monocyte) (NCT02578706)
Timeframe: baseline and 24 weeks
| Intervention | 10^3 cells/µl (Mean) |
|---|---|
| Aspirin and Placebo | -0.09 |
| Clopidogrel and Placebo | -0.12 |
| Placebo Only | -0.04 |
Clot formation time is measured using thromboelastography. time from 2 to 20 mm amplitude in seconds. (NCT02578706)
Timeframe: baseline and 24 weeks
| Intervention | seconds (Mean) |
|---|---|
| Aspirin and Placebo | -1.00 |
| Clopidogrel and Placebo | 2.00 |
| Placebo Only | 1.63 |
Clot formation kinetics, or coagulation time, is measured using thromboelastography. time to 2mm amplitude in seconds. (NCT02578706)
Timeframe: baseline and 24 weeks
| Intervention | seconds (Mean) |
|---|---|
| Aspirin and Placebo | 3.00 |
| Clopidogrel and Placebo | 1.00 |
| Placebo Only | -13.13 |
D-Dimer level looks at coagulation of blood. D-dimers are not normally present in blood except when coagulation has occurred. (NCT02578706)
Timeframe: Baseline and 24 weeks
| Intervention | mcg/L (Mean) |
|---|---|
| Aspirin and Placebo | -295.99 |
| Clopidogrel and Placebo | 151.96 |
| Placebo Only | 1109.38 |
Interleukin 6 gene encodes a cytokine that functions in inflammation and implicated in a variety of inflammatory-associated disease states. (NCT02578706)
Timeframe: baseline and 24 weeks
| Intervention | pg/mL (Mean) |
|---|---|
| Aspirin and Placebo | -0.36 |
| Clopidogrel and Placebo | 0.02 |
| Placebo Only | 0.85 |
The intermediate monocyte with high level expression of CD14 and low level expression of CD16 (CD14++CD16+ monocytes). (NCT02578706)
Timeframe: Baseline and 24 weeks
| Intervention | 10^3 cells/µl (Mean) |
|---|---|
| Aspirin and Placebo | 0.02 |
| Clopidogrel and Placebo | 0.06 |
| Placebo Only | 0.04 |
Maximum Clot Firmness (MCF) is measured using thromboelastography. maximum ampliture in mm (NCT02578706)
Timeframe: baseline and 24 weeks
| Intervention | mm (Mean) |
|---|---|
| Aspirin and Placebo | 1.38 |
| Clopidogrel and Placebo | 1.20 |
| Placebo Only | 0.38 |
Soluble CD163 is a specific macrophage activation marker, associated with morphological disease grade. A high sCD163 indicates more disease. (NCT02578706)
Timeframe: baseline and 24 weeks
| Intervention | 10^3 cells/µl (Mean) |
|---|---|
| Aspirin and Placebo | 26.88 |
| Clopidogrel and Placebo | 15.8 |
| Placebo Only | -63.38 |
Change in % platelet monocyte aggregates from baseline to week 24 (NCT02578706)
Timeframe: baseline and 24 weeks
| Intervention | % platelet monocyte aggregates (Mean) |
|---|---|
| Aspirin and Placebo | 10.55 |
| Clopidogrel and Placebo | 3.88 |
| Placebo Only | 8.96 |
The non-classical monocyte shows low level expression of CD14 and additional co-expression of the CD16 receptor (CD14+CD16++ monocyte).[ (NCT02578706)
Timeframe: baseline and 24 weeks
| Intervention | 10^3 cells/µl (Mean) |
|---|---|
| Aspirin and Placebo | 0.002 |
| Clopidogrel and Placebo | 0.03 |
| Placebo Only | -0.03 |
Change in % platelet aggregation in response to stimulation by Adenosine Diphosphate (ADP) from baseline to week 24 (NCT02578706)
Timeframe: baseline and 24 weeks
| Intervention | % platelet aggregation (Mean) |
|---|---|
| Aspirin and Placebo | -7.25 |
| Clopidogrel and Placebo | -32.40 |
| Placebo Only | -6.50 |
Change in % platelet aggregation in response to stimulation by arachidonic acid 1500µM from baseline to week 24 (NCT02578706)
Timeframe: baseline and 24 weeks
| Intervention | % platelet aggregation (Mean) |
|---|---|
| Aspirin and Placebo | -53.33 |
| Clopidogrel and Placebo | -31.00 |
| Placebo Only | -13.25 |
Change in % platelet aggregation in response to stimulation by Collagen 2µg/mL from baseline to week 24 (NCT02578706)
Timeframe: baseline and 24 weeks
| Intervention | % platelet aggregation (Mean) |
|---|---|
| Aspirin and Placebo | -40.37 |
| Clopidogrel and Placebo | -9.60 |
| Placebo Only | 8.62 |
Change in % platelet aggregation in response to stimulation by light transmission aggregometry as measured by epinephrine 5µM from baseline to week 24 (NCT02578706)
Timeframe: baseline and 24 weeks
| Intervention | % platelet aggregation (Mean) |
|---|---|
| Aspirin and Placebo | -35.25 |
| Clopidogrel and Placebo | -21.40 |
| Placebo Only | -10.63 |
Soluble CD14 (sCD14) levels in blood. sCD14 is a nonspecific maker of monocyte activation. (NCT02578706)
Timeframe: baseline and 24 weeks
| Intervention | pg/mL (Mean) |
|---|---|
| Aspirin and Placebo | 35.75 |
| Clopidogrel and Placebo | -251.40 |
| Placebo Only | -101.75 |
Soluble CD40-ligand levels (NCT02578706)
Timeframe: baseline and 24 weeks
| Intervention | pg/mL (Mean) |
|---|---|
| Aspirin and Placebo | -28.05 |
| Clopidogrel and Placebo | -25.68 |
| Placebo Only | 13.65 |
Change in spontaneous % platelet from baseline to week 24. Spontaneous platelet aggregation? (NCT02578706)
Timeframe: baseline and 24 weeks
| Intervention | % platelet (Mean) |
|---|---|
| Aspirin and Placebo | -0.75 |
| Clopidogrel and Placebo | -0.60 |
| Placebo Only | -0.88 |
Soluble tumor necrosis factor receptor (sTNFR) serum concentration (NCT02578706)
Timeframe: baseline and 24 weeks
| Intervention | pg/ml (Mean) |
|---|---|
| Aspirin and Placebo | 137.77 |
| Clopidogrel and Placebo | 59.46 |
| Placebo Only | 19.78 |
Soluble tumor necrosis factor receptor (sTNFR) serum concentration (NCT02578706)
Timeframe: baseline and 24 weeks
| Intervention | pg/ml (Mean) |
|---|---|
| Aspirin and Placebo | 283.13 |
| Clopidogrel and Placebo | 347.00 |
| Placebo Only | 4.25 |
substudy - Change in thrombus formation by Badimon chamber (high shear) from baseline to 24 weeks. Thrombus formation on a blood vessel measured by immunohistochemistry staining of tissue cross sections. The high shear chambers (inner lumen diameter 0.1 mm, Reynolds number 60, shear rate 1690 s- 1) mimic the rheologic conditions of a moderately stenosed coronary artery. (NCT02578706)
Timeframe: baseline and 24 weeks
| Intervention | μ(2)/mm (Mean) |
|---|---|
| Aspirin and Placebo | -3052.20 |
| Clopidogrel and Placebo | -2798.80 |
| Placebo Only | -753.00 |
substudy - Change in thrombus formation by Badimon chamber (low shear) from baseline to 24 weeks. Thrombus formation on a blood vessel measured by immunohistochemistry staining of tissue cross sections. μ(2)/mm is the area of thrombus. The low shear chamber (inner lumen diameter 0.2 mm, Reynolds number 30, shear rate 500 s- 1) simulates flow conditions of a normal coronary artery. (NCT02578706)
Timeframe: baseline and 24 weeks
| Intervention | μ(2)/mm (Mean) |
|---|---|
| Aspirin and Placebo | -1036 |
| Clopidogrel and Placebo | -899.20 |
| Placebo Only | -203.75 |
Safety as measured by a Summary of the number of subjects with at least one grade 3 or higher sign/symptom or laboratory abnormality. A grade 3 sign/symptom was defined as medically significant but not immediately life threatening. (NCT02578706)
Timeframe: 24 weeks
| Intervention | Participants (Count of Participants) |
|---|---|
| Aspirin and Placebo | 0 |
| Clopidogrel and Placebo | 1 |
| Placebo Only | 0 |
(NCT00000479)
Timeframe: Average follow-up 10.1 years
| Intervention | participants (Number) | |
|---|---|---|
| Total invasive cancer | Cancer death | |
| Aspirin + Vitamin E | 716 | 152 |
| Aspirin Only | 722 | 132 |
| Both Placebos | 706 | 143 |
| Vitamin E Only | 721 | 156 |
(NCT00000479)
Timeframe: Average follow-up 10.1 years
| Intervention | Participants (Number) | |||
|---|---|---|---|---|
| Major cardiovascular event | Stroke | Myocardial infarction | Cardiovascular death | |
| Aspirin + Vitamin E | 232 | 108 | 102 | 54 |
| Aspirin Only | 245 | 113 | 96 | 66 |
| Both Placebos | 272 | 133 | 99 | 74 |
| Vitamin E Only | 250 | 133 | 94 | 52 |
The inhibition of platelet aggregation 4 hours after the loading dose was administered was assessed using the Accumetrics VerifyNow™ P2Y12 assay. Percentage inhibition, as reported by VerifyNow™ P2Y12, was calculated from P2Y12 Reaction Unit (PRU) (rate and extent of adenosine diphosphate [ADP]-stimulated platelet aggregation) and BASE (estimate of baseline platelet reactivity independent of P2Y12 receptor inhibition [reference values]: rate and extent of Thrombin Receptor-Activated Peptide-stimulated platelet aggregation) values as follows: Percentage (%) inhibition = (1-PRU/BASE) x 100. (NCT00642174)
Timeframe: 4 hours after loading dose
| Intervention | percent inhibition (Least Squares Mean) | |
|---|---|---|
| Baseline | 4 Hours After Loading Dose | |
| Clopidogrel | 9.3 | 27.7 |
| Prasugrel | 9.4 | 89.3 |
Inhibition of platelet aggregation 1- and 24-hours after loading dose and 24-hours after last maintenance dose was administered was assessed using Accumetrics VerifyNow™ P2Y12 assay. Percentage inhibition, as reported by VerifyNow™ P2Y12, was calculated from PRU (rate and extent of ADP-stimulated platelet aggregation) and BASE (estimate of baseline platelet reactivity independent of P2Y12 receptor inhibition [reference values]: rate and extent of Thrombin Receptor-Activated Peptide-stimulated platelet aggregation) values as follows: Percentage (%) inhibition = (1-PRU/BASE) x 100. (NCT00642174)
Timeframe: 1 hour and 24 hours after the loading dose (LD) and 24 hours after the last maintenance dose (LMD)
| Intervention | percent inhibition (Least Squares Mean) | ||
|---|---|---|---|
| 1 Hour After Loading Dose | 24 Hours After Loading Dose | 24 Hours After Last Maintenance Dose | |
| Clopidogrel | 13.4 | 29.3 | 44.2 |
| Prasugrel | 49.9 | 87.1 | 61.8 |
Thromboelastography (TEG) platelet mapping (MP) maximum amplitude (MA) - Adenosine Diphosphate (ADP) millimeters (mm) at each time point. The TEG-MP MA measures strength of clot formation in whole blood. MA-ADP is the maximal amplitude resulting from fibrin and platelets not blocked by ADP-receptor inhibiting drugs. Fibrin strands in blood sample link a rotating sample cup with a stationary pin suspended by a torsion wire. The degree of platelet contribution to the MA through platelet-fibrin bonding directly influences the magnitude of pin movement and ultimately the amplitude of the tracing. (NCT00642174)
Timeframe: Baseline, 1 Hour, 4 Hours, and 24 Hours after loading dose, and 24 Hours after last maintenance dose
| Intervention | millimeters (mm) (Least Squares Mean) | ||||
|---|---|---|---|---|---|
| Baseline | 1 Hour After Loading Dose | 4 Hours After Loading Dose | 24 Hours After Loading Dose | 24 Hours After Last Maintenance Dose | |
| Clopidogrel | 58.1 | 54.8 | 48.1 | 49.2 | 46.8 |
| Prasugrel | 56.8 | 38.5 | 24.2 | 29.3 | 44.2 |
Mean platelet aggregation (MPA) to 5 and 20 µM adenosine diphosphate (ADP) was assessed by light transmittance aggregometry (LTA). Platelet aggregation was monitored for a total of 7 minutes after addition of ADP. Maximum platelet aggregation was the maximal aggregation value achieved during the 7-minute observation period following addition of agonists. (NCT00642174)
Timeframe: Baseline, 1 Hour, 4 Hours, and 24 Hours after loading dose, and 24 Hours after last maintenance dose
| Intervention | percent platelet aggregation (Least Squares Mean) | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Baseline (5 μM ADP) | 1 Hour After Loading Dose (5 μM ADP) | 4 Hours After Loading Dose (5 μM ADP) | 24 Hours After Loading Dose (5 μM ADP) | 24 Hours After Last Maintenance Dose (5 μM ADP) | Baseline (20 μM ADP) | 1 Hour After Loading Dose (20 μM ADP) | 4 Hours After Loading Dose (20 μM ADP) | 24 Hours After Loading Dose (20 μM ADP) | 24 Hours After Last Maintenance Dose (20 μM ADP) | |
| Clopidogrel | 65.7 | 56.7 | 44.6 | 45.6 | 38.3 | 76.9 | 69.8 | 57.5 | 58.4 | 50.7 |
| Prasugrel | 64.9 | 33.7 | 18.0 | 22.3 | 29.6 | 77.1 | 44.7 | 22.4 | 27.4 | 38.3 |
Data from the Vasodilator-associated stimulated phosphoprotein assay were reported as the platelet reactivity index (PRI) which was calculated from corrected mean fluorescence intensity (cMFI) following incubation of platelets with either prostaglandin E1 (PGE1) alone or PGE1 plus ADP: Platelet Reactivity Index (%) = [1-(cMFI PGEI+ADP/cMFI PGEI)] x 100. Lower PRI values indicate greater platelet P2Y12 inhibition. (NCT00642174)
Timeframe: Baseline, 1 Hour, 4 Hours, and 24 Hours after loading dose, and 24 Hours after last maintenance dose
| Intervention | percent inhibition (Least Squares Mean) | ||||
|---|---|---|---|---|---|
| Baseline | 1 Hour After Loading Dose | 4 Hours After Loading Dose | 24 Hours After Loading Dose | 24 Hours After Last Maintenance Dose | |
| Clopidogrel | 80.6 | 76.2 | 67.5 | 58.5 | 42.3 |
| Prasugrel | 83.5 | 40.0 | 14.5 | 15.7 | 27.4 |
Collagen induced aggregation using light transmittance aggregometry (NCT01201785)
Timeframe: after 1 -week of treatment
| Intervention | percentage of platelet aggregation (Mean) |
|---|---|
| Aspirin Dose Range | 32 |
Change in area of retinal capillary non-perfusion outside of the macula from baseline to week 52 and week 100. (NCT02863354)
Timeframe: 52 weeks and 100 weeks
| Intervention | mm^2 (Mean) | |
|---|---|---|
| Week 52 | Week 100 | |
| Q12WKS | 240.472 | 387.204 |
| Q4WKS | 182.467 | 342.651 |
Change in area of retinal capillary non-perfusion within the macula compared to baseline, as assessed by ultrawide-field fluorescein angiogram from baseline to week 52 and week 100. (NCT02863354)
Timeframe: 52 weeks and 100 weeks
| Intervention | mm^2 (Mean) | |
|---|---|---|
| Week 52 | Week 100 | |
| Q12WKS | 0.217 | 0.940 |
| Q4WKS | 0.048 | 2.627 |
Change in area of total retinal capillary non-perfusion, as assessed by the central reading center, at week 52 and week 100 compared to baseline. (NCT02863354)
Timeframe: 52 weeks and 100 weeks
| Intervention | mm^2 (Mean) | |
|---|---|---|
| Week 52 | Week 100 | |
| Q12WKS | 66.752 | 245.694 |
| Q4WKS | -11.994 | 141.317 |
Mean change in Early Treatment of Diabetic Retinopathy Study Best Corrected Visual Acuity (ETDRS-BCVA) from baseline to week 52 and week 100. (NCT02863354)
Timeframe: 52 weeks and 100 weeks
| Intervention | ETDRS letters (Mean) | |
|---|---|---|
| Week 52 | Week 100 | |
| Q12WKS | 4.53 | 8.88 |
| Q4WKS | 4.26 | 4.06 |
Changes in self reported visual function utilizing the National Eye Institute Visual Function Questionnaire-25 (NEI VFQ-25) from baseline to week 52 and week 100. The NEI VFQ is a validated measure of patient-reported visual function measured on a scale from 0 (worst function) to 100 (best function). (NCT02863354)
Timeframe: 52 weeks and 100 weeks
| Intervention | units on a scale (Mean) | |
|---|---|---|
| Week 52 | Week 100 | |
| Q12WKS | 2.23 | 8.82 |
| Q4WKS | 6.27 | 8.91 |
Mean change in central subfield thickness (CST) from baseline to week 52 and week 100 (NCT02863354)
Timeframe: 52 weeks and 100 weeks
| Intervention | micrometers (Mean) | |
|---|---|---|
| Week 52 | Week 100 | |
| Q12WKS | -20.813 | -23.313 |
| Q4WKS | -32.947 | -35.059 |
• Assess the safety and tolerability of IAI for the treatment of proliferative diabetic retinopathy by evaluating the incidence and severity of ocular and systemic adverse events through week 52 and week 100. (NCT02863354)
Timeframe: 52 and 100 weeks
| Intervention | Participants (Count of Participants) | |
|---|---|---|
| Week 52 | Week 100 | |
| Q12WKS | 0 | 0 |
| Q4WKS | 0 | 0 |
Percentage of subjects treated with PRP or vitrectomy for progression of PDR from baseline to week 52 and week 100. (NCT02863354)
Timeframe: 52 Weeks and 100 Weeks
| Intervention | Participants (Count of Participants) | |
|---|---|---|
| Week 52 | Week 100 | |
| Q12WKS | 0 | 0 |
| Q4WKS | 0 | 0 |
Percentage of subjects, at week 52 and week 100, who develop center-involving diabetic macular edema who did not have center-involving diabetic macular edema at baseline (NCT02863354)
Timeframe: 52 Weeks and 100 Weeks
| Intervention | Participants (Count of Participants) | |
|---|---|---|
| Week 52 | Week 100 | |
| Q12WKS | 0 | 0 |
| Q4WKS | 0 | 0 |
Percentage of subjects who develop vitreous hemorrhage from baseline to week 52 and week 100. (NCT02863354)
Timeframe: 52 Weeks and 100 Weeks
| Intervention | Participants (Count of Participants) | |
|---|---|---|
| Week 52 | Week 100 | |
| Q12WKS | 1 | 1 |
| Q4WKS | 2 | 4 |
Percentage of subjects with increased neovascularization from baseline to week 52 and week 100. (NCT02863354)
Timeframe: 52 Weeks and 100 Weeks
| Intervention | Participants (Count of Participants) | |
|---|---|---|
| Week 52 | Week 100 | |
| Q12WKS | 0 | 0 |
| Q4WKS | 1 | 0 |
Percentage of subjects with neovascularization regression (reduced area of neovascularization) as measured by the central image reading center from baseline to week 52 and week 100. (NCT02863354)
Timeframe: 52 Weeks and 100 Weeks
| Intervention | Participants (Count of Participants) | |
|---|---|---|
| Week 52 | Week 100 | |
| Q12WKS | 18 | 15 |
| Q4WKS | 17 | 17 |
75 reviews available for aspirin and Diabetes Mellitus, Adult-Onset
| Article | Year |
|---|---|
Life and limb protection with dual anti-thrombotic pathway inhibition: COMPASS ushers in a new day in atherothrombotic risk reduction.
Topics: Aspirin; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Humans; Platelet Aggregation Inhibito | 2021 |
Prediction and prevention of preeclampsia in women with preexisting diabetes: the role of home blood pressure, physical activity, and aspirin.
Topics: Aspirin; Blood Pressure; Diabetes Mellitus, Type 2; Exercise; Female; Humans; Pre-Eclampsia; Pregnan | 2023 |
[Acetylsalicylic acid for primary prevention of cardiovascular events in patients with Type 2 diabetes mellitus].
Topics: Aspirin; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Humans; Platelet Aggregation Inhibitors | 2019 |
The role of acetylsalicylic acid and circulating microRNAs in primary prevention of cardiovascular events in patients with Diabetes Mellitus Type 2 - A Review.
Topics: Animals; Aspirin; Blood Platelets; Cardiovascular Diseases; Circulating MicroRNA; Diabetes Mellitus, | 2019 |
Aspirin in the primary prevention of cardiovascular disease in diabetes mellitus: A new perspective.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cardiovascular Diseases; Diabetes Mellitus, | 2020 |
[Choosing Antithrombotic Therapy in Patients with Coronary Heart Disease and Type 2 Diabetes Mellitus: How to Reduce the Risk of Death].
Topics: Aspirin; Coronary Disease; Diabetes Mellitus, Type 2; Fibrinolytic Agents; Humans | 2020 |
The impact of metformin and aspirin on T-cell mediated inflammation: A systematic review of in vitro and in vivo findings.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cardiovascular Diseases; Diabetes Mellitu | 2020 |
Lifestyle and Environmental Approaches for the Primary Prevention of Hepatocellular Carcinoma.
Topics: Alcohol Drinking; Aspirin; Carcinoma, Hepatocellular; Chronic Disease; Diabetes Mellitus, Type 2; Di | 2020 |
The Role of Aspirin for Preeclampsia Prevention in Women with Diabetes.
Topics: Aspirin; Diabetes Mellitus, Type 2; Female; Humans; Platelet Aggregation Inhibitors; Pre-Eclampsia; | 2020 |
AGA Clinical Practice Update on Chemoprevention for Colorectal Neoplasia: Expert Review.
Topics: Aspirin; Chemoprevention; Colorectal Neoplasms; Diabetes Mellitus, Type 2; Humans; Neoplasm Recurren | 2021 |
Management of Atherosclerotic Cardiovascular Disease Risk Factors in the Older Adult Patient With Diabetes.
Topics: Aged; Aspirin; Atherosclerosis; Blood Glucose; Blood Pressure; Diabetes Mellitus, Type 2; Disease Ma | 2017 |
Platelets, diabetes and myocardial ischemia/reperfusion injury.
Topics: Animals; Aspirin; Blood Platelets; Diabetes Mellitus, Type 2; Drug Resistance; Humans; Ischemic Prec | 2017 |
Effect of non-insulin-based glucose-lowering therapies on cardiovascular outcomes in patients with type 2 diabetes.
Topics: Adult; Aged; Aspirin; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Female; Hum | 2017 |
Aspirin in primary prevention for patients with diabetes: Still a matter of debate.
Topics: Aspirin; Blood Platelets; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Diabetic Angiopathie | 2018 |
Role of and Recent Evidence for Antiplatelet Therapy in Prevention of Cardiovascular Disease in Diabetes.
Topics: Aspirin; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Humans; Perc | 2019 |
[Cardiovascular event in elderly patients with diabetes mellitus].
Topics: Antihypertensive Agents; Aspirin; Atherosclerosis; Cardiovascular Diseases; Cause of Death; Clinical | 2013 |
Type 2 diabetes and cardiovascular disease: what next?
Topics: Anticholesteremic Agents; Aspirin; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2 | 2014 |
Oxidative stress-related mechanisms affecting response to aspirin in diabetes mellitus.
Topics: Aldehyde Reductase; Aspirin; Blood Platelets; Diabetes Mellitus, Type 2; F2-Isoprostanes; Glucose; G | 2015 |
[Aspirin and statins for every diabetic?].
Topics: Aged; Aspirin; Cardiovascular Diseases; Diabetes Complications; Diabetes Mellitus, Type 2; Drug Ther | 2015 |
Aspirin for primary prevention in diabetes mellitus: from the calculation of cardiovascular risk and risk/benefit profile to personalised treatment.
Topics: Animals; Aspirin; Biomarkers, Pharmacological; Blood Platelets; Cardiovascular Diseases; Cyclooxygen | 2015 |
Comparing the effectiveness and safety between triple antiplatelet therapy and dual antiplatelet therapy in type 2 diabetes mellitus patients after coronary stents implantation: a systematic review and meta-analysis of randomized controlled trials.
Topics: Acute Coronary Syndrome; Aspirin; Cilostazol; Clopidogrel; Coronary Artery Disease; Diabetes Mellitu | 2015 |
Platelets and Antiplatelet Therapy in Patients with Coronary Artery Disease and Diabetes.
Topics: Aspirin; Blood Coagulation; Blood Platelets; Coronary Artery Disease; Diabetes Mellitus, Type 2; Hum | 2016 |
Psoriasis: an opportunity to identify cardiovascular risk.
Topics: Aspirin; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Dyslipidemias; F | 2009 |
Aspirin and Diabetes Mellitus: revisiting an old player.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Diabetes Mellitus, Type 2; Diabetic Angiopathies; | 2008 |
Trials of cardiovascular risk factor management in type 2 diabetes.
Topics: Aspirin; Blood Glucose; Blood Pressure; Cardiovascular Diseases; Clinical Trials as Topic; Diabetes | 2009 |
Platelet perturbations in diabetes: implications for cardiovascular disease risk and treatment.
Topics: Aspirin; Blood Platelets; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Humans; Platelet Activ | 2009 |
Diabetes mellitus: a prothrombotic state implications for outcomes after coronary revascularization.
Topics: Angioplasty, Balloon, Coronary; Aspirin; Cardiovascular Agents; Clopidogrel; Coronary Angiography; C | 2009 |
Diabetes and acute coronary syndromes.
Topics: Acute Coronary Syndrome; Anticoagulants; Aspirin; Blood Glucose; Clopidogrel; Diabetes Mellitus; Dia | 2009 |
Utility of aspirin therapy in patients with the cardiometabolic syndrome and diabetes.
Topics: Aspirin; Blood Coagulation; Blood Glucose; Blood Platelets; Cardiovascular Agents; Cardiovascular Di | 2009 |
Aspirin for primary prevention of cardiovascular events in patients with diabetes: A meta-analysis.
Topics: Aspirin; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Humans; | 2010 |
Role of aspirin in the primary prevention of cardiovascular disease in diabetes mellitus: a meta-analysis.
Topics: Aspirin; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Humans; Primary Prevention | 2010 |
Aspirin for primary prevention of cardiovascular events in people with diabetes.
Topics: Aged; Aspirin; Cardiovascular Diseases; Coronary Disease; Diabetes Mellitus, Type 2; Diabetic Angiop | 2010 |
TP receptor activation and inhibition in atherothrombosis: the paradigm of diabetes mellitus.
Topics: Aspirin; Diabetes Complications; Diabetes Mellitus, Type 2; Humans; Plaque, Atherosclerotic; Platele | 2011 |
Management of type-2 diabetes with anti-platelet therapies: special reference to aspirin.
Topics: Arachidonic Acid; Aspirin; Blood Platelets; Clopidogrel; Diabetes Mellitus, Type 2; Drug Resistance; | 2011 |
Antiplatelet therapy in patients with diabetes mellitus.
Topics: Animals; Aspirin; Blood Platelets; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Diabetic An | 2012 |
Challenges and perspectives of antiplatelet therapy in patients with diabetes mellitus and coronary artery disease.
Topics: Aspirin; Blood Glucose; Blood Platelets; Clopidogrel; Coronary Artery Disease; Diabetes Mellitus, Ty | 2012 |
Statin and aspirin therapy for the prevention of cardiovascular events in patients with type 2 diabetes mellitus.
Topics: Aspirin; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Humans; Hydroxymethylglutaryl-CoA Reduc | 2012 |
Obstetric nephrology: pregnancy in women with diabetic nephropathy--the role of antihypertensive treatment.
Topics: Albuminuria; Antihypertensive Agents; Aspirin; Counseling; Diabetes Mellitus, Type 1; Diabetes Melli | 2012 |
Does inhibiting Sur1 complement rt-PA in cerebral ischemia?
Topics: Animals; Antioxidants; Aspirin; ATP-Binding Cassette Transporters; Brain Ischemia; Cells, Cultured; | 2012 |
Adenosine-diphosphate (ADP) receptor antagonists for the prevention of cardiovascular disease in type 2 diabetes mellitus.
Topics: Aspirin; Cardiovascular Diseases; Clopidogrel; Diabetes Mellitus, Type 2; Dipyridamole; Drug Therapy | 2012 |
Aspirin dose for prevention of cardiovascular disease in diabetics.
Topics: Aspirin; Cardiovascular Diseases; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Dose-Response | 2003 |
Screening adults for type 2 diabetes: a review of the evidence for the U.S. Preventive Services Task Force.
Topics: Adult; Aspirin; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diet; Evidence-Based Medicine; E | 2003 |
Inflammation, the metabolic syndrome and cardiovascular risk.
Topics: Arteriosclerosis; Aspirin; Biomarkers; C-Reactive Protein; Cardiovascular Diseases; Diabetes Mellitu | 2003 |
Managing diabetes: what to do about cardiovascular disease.
Topics: Angioplasty, Balloon, Coronary; Anticholesteremic Agents; Antihypertensive Agents; Aspirin; Cardiova | 2003 |
Intense management of diabetes mellitus: role of glucose control and antiplatelet agents.
Topics: Aspirin; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Drug Therapy, Combinatio | 2004 |
The Polypill and type 2 diabetes.
Topics: Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Aspirin; Diabetes Mellitus, Type | 2004 |
[Inflammation and diabetes].
Topics: Adiponectin; Angiotensin-Converting Enzyme Inhibitors; Anti-Inflammatory Agents, Non-Steroidal; Arte | 2004 |
Prevention of cardiovascular disease in type-2 diabetes: how to improve the clinical efficacy of aspirin.
Topics: Angiotensin-Converting Enzyme Inhibitors; Aspirin; Cardiovascular Diseases; Diabetes Complications; | 2005 |
Aspirin response and failure in diabetic patients with cardiovascular disease.
Topics: Aspirin; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Humans | 2005 |
Keeping the diabetic heart healthy.
Topics: Aspirin; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Family Practice; | 2005 |
[Cardiovascular protection and prevention in patients with cardiac conditions and diabetes].
Topics: Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Aspirin; Blood Glucose; Cardi | 2005 |
Blood platelet abnormalities and pharmacological modulation of platelet reactivity in patients with diabetes mellitus.
Topics: Aspirin; Blood Platelets; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Diabetic Angiopathie | 2005 |
"Anti-inflammatory" drugs and their effects on type 2 diabetes.
Topics: Angiotensin-Converting Enzyme Inhibitors; Anti-Inflammatory Agents; Aspirin; Cardiotonic Agents; Dia | 2006 |
Exercise rehabilitation in heart disease: the real "polypill" for primary and secondary prevention.
Topics: Aspirin; Chronic Disease; Coronary Disease; Diabetes Mellitus; Diabetes Mellitus, Type 2; Exercise; | 2005 |
Metabolic syndrome.
Topics: Aspirin; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Exercise; Humans; Hydroxymethylglutaryl | 2006 |
[The Polypill: between myths and reality in the treatment of type 2 diabetes mellitus].
Topics: Antihypertensive Agents; Aspirin; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Drug Combinati | 2006 |
Reducing cardiovascular disease risk in patients with diabetes: a message from the National Diabetes Education Program.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Antihypertensive Agents; Aspirin; Cardiovascular Diseases; | 2006 |
[Screening and management of coronary artery disease in diabetic patients].
Topics: Adrenergic beta-Antagonists; Aged; Angioplasty, Balloon, Coronary; Angiotensin-Converting Enzyme Inh | 2006 |
[Overview of cardiovascular risk factors].
Topics: Age Factors; Aged; Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; As | 2006 |
Coronary heart disease in patients with diabetes: part I: recent advances in prevention and noninvasive management.
Topics: Angiotensin-Converting Enzyme Inhibitors; Aspirin; Cardiovascular Agents; Coronary Disease; Diabetes | 2007 |
Preventing macrovascular complications in type 2 diabetes mellitus: glucose control and beyond.
Topics: Angiotensin-Converting Enzyme Inhibitors; Aspirin; Blood Glucose; Clinical Trials as Topic; Diabetes | 2007 |
Response variability to aspirin as assessed by the platelet function analyzer (PFA)-100. A systematic review.
Topics: Adult; Aged; Aspirin; Blood Platelets; Diabetes Mellitus, Type 2; Drug Monitoring; Drug Tolerance; E | 2008 |
[Cancer of the pancreas. Epidemiology and risk factors].
Topics: Adenomatous Polyposis Coli; Age Factors; Aged; Aspirin; Breast Neoplasms; Diabetes Mellitus, Type 2; | 2007 |
Diabetes, colorectal cancer and cyclooxygenase 2 inhibition.
Topics: Anticarcinogenic Agents; Aspirin; Colorectal Neoplasms; Cost-Benefit Analysis; Cyclooxygenase 2 Inhi | 2008 |
The benefit of aspirin therapy in type 2 diabetes: what is the evidence?
Topics: Aspirin; Cardiovascular Diseases; Diabetes Complications; Diabetes Mellitus, Type 2; Disease Progres | 2008 |
Multifactorial aspects of the treatment of the type II diabetic patient.
Topics: Arteriosclerosis; Aspirin; Cardiovascular Diseases; Cardiovascular Physiological Phenomena; Diabetes | 1997 |
[Intensified treatment of type 2 diabetes mellitus. Is polypharmacy necessary and justified?].
Topics: Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Aspirin; Cardiovascular Diseases; | 2000 |
[Prevention of cardiovascular disease in type 2 diabetes].
Topics: Antihypertensive Agents; Aspirin; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Dietary Servic | 2000 |
Multiple risk factor intervention in type 2 diabetes: an opportunity not to be missed.
Topics: Aspirin; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Endothelium, Vascular; Humans; Hypercho | 2001 |
[Prevention of cardiovascular diseases in type 2 diabetes with aspirin].
Topics: Aspirin; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Drug Prescriptions; Evidence-Based Medi | 2001 |
Glycemic control and beyond: the ABCs of standards of care for type 2 diabetes and cardiovascular disease.
Topics: Aspirin; Blood Pressure; Cholesterol; Coronary Disease; Diabetes Mellitus, Type 2; Diet; Exercise; H | 2002 |
Cardiovascular disease: much more aggressive in patients with type 2 diabetes.
Topics: Angioplasty, Balloon, Coronary; Angiotensin-Converting Enzyme Inhibitors; Aspirin; Cardiovascular Di | 2002 |
[Do all the patients with adult-onset diabetes mellitus need acetylsalicylic acid?].
Topics: Arteriosclerosis; Aspirin; Blood Coagulation; Contraindications; Diabetes Mellitus, Type 2; Fibrinol | 1999 |
[Treatment of coronary artery disease in a patient with adult-onset diabetes mellitus].
Topics: Adrenergic beta-Antagonists; Angioplasty, Balloon, Coronary; Angiotensin-Converting Enzyme Inhibitor | 1999 |
Morning peak in the incidence of myocardial infarction: experience in the ISIS-2 trial. ISIS-2 (Second International Study of Infarct Survival) Collaborative Group.
Topics: Adult; Age Factors; Aged; Aspirin; Circadian Rhythm; Diabetes Mellitus, Type 2; Diabetic Angiopathie | 1992 |
133 trials available for aspirin and Diabetes Mellitus, Adult-Onset
| Article | Year |
|---|---|
Rivaroxaban compared with low-dose aspirin in individuals with type 2 diabetes and high cardiovascular risk: a randomised trial to assess effects on endothelial function, platelet activation and vascular biomarkers.
Topics: Aspirin; Biomarkers; Cardiovascular Diseases; Cell-Derived Microparticles; Diabetes Mellitus, Type 2 | 2021 |
Efficacy and safety of alogliptin versus acarbose in Chinese type 2 diabetes patients with high cardiovascular risk or coronary heart disease treated with aspirin and inadequately controlled with metformin monotherapy or drug-naive: A multicentre, randomi
Topics: Acarbose; Adult; Aspirin; Coronary Disease; Diabetes Mellitus, Type 2; Double-Blind Method; Glycated | 2022 |
Incidence of atrial fibrillation in elderly patients with type 2 diabetes mellitus.
Topics: Aged; Aspirin; Atrial Fibrillation; Diabetes Mellitus, Type 2; Follow-Up Studies; Humans; Incidence | 2022 |
Ultrasonography evaluation on the protective effect of combination therapy of beraprost sodium and aspirin on arteries occlusion and stiffness in patients with type 2 diabetes mellitus - a prospective, randomized study.
Topics: Arteries; Aspirin; Carotid Intima-Media Thickness; Diabetes Mellitus, Type 2; Epoprostenol; Humans; | 2022 |
Comparative Study of Ex Vivo Antiplatelet Activity of Aspirin and Cilostazol in Patients with Diabetes and High Risk of Cardiovascular Disease.
Topics: Aspirin; Cardiovascular Diseases; Cilostazol; Diabetes Mellitus, Type 2; Drug Therapy, Combination; | 2022 |
Cost-effectiveness of ticagrelor in patients with type 2 diabetes and coronary artery disease: a European economic evaluation of the THEMIS trial.
Topics: Aspirin; Coronary Artery Disease; Cost-Benefit Analysis; Diabetes Mellitus, Type 2; Humans; Percutan | 2022 |
Cilostazol treatment for preventing adverse cardiovascular events in patients with type 2 diabetes and coronary atherosclerosis: Long-term follow-up of the ESCAPE study.
Topics: Aspirin; Cilostazol; Coronary Artery Disease; Coronary Stenosis; Diabetes Mellitus, Type 2; Drug The | 2022 |
External applicability of the Effect of ticagrelor on Health Outcomes in diabEtes Mellitus patients Intervention Study (THEMIS) trial: An analysis of patients with diabetes and coronary artery disease in the REduction of Atherothrombosis for Continued Hea
Topics: Aspirin; Coronary Artery Disease; Diabetes Mellitus, Type 2; Humans; Myocardial Infarction; Outcome | 2023 |
Association of metformin, aspirin, and cancer incidence with mortality risk in adults with diabetes.
Topics: Aged; Aspirin; Diabetes Mellitus, Type 2; Humans; Incidence; Metformin; Neoplasms | 2023 |
Ticagrelor in Patients with Stable Coronary Disease and Diabetes.
Topics: Aged; Aspirin; Coronary Artery Disease; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy | 2019 |
Sex Difference in Effects of Low-Dose Aspirin on Prevention of Dementia in Patients With Type 2 Diabetes: A Long-term Follow-up Study of a Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Atherosclerosis; Cohort Studies; Dementia; Diabetes Mellitu | 2020 |
Aspirin, clopidogrel and prasugrel monotherapy in patients with type 2 diabetes mellitus: a double-blind randomised controlled trial of the effects on thrombotic markers and microRNA levels.
Topics: Aged; Aspirin; Biomarkers; Blood Coagulation; Clopidogrel; Cross-Over Studies; Diabetes Mellitus, Ty | 2020 |
Omega-3 PUFA and aspirin as adjuncts to periodontal debridement in patients with periodontitis and type 2 diabetes mellitus: Randomized clinical trial.
Topics: Aspirin; Chronic Periodontitis; Diabetes Mellitus, Type 2; Double-Blind Method; Humans; Periodontal | 2020 |
The effects of aspirin and N-3 fatty acids on telomerase activity in adults with diabetes mellitus.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Diabetes Mellitus, Type 2; Docosahexaenoic Acids; Eicosapen | 2020 |
Diabetes-Related Factors and the Effects of Ticagrelor Plus Aspirin in the THEMIS and THEMIS-PCI Trials.
Topics: Aspirin; Coronary Artery Disease; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Foll | 2021 |
[IMPACT OF ATORVASTATIN AND ROSUVASTATIN ON RESIDUAL ON-CLOPIDOGREL TREATMENT PLATELET REACTIVITY IN PATIENTS WITH ISCHEMIC HEART DISEASE AND TYPE 2 DIABETES MELLITUS AFTER ACUTE CORONARY SYNDROME].
Topics: Acute Coronary Syndrome; Aspirin; Atorvastatin; Blood Platelets; Clopidogrel; Diabetes Mellitus, Typ | 2017 |
The effect of trimetazidine treatment in patients with type 2 diabetes undergoing percutaneous coronary intervention for AMI.
Topics: Adenosine; Aged; Alanine Transaminase; Aspartate Aminotransferases; Aspirin; Blood Glucose; Cardiac | 2017 |
Effect of aspirin on renal disease progression in patients with type 2 diabetes: A multicenter, double-blind, placebo-controlled, randomized trial. The renaL disEase progression by aspirin in diabetic pAtients (LEDA) trial. Rationale and study design.
Topics: Aspirin; Cyclooxygenase Inhibitors; Diabetes Mellitus, Type 2; Disease Progression; Dose-Response Re | 2017 |
Secondary Prevention of Cardiovascular Disease in Patients With Type 2 Diabetes Mellitus: International Insights From the TECOS Trial (Trial Evaluating Cardiovascular Outcomes With Sitagliptin).
Topics: Aged; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Aspirin; Blood Pre | 2017 |
Combined effect of metformin with ascorbic acid versus acetyl salicylic acid on diabetes-related cardiovascular complication; a 12-month single blind multicenter randomized control trial.
Topics: Adult; Ascorbic Acid; Aspirin; Cardiovascular Diseases; Diabetes Complications; Diabetes Mellitus, T | 2017 |
Comparison of pharmacodynamic effects of ticagrelor vs prasugrel in type 2 diabetes mellitus patients with coronary heart disease.
Topics: Adenosine; Aged; Aspirin; Coronary Disease; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Fe | 2018 |
Effects of Ramadan fasting on aspirin resistance in type 2 diabetic patients.
Topics: Aged; Aspirin; Blood Glucose; Blood Platelets; Cardiovascular Diseases; Diabetes Mellitus, Type 2; D | 2018 |
Effect of Aspirin on Cancer Chemoprevention in Japanese Patients With Type 2 Diabetes: 10-Year Observational Follow-up of a Randomized Controlled Trial.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Chemoprevention; Diabetes Mellitus | 2018 |
Ticagrelor and the Prevention of Microvascular Complications in Diabetes Patients with Lower Extremity Arterial Disease; Rationale and Design of the Hema-Kinesis Trial.
Topics: Aspirin; Blood Flow Velocity; Blood Viscosity; Cross-Over Studies; Diabetes Mellitus, Type 2; Diabet | 2018 |
Rationale, design and baseline characteristics of the effect of ticagrelor on health outcomes in diabetes mellitus patients Intervention study.
Topics: Aged; Aspirin; Clinical Trials, Phase III as Topic; Coronary Artery Disease; Diabetes Mellitus, Type | 2019 |
Differential vascular effects of aspirin in people with Type 2 diabetes without cardiovascular disease and matched controls without diabetes.
Topics: Aged; Aspirin; Cardiovascular System; Diabetes Mellitus, Type 2; Endothelium, Vascular; Female; Huma | 2019 |
Randomized control trial comparing the effect of cilostazol and aspirin on changes in carotid intima-medial thickness.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Atherosclerosis; Carotid Intima-Media Thickness; Cilostazol | 2019 |
Antithrombotic treatment gap among patients with atrial fibrillation and type 2 diabetes.
Topics: Aspirin; Atrial Fibrillation; Clopidogrel; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Ther | 2019 |
Effects of low-dose aspirin and fish oil on platelet function and NF-kappaB in adults with diabetes mellitus.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Diabetes Mellitus, Type 2; Female; Fish Oils; Humans; Male; | 2013 |
Homocysteine is a novel risk factor for suboptimal response of blood platelets to acetylsalicylic acid in coronary artery disease: a randomized multicenter study.
Topics: Adult; Arachidonic Acid; Aspirin; Blood Platelets; Collagen; Coronary Artery Disease; Diabetes Melli | 2013 |
Aspirin Half Maximal Inhibitory Concentration Value on Platelet Cyclooxygenase1 in Severe Type-2 Diabetes Mellitus is not Significantly Different from that of Healthy Individuals.
Topics: Adult; Aged; Aspirin; Blood Platelets; Cyclooxygenase 1; Cyclooxygenase Inhibitors; Diabetes Mellitu | 2014 |
Effect of common single-nucleotide polymorphisms in acetylsalicylic acid metabolic pathway genes on platelet reactivity in patients with diabetes.
Topics: Aged; Aspirin; Blood Platelets; Demography; Diabetes Mellitus, Type 2; Female; Gene Frequency; Genot | 2013 |
Aspirin possibly reduces cerebrovascular events in type 2 diabetic patients with higher C-reactive protein level: subanalysis from the JPAD trial.
Topics: Aged; Aspirin; Atherosclerosis; Biomarkers; C-Reactive Protein; Diabetes Mellitus, Type 2; Female; F | 2013 |
The effect of doubling the dose of acetylsalicylic acid (ASA) on platelet function parameters in patients with type 2 diabetes and platelet hyperreactivity during treatment with 75 mg of ASA: a subanalysis of the AVOCADO study.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Blood Platelets; Clopidogrel; Diabetes Mellitus, Type 2; Di | 2013 |
Cilostazol attenuates spontaneous microaggregation of platelets in type 2 diabetic patients with insufficient platelet response to aspirin.
Topics: Aged; Aspirin; Cilostazol; Diabetes Mellitus, Type 2; Female; Humans; Male; Platelet Aggregation; Pl | 2013 |
Predictors of high platelet reactivity during aspirin treatment in patients with type 2 diabetes.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Biomarkers; Blood Platelet Disorders; Blood Platelets; Card | 2013 |
Study of pharmacodynamic interaction of Phyllanthus emblica extract with clopidogrel and ecosprin in patients with type II diabetes mellitus.
Topics: Aged; Aspirin; Clopidogrel; Cross-Over Studies; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Fe | 2014 |
Acetylsalicylic acid therapy: influence of metformin use and other variables on urinary 11-dehydrothromboxane B2 levels.
Topics: Aspirin; Biological Transport; Diabetes Mellitus, Type 2; Female; Glucose; Humans; Hypoglycemic Agen | 2014 |
Aspirin in type 2 diabetes, a randomised controlled study: effect of different doses on inflammation, oxidative stress, insulin resistance and endothelial function.
Topics: Adult; Aged; Aspirin; Biomarkers; Blood Glucose; Blood Pressure; Diabetes Mellitus, Type 2; Diabetic | 2014 |
Effect of ASA dose doubling versus switching to clopidogrel on plasma inflammatory markers concentration in patients with type 2 diabetes and high platelet reactivity: the AVOCADO study.
Topics: Aspirin; Biomarkers; Blood Platelets; C-Reactive Protein; CD40 Ligand; Chi-Square Distribution; Clop | 2013 |
Laboratory aspirin resistance reversibility in diabetic patients: a pilot study using different pharmaceutical formulations.
Topics: Aged; Aspirin; Chemistry, Pharmaceutical; Diabetes Mellitus, Type 2; Drug Resistance; Female; Humans | 2014 |
Low dose of acetylsalicylic acid and oxidative stress-mediated endothelial dysfunction in diabetes: a short-term evaluation.
Topics: Aged; Aspirin; Blood Pressure; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Dose-Response Rel | 2015 |
Lack of effect of aspirin in primary CV prevention in type 2 diabetic patients with nephropathy: results from 8 years follow-up of NID-2 study.
Topics: Aged; Aspirin; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Drug Eval | 2015 |
Younger age, higher body mass index and lower adiponectin concentration predict higher serum thromboxane B2 level in aspirin-treated patients with type 2 diabetes: an observational study.
Topics: Adiponectin; Age Factors; Aged; Aspirin; Biomarkers; Body Mass Index; Diabetes Mellitus, Type 2; Fem | 2014 |
Effect of acetylsalicylic acid on platelet activation and oxidative profile in a set of Brazilian patients with type 2 diabetes mellitus.
Topics: Aspirin; Brazil; Diabetes Mellitus, Type 2; Female; Humans; Male; Middle Aged; Oxidative Stress; Pla | 2015 |
The effects of aspirin on platelet function and lysophosphatidic acids depend on plasma concentrations of EPA and DHA.
Topics: Adult; Aged; Aspirin; Blood Platelets; Diabetes Mellitus, Type 2; Docosahexaenoic Acids; Eicosapenta | 2015 |
Effect of omega 3 fatty acids plus low-dose aspirin on both clinical and biochemical profiles of patients with chronic periodontitis and type 2 diabetes: a randomized double blind placebo-controlled study.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Biomarkers; Chemokine CCL7; Chronic Periodo | 2015 |
Intensive multifactorial treatment modifies the effect of family history of diabetes on glycaemic control in people with Type 2 diabetes: a post hoc analysis of the ADDITION-Denmark randomized controlled trial.
Topics: Aged; Antihypertensive Agents; Aspirin; Blood Pressure; Body Mass Index; Cardiovascular Diseases; Ch | 2015 |
Randomized controlled trial comparing impact on platelet reactivity of twice-daily with once-daily aspirin in people with Type 2 diabetes.
Topics: Adult; Aspirin; Cardiovascular Diseases; Cross-Over Studies; Cyclooxygenase Inhibitors; Diabetes Mel | 2016 |
Effect of six years intensified multifactorial treatment on levels of hs-CRP and adiponectin in patients with screen detected type 2 diabetes: the ADDITION-Netherlands randomized trial.
Topics: Adiponectin; Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Antihypert | 2015 |
The Influence of Haemoglobin A1c Levels on Platelet Aggregation and Platelet Turnover in Patients with Coronary Artery Disease Treated with Aspirin.
Topics: Aged; Aspirin; Blood Platelets; Cohort Studies; Coronary Artery Disease; Diabetes Complications; Dia | 2015 |
A study about the relevance of adding acetylsalicylic acid in primary prevention in subjects with type 2 diabetes mellitus: effects on some new emerging biomarkers of cardiovascular risk.
Topics: Aged; Amlodipine; Antihypertensive Agents; Aspirin; Biomarkers; Calcium Channel Blockers; Cardiovasc | 2015 |
Serum Brain-Derived Neurotrophic Factor is Related to Platelet Reactivity but not to Genetic Polymorphisms within BDNF Encoding Gene in Patients with Type 2 Diabetes.
Topics: Aged; Alleles; Aspirin; Blood Platelets; Brain-Derived Neurotrophic Factor; Diabetes Mellitus, Type | 2016 |
Is Long-Term Low-Dose Aspirin Therapy Associated with Renal Dysfunction in Patients with Type 2 Diabetes? JPAD2 Cohort Study.
Topics: Aged; Aspirin; Cohort Studies; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Female; | 2016 |
Association between insulin receptor substrate-1 polymorphisms and high platelet reactivity with clopidogrel therapy in coronary artery disease patients with type 2 diabetes mellitus.
Topics: Aged; Aspirin; Blood Platelets; Clopidogrel; Coronary Artery Disease; Diabetes Mellitus, Type 2; Dru | 2016 |
New single-nucleotide polymorphisms associated with differences in platelet reactivity and their influence on survival in patients with type 2 diabetes treated with acetylsalicylic acid: an observational study.
Topics: Aged; Alleles; Aspirin; Blood Platelets; Clopidogrel; Diabetes Mellitus, Type 2; Female; Genotype; H | 2017 |
Effect of sarpogrelate, a selective 5-HT
Topics: Adult; Aged; Ankle Brachial Index; Anti-Inflammatory Agents; Aspirin; Biomarkers; Computed Tomograph | 2017 |
A randomized study assessing the impact of cilostazol on platelet function profiles in patients with diabetes mellitus and coronary artery disease on dual antiplatelet therapy: results of the OPTIMUS-2 study.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Cilostazol; Clopidogrel; Coronary Artery Disease; Cross-Ove | 2008 |
Comparison of increased aspirin dose versus combined aspirin plus clopidogrel therapy in patients with diabetes mellitus and coronary heart disease and impaired antiplatelet response to low-dose aspirin.
Topics: Aspirin; Blood Platelets; Clopidogrel; Coronary Artery Disease; Diabetes Mellitus, Type 2; Drug Ther | 2008 |
Influence of the timing of low-dose aspirin on tolerability of prolonged-release nicotinic acid in patients at elevated cardiovascular risk.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Cholesterol, HDL; Dela | 2008 |
A randomized trial of low-dose aspirin in the prevention of clinical type 2 diabetes in women.
Topics: Aged; Aspirin; Cardiotonic Agents; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Ethnicity; Fe | 2009 |
The prevention of progression of arterial disease and diabetes (POPADAD) trial: factorial randomised placebo controlled trial of aspirin and antioxidants in patients with diabetes and asymptomatic peripheral arterial disease.
Topics: Adult; Aged; Antioxidants; Aspirin; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Diabetic A | 2008 |
Low-dose aspirin for primary prevention of atherosclerotic events in patients with type 2 diabetes: a randomized controlled trial.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Atherosclerosis; Cardiovascular Diseases; Diabetes Mellitus | 2008 |
Low-dose aspirin for primary prevention of atherosclerotic events in patients with type 2 diabetes: a randomized controlled trial.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Atherosclerosis; Cardiovascular Diseases; Diabetes Mellitus | 2008 |
Low-dose aspirin for primary prevention of atherosclerotic events in patients with type 2 diabetes: a randomized controlled trial.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Atherosclerosis; Cardiovascular Diseases; Diabetes Mellitus | 2008 |
Low-dose aspirin for primary prevention of atherosclerotic events in patients with type 2 diabetes: a randomized controlled trial.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Atherosclerosis; Cardiovascular Diseases; Diabetes Mellitus | 2008 |
Low-dose aspirin for primary prevention of atherosclerotic events in patients with type 2 diabetes: a randomized controlled trial.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Atherosclerosis; Cardiovascular Diseases; Diabetes Mellitus | 2008 |
Low-dose aspirin for primary prevention of atherosclerotic events in patients with type 2 diabetes: a randomized controlled trial.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Atherosclerosis; Cardiovascular Diseases; Diabetes Mellitus | 2008 |
Low-dose aspirin for primary prevention of atherosclerotic events in patients with type 2 diabetes: a randomized controlled trial.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Atherosclerosis; Cardiovascular Diseases; Diabetes Mellitus | 2008 |
Low-dose aspirin for primary prevention of atherosclerotic events in patients with type 2 diabetes: a randomized controlled trial.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Atherosclerosis; Cardiovascular Diseases; Diabetes Mellitus | 2008 |
Low-dose aspirin for primary prevention of atherosclerotic events in patients with type 2 diabetes: a randomized controlled trial.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Atherosclerosis; Cardiovascular Diseases; Diabetes Mellitus | 2008 |
Aspirin use and risk of type 2 diabetes in apparently healthy men.
Topics: Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Diabetes Mellitus, | 2009 |
Factors influencing clopidogrel efficacy in patients with stable coronary artery disease undergoing elective percutaneous coronary intervention: statin's advantage and the smoking "paradox".
Topics: Age Factors; Aged; Angioplasty, Balloon, Coronary; Aspirin; Body Mass Index; Cell Adhesion Molecules | 2009 |
The ADDITION-Cambridge trial protocol: a cluster -- randomised controlled trial of screening for type 2 diabetes and intensive treatment for screen-detected patients.
Topics: Adult; Aged; Anti-Inflammatory Agents; Aspirin; Cost-Benefit Analysis; Diabetes Mellitus, Type 2; Ea | 2009 |
Sarpogrelate versus aspirin in secondary prevention of cerebral infarction: differential efficacy in diabetes? Subgroup analysis from S-ACCESS.
Topics: Aged; Aspirin; Cerebral Infarction; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Follow-U | 2009 |
Antibodies to platelet factor 4-heparin complex and outcome in hemodialysis patients with diabetes.
Topics: Aged; Antibodies; Aspirin; Atorvastatin; Cause of Death; Chi-Square Distribution; Death, Sudden; Dia | 2010 |
Aspirin resistance is associated with glycemic control, the dose of aspirin, and obesity in type 2 diabetes mellitus.
Topics: Adult; Alanine Transaminase; Aspirin; Blood Glucose; Body Mass Index; Cholesterol, LDL; Confidence I | 2010 |
[Investigation of the effects of low dose aspirin therapy on primary and secondary prevention of cardiovascular disease].
Topics: Aspirin; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Humans; Platelet Aggregation Inhibitors; | 2010 |
Asthma, chronic obstructive pulmonary disease, and type 2 diabetes in the Women's Health Study.
Topics: Aspirin; Asthma; Bronchitis, Chronic; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Female; Hu | 2010 |
Effects of low-dose of niacin associated to simvastatin in the treatment of mixed dyslipidemia Salgad.
Topics: Aged; Aspirin; Delayed-Action Preparations; Diabetes Mellitus, Type 2; Drug Combinations; Dyslipidem | 2010 |
A pharmacodynamic comparison of prasugrel vs. high-dose clopidogrel in patients with type 2 diabetes mellitus and coronary artery disease: results of the Optimizing anti-Platelet Therapy In diabetes MellitUS (OPTIMUS)-3 Trial.
Topics: Adolescent; Adult; Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Cross-Over Studies; Diabetes | 2011 |
A pharmacodynamic comparison of prasugrel vs. high-dose clopidogrel in patients with type 2 diabetes mellitus and coronary artery disease: results of the Optimizing anti-Platelet Therapy In diabetes MellitUS (OPTIMUS)-3 Trial.
Topics: Adolescent; Adult; Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Cross-Over Studies; Diabetes | 2011 |
A pharmacodynamic comparison of prasugrel vs. high-dose clopidogrel in patients with type 2 diabetes mellitus and coronary artery disease: results of the Optimizing anti-Platelet Therapy In diabetes MellitUS (OPTIMUS)-3 Trial.
Topics: Adolescent; Adult; Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Cross-Over Studies; Diabetes | 2011 |
A pharmacodynamic comparison of prasugrel vs. high-dose clopidogrel in patients with type 2 diabetes mellitus and coronary artery disease: results of the Optimizing anti-Platelet Therapy In diabetes MellitUS (OPTIMUS)-3 Trial.
Topics: Adolescent; Adult; Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Cross-Over Studies; Diabetes | 2011 |
Low-dose aspirin therapy in patients with type 2 diabetes and reduced glomerular filtration rate: subanalysis from the JPAD trial.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Atherosclerosis; Creatinine; Diabetes Mellit | 2011 |
[Effect of compound danshen dripping pill on arterial intima-media thickness in patients with newly diagnosed type 2 diabetes mellitus].
Topics: Adult; Aged; Aspirin; Blood Glucose; Carotid Intima-Media Thickness; Cholesterol; Diabetes Mellitus, | 2010 |
Pharmacodynamic effects of different aspirin dosing regimens in type 2 diabetes mellitus patients with coronary artery disease.
Topics: Aged; Aspirin; Coronary Artery Disease; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Dose-Respo | 2011 |
[Series, clinical study from Japan and its reflections; Japanese Primary Prevention of Atherosclerosis with Aspirin for Diabetes (JPAD) Trial].
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Atherosclerosis; Diabetes Mellitus, Type 2; Female; Humans; | 2011 |
Differential effect of low-dose aspirin for primary prevention of atherosclerotic events in diabetes management: a subanalysis of the JPAD trial.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Atherosclerosis; Diabetes Mellitus, Type 2; Diabetic Angiop | 2011 |
Multifactorial intervention in individuals with type 2 diabetes and microalbuminuria: the Microalbuminuria Education and Medication Optimisation (MEMO) study.
Topics: Adult; Aged; Aged, 80 and over; Albuminuria; Antihypertensive Agents; Aspirin; Blood Pressure; Chole | 2011 |
Effect of polymorphism and type II diabetes on aspirin resistance in patients with unstable coronary artery disease.
Topics: Aged; Aged, 80 and over; Arachidonic Acid; Aspirin; Coronary Artery Disease; Diabetes Mellitus, Type | 2011 |
Twice daily dosing of aspirin improves platelet inhibition in whole blood in patients with type 2 diabetes mellitus and micro- or macrovascular complications.
Topics: Aspirin; Blood Platelets; Cells, Cultured; Clinical Protocols; Diabetes Mellitus, Type 2; Diabetic A | 2011 |
Impact of pentoxifylline on platelet function profiles in patients with type 2 diabetes mellitus and coronary artery disease on dual antiplatelet therapy with aspirin and clopidogrel.
Topics: Aged; Aspirin; Blood Platelets; Cell Adhesion Molecules; Clopidogrel; Coronary Artery Disease; Diabe | 2011 |
The influence of aspirin dose and glycemic control on platelet inhibition in patients with type 2 diabetes mellitus.
Topics: Adult; Aged; Aspirin; Biomarkers; Blood Platelets; Cardiovascular Diseases; Chi-Square Distribution; | 2012 |
A diabetes scorecard does not improve HbA(1c), blood pressure, lipids, aspirin usage, exercise and diabetes knowledge over 9 months: a randomized controlled trial.
Topics: Aged; Aspirin; Black People; Blood Pressure; Cholesterol, LDL; Diabetes Mellitus, Type 2; Disease Ma | 2012 |
Platelet isoprostane overproduction in diabetic patients treated with aspirin.
Topics: Aged; Aged, 80 and over; Aspirin; Blood Platelets; Cross-Sectional Studies; Cyclooxygenase Inhibitor | 2012 |
Aspirin reduces cerebrovascular events in type 2 diabetic patients with poorly controlled blood pressure. Subanalysis from the JPAD trial.
Topics: Aged; Aspirin; Blood Pressure; Cardiovascular Agents; Cerebrovascular Disorders; Chi-Square Distribu | 2012 |
Statins but not aspirin reduce thrombotic risk assessed by thrombin generation in diabetic patients without cardiovascular events: the RATIONAL trial.
Topics: Anticholesteremic Agents; Aspirin; Atorvastatin; Cardiovascular Diseases; Diabetes Mellitus, Type 2; | 2012 |
The recovery of platelet cyclooxygenase activity explains interindividual variability in responsiveness to low-dose aspirin in patients with and without diabetes.
Topics: Aged; Aspirin; Blood Platelets; Case-Control Studies; Cyclooxygenase 1; Diabetes Mellitus, Type 2; D | 2012 |
Aspirin insensitive thromboxane generation is associated with oxidative stress in type 2 diabetes mellitus.
Topics: Administration, Oral; Antioxidants; Aspirin; Diabetes Mellitus, Type 2; Female; Humans; Male; Middle | 2012 |
Impact of clopidogrel and aspirin treatment on the expression of proteins in platelets from type-2 diabetic patients with stable coronary ischemia.
Topics: Aged; Amino Acid Sequence; Aspirin; Blood Platelets; Clopidogrel; Coronary Disease; Cytoskeletal Pro | 2012 |
The impact of decision aids to enhance shared decision making for diabetes (the DAD study): protocol of a cluster randomized trial.
Topics: Aspirin; Cardiovascular Diseases; Choice Behavior; Cluster Analysis; Comparative Effectiveness Resea | 2012 |
Evaluation of the effectiveness of sarpogrelate on the surrogate markers for macrovascular complications in patients with type 2 diabetes.
Topics: Adiponectin; Adult; Aged; Ankle Brachial Index; Aspirin; Biomarkers; C-Reactive Protein; Carotid Int | 2012 |
Effects of pioglitazone on platelet P2Y12-mediated signalling in clopidogrel-treated patients with type 2 diabetes mellitus.
Topics: Aged; Aspirin; Clopidogrel; Cross-Over Studies; Diabetes Mellitus, Type 2; Double-Blind Method; Drug | 2012 |
Effect of intensive multifactorial treatment compared with routine care on aortic stiffness and central blood pressure among individuals with screen-detected type 2 diabetes: the ADDITION-Denmark study.
Topics: Aged; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive A | 2012 |
Thrombus and antiplatelet therapy in type 2 diabetes mellitus. A prospective study after non-ST elevation acute coronary syndrome and a randomised, blinded, placebo-controlled study in stable angina.
Topics: Acute Coronary Syndrome; Aged; Angina, Stable; Aspirin; Clopidogrel; Diabetes Mellitus, Type 2; Fema | 2012 |
Do statins influence platelet reactivity on acetylsalicylic acid therapy in patients with type 2 diabetes?
Topics: Aged; Aspirin; Biomarkers; Blood Platelets; Cardiovascular Diseases; Chi-Square Distribution; Diabet | 2012 |
New single nucleotide polymorphisms associated with differences in platelets reactivity in patients with type 2 diabetes treated with acetylsalicylic acid: genome-wide association approach and pooled DNA strategy.
Topics: Aged; Alleles; Aspirin; Blood Platelets; Diabetes Mellitus, Type 2; DNA; Female; Genome-Wide Associa | 2013 |
Biological efficacy of twice daily aspirin in type 2 diabetic patients with coronary artery disease.
Topics: Analysis of Variance; Arachidonic Acid; Aspirin; Clopidogrel; Coronary Artery Disease; Cross-Over St | 2012 |
Impact of low-dose acetylsalicylic acid on kidney function in type 2 diabetic patients with elevated urinary albumin excretion rate.
Topics: Adult; Aged; Albuminuria; Aspirin; Cardiovascular Diseases; Cross-Over Studies; Diabetes Mellitus, T | 2003 |
Reducing CVD risk in type 2 DM.
Topics: Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; | 2003 |
Primary prevention of cardiovascular events with low-dose aspirin and vitamin E in type 2 diabetic patients: results of the Primary Prevention Project (PPP) trial.
Topics: Aged; Aspirin; Blood Pressure; Body Mass Index; Cardiovascular Diseases; Diabetes Mellitus, Type 2; | 2003 |
Increased protein glycation in diabetes mellitus is associated with decreased aspirin-mediated protein acetylation and reduced sensitivity of blood platelets to aspirin.
Topics: Acetylation; Adult; Aspirin; Blood Platelets; Collagen; Diabetes Mellitus, Type 2; Epinephrine; Fema | 2005 |
Aspirin sensitivity of platelet aggregation in diabetes mellitus.
Topics: Aspirin; Cardiotonic Agents; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Female; Humans; M | 2005 |
Monocyte matrix and ADAM metalloproteinase expression in type 2 diabetes after aspirin therapy.
Topics: ADAM Proteins; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Diabetes Mellitus, Type 2; Humans; | 2006 |
A randomized, double-blind, placebo-controlled trial of abciximab for prevention of in-stent restenosis in diabetic patients after coronary stenting: results of the ASIAD (Abciximab in Stenting Inhibits restenosis Among Diabetics) Trial.
Topics: Abciximab; Antibodies, Monoclonal; Aspirin; Blood Coagulation; Clopidogrel; Coronary Angiography; Co | 2005 |
Inhibition of thromboxane biosynthesis by triflusal in type 2 diabetes mellitus.
Topics: Adult; Aged; Aspirin; Biomarkers; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Doubl | 2005 |
Thromboxane-dependent CD40 ligand release in type 2 diabetes mellitus.
Topics: Aged; Aspirin; CD40 Ligand; Cross-Sectional Studies; Diabetes Mellitus, Type 2; Dinoprost; Female; H | 2006 |
Coronary revascularization (surgical or percutaneous) decreases mortality after the first year in diabetic subjects but not in nondiabetic subjects with multivessel disease: an analysis from the Medicine, Angioplasty, or Surgery Study (MASS II).
Topics: Adrenergic beta-Antagonists; Aged; Angioplasty, Balloon, Coronary; Angioplasty, Balloon, Laser-Assis | 2006 |
Functional effects of nitric oxide-releasing aspirin on vein conduits of diabetic patients undergoing CABG.
Topics: Acetylcholine; Aged; Aspirin; Coronary Artery Bypass; Coronary Artery Disease; Diabetes Mellitus, Ty | 2007 |
Aspirin therapy is still underutilized among patients with type 2 diabetes.
Topics: Adult; Analysis of Variance; Aspirin; Brazil; Cardiovascular Diseases; Contraindications; Diabetes M | 2006 |
Single dose of acetylsalicylic acid in patients with Type 2 diabetes mellitus and/or chronic renal failure ameliorates anaemia by decreasing the rate of neocytolysis.
Topics: Aged; Anemia; Aspirin; Cross-Sectional Studies; Diabetes Mellitus, Type 2; Erythropoietin; Female; H | 2007 |
The effect of aspirin on the antiproteinuric properties of enalapril in microalbuminuric type 2 diabetic patients: a randomized, double-blind, placebo-controlled study.
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Aspirin; Cardiovascular Agents; Cross-Over Studies; | 2007 |
Persistent platelet activation in patients with type 2 diabetes treated with low doses of aspirin.
Topics: Aspirin; Biomarkers; Blood Glucose; Case-Control Studies; Diabetes Mellitus, Type 2; Glycemic Index; | 2007 |
Plasma sex steroid hormones and risk of developing type 2 diabetes in women: a prospective study.
Topics: Aspirin; Body Mass Index; Cardiovascular Diseases; Dehydroepiandrosterone Sulfate; Diabetes Mellitus | 2007 |
Effects of aspirin on serum C-reactive protein and interleukin-6 levels in patients with type 2 diabetes without cardiovascular disease: a randomized placebo-controlled crossover trial.
Topics: Aspirin; Atherosclerosis; C-Reactive Protein; Cross-Over Studies; Diabetes Mellitus, Type 2; Diabeti | 2008 |
Effects of clopidogrel and aspirin in combination versus aspirin alone on platelet activation and major receptor expression in diabetic patients: the PLavix Use for Treatment Of Diabetes (PLUTO-Diabetes) trial.
Topics: Adult; Analysis of Variance; Aspirin; Biomarkers; Blood Chemical Analysis; Clopidogrel; Diabetes Mel | 2008 |
Reduced albuminuria with sarpogrelate is accompanied by a decrease in monocyte chemoattractant protein-1 levels in type 2 diabetes.
Topics: Aged; Albuminuria; Angiotensin II Type 1 Receptor Blockers; Arteriosclerosis Obliterans; Aspirin; Ch | 2008 |
Effect of a multifactorial intervention on mortality in type 2 diabetes.
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Aspirin; Behavior Therapy; Cardiovascular Diseases; | 2008 |
Effect of a multifactorial intervention on mortality in type 2 diabetes.
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Aspirin; Behavior Therapy; Cardiovascular Diseases; | 2008 |
Effect of a multifactorial intervention on mortality in type 2 diabetes.
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Aspirin; Behavior Therapy; Cardiovascular Diseases; | 2008 |
Effect of a multifactorial intervention on mortality in type 2 diabetes.
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Aspirin; Behavior Therapy; Cardiovascular Diseases; | 2008 |
Effect of a multifactorial intervention on mortality in type 2 diabetes.
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Aspirin; Behavior Therapy; Cardiovascular Diseases; | 2008 |
Effect of a multifactorial intervention on mortality in type 2 diabetes.
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Aspirin; Behavior Therapy; Cardiovascular Diseases; | 2008 |
Effect of a multifactorial intervention on mortality in type 2 diabetes.
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Aspirin; Behavior Therapy; Cardiovascular Diseases; | 2008 |
Effect of a multifactorial intervention on mortality in type 2 diabetes.
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Aspirin; Behavior Therapy; Cardiovascular Diseases; | 2008 |
Effect of a multifactorial intervention on mortality in type 2 diabetes.
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Aspirin; Behavior Therapy; Cardiovascular Diseases; | 2008 |
Lack of interference of aspirin in HbA1c measured by ion-exchange HPLC in type 2 diabetic patients: a randomized, double-blind, placebo-controlled study.
Topics: Aspirin; Chromatography, Ion Exchange; Cross-Over Studies; Diabetes Mellitus, Type 2; Double-Blind M | 2008 |
Antiplatelet profiles of the fixed-dose combination of extended-release dipyridamole and low-dose aspirin compared with clopidogrel with or without aspirin in patients with type 2 diabetes and a history of transient ischemic attack: a randomized, single-b
Topics: Adult; Aged; Aspirin; Aspirin, Dipyridamole Drug Combination; Biomarkers; Clopidogrel; Diabetes Mell | 2008 |
Accommodative amplitudes in the Early Treatment Diabetic Retinopathy Study.
Topics: Accommodation, Ocular; Adolescent; Adult; Age Factors; Aspirin; Diabetes Mellitus, Type 1; Diabetes | 1995 |
Intensive insulin therapy in type II diabetes: rationale and collaborative clinical trial results.
Topics: Arteriosclerosis; Aspirin; Blood Glucose; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Dose-Res | 1996 |
Early photocoagulation in patients with either type I or type II diabetes.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Diabetes Mellitus, Type 1; Diabetes Mellitu | 1996 |
Early photocoagulation in patients with either type I or type II diabetes.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Diabetes Mellitus, Type 1; Diabetes Mellitu | 1996 |
Early photocoagulation in patients with either type I or type II diabetes.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Diabetes Mellitus, Type 1; Diabetes Mellitu | 1996 |
Early photocoagulation in patients with either type I or type II diabetes.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Diabetes Mellitus, Type 1; Diabetes Mellitu | 1996 |
Early photocoagulation in patients with either type I or type II diabetes.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Diabetes Mellitus, Type 1; Diabetes Mellitu | 1996 |
Early photocoagulation in patients with either type I or type II diabetes.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Diabetes Mellitus, Type 1; Diabetes Mellitu | 1996 |
Early photocoagulation in patients with either type I or type II diabetes.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Diabetes Mellitus, Type 1; Diabetes Mellitu | 1996 |
Early photocoagulation in patients with either type I or type II diabetes.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Diabetes Mellitus, Type 1; Diabetes Mellitu | 1996 |
Early photocoagulation in patients with either type I or type II diabetes.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Diabetes Mellitus, Type 1; Diabetes Mellitu | 1996 |
Early photocoagulation in patients with either type I or type II diabetes.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Diabetes Mellitus, Type 1; Diabetes Mellitu | 1996 |
Early photocoagulation in patients with either type I or type II diabetes.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Diabetes Mellitus, Type 1; Diabetes Mellitu | 1996 |
Early photocoagulation in patients with either type I or type II diabetes.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Diabetes Mellitus, Type 1; Diabetes Mellitu | 1996 |
Early photocoagulation in patients with either type I or type II diabetes.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Diabetes Mellitus, Type 1; Diabetes Mellitu | 1996 |
Early photocoagulation in patients with either type I or type II diabetes.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Diabetes Mellitus, Type 1; Diabetes Mellitu | 1996 |
Early photocoagulation in patients with either type I or type II diabetes.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Diabetes Mellitus, Type 1; Diabetes Mellitu | 1996 |
Early photocoagulation in patients with either type I or type II diabetes.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Diabetes Mellitus, Type 1; Diabetes Mellitu | 1996 |
Early photocoagulation in patients with either type I or type II diabetes.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Diabetes Mellitus, Type 1; Diabetes Mellitu | 1996 |
Early photocoagulation in patients with either type I or type II diabetes.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Diabetes Mellitus, Type 1; Diabetes Mellitu | 1996 |
Early photocoagulation in patients with either type I or type II diabetes.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Diabetes Mellitus, Type 1; Diabetes Mellitu | 1996 |
Early photocoagulation in patients with either type I or type II diabetes.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Diabetes Mellitus, Type 1; Diabetes Mellitu | 1996 |
Early photocoagulation in patients with either type I or type II diabetes.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Diabetes Mellitus, Type 1; Diabetes Mellitu | 1996 |
Early photocoagulation in patients with either type I or type II diabetes.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Diabetes Mellitus, Type 1; Diabetes Mellitu | 1996 |
Early photocoagulation in patients with either type I or type II diabetes.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Diabetes Mellitus, Type 1; Diabetes Mellitu | 1996 |
Early photocoagulation in patients with either type I or type II diabetes.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Diabetes Mellitus, Type 1; Diabetes Mellitu | 1996 |
Early photocoagulation in patients with either type I or type II diabetes.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Diabetes Mellitus, Type 1; Diabetes Mellitu | 1996 |
Effects of aspirin or basic amino acids on collagen cross-links and complications in NIDDM.
Topics: Analysis of Variance; Arginine; Aspirin; Biopsy; Blood Glucose; Collagen; Cross-Linking Reagents; Cy | 1997 |
Is low-dose aspirin a useful adjuvant therapy in the treatment of NIDDM?
Topics: Aspirin; Blood Glucose; Diabetes Mellitus, Type 2; Glycated Hemoglobin; Humans; Hypoglycemic Agents | 1997 |
Diabetes mellitus, hypercholesterolemia, and hypertension but not vascular disease per se are associated with persistent platelet activation in vivo. Evidence derived from the study of peripheral arterial disease.
Topics: Adult; Aged; Aspirin; Cross-Sectional Studies; Diabetes Mellitus, Type 2; Female; Follow-Up Studies; | 1997 |
Risk factors for high-risk proliferative diabetic retinopathy and severe visual loss: Early Treatment Diabetic Retinopathy Study Report #18.
Topics: Adolescent; Adult; Aged; Aspirin; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Diabetic Neu | 1998 |
[Lowering of diastolic blood pressure < or = 90 mmHg should not be attempted, except in type 2 diabetics; the 'Hypertension optimal treatment' (HOT) trial].
Topics: Adult; Aged; Aspirin; Blood Pressure; Calcium Channel Blockers; Cardiovascular Diseases; Diabetes Me | 1999 |
[Beneficial effect of aspirin in diabetic coronary disease: facts to prove it].
Topics: Aspirin; Coronary Disease; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Humans; Retrospective S | 1999 |
Risks of preeclampsia and adverse neonatal outcomes among women with pregestational diabetes mellitus. National Institute of Child Health and Human Development Network of Maternal-Fetal Medicine Units.
Topics: Aspirin; Birth Weight; Blood Pressure; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Female; | 2000 |
A comparative randomized and placebo-controlled short-term trial of aspirin and dipyridamole for overt type-2 diabetic nephropathy.
Topics: Adult; Aged; Aspirin; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Dipyridamole; Drug Administ | 2002 |
Morning peak in the incidence of myocardial infarction: experience in the ISIS-2 trial. ISIS-2 (Second International Study of Infarct Survival) Collaborative Group.
Topics: Adult; Age Factors; Aged; Aspirin; Circadian Rhythm; Diabetes Mellitus, Type 2; Diabetic Angiopathie | 1992 |
Effect of aspirin alone and aspirin plus dipyridamole in early diabetic retinopathy. A multicenter randomized controlled clinical trial. The DAMAD Study Group.
Topics: Adult; Aspirin; Blood Pressure; Clinical Trials as Topic; Diabetes Mellitus, Type 1; Diabetes Mellit | 1989 |
254 other studies available for aspirin and Diabetes Mellitus, Adult-Onset
| Article | Year |
|---|---|
Identification of a promising drug candidate for the treatment of type 2 diabetes based on a P2Y(1) receptor agonist.
Topics: Animals; Blood Glucose; Cell Line, Tumor; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2 | 2012 |
Towards multi-target antidiabetic agents: Discovery of biphenyl-benzimidazole conjugates as AMPK activators.
Topics: AMP-Activated Protein Kinases; Animals; Benzimidazoles; Biphenyl Compounds; Cattle; Diabetes Mellitu | 2019 |
Clinical and Pharmacological Parameters Determine Relapse During Clopidogrel Treatment of Acute Coronary Syndrome.
Topics: Acute Coronary Syndrome; Aspirin; Calcium Channel Blockers; Clopidogrel; Coronary Artery Disease; Cy | 2022 |
Managing Hypertension, Diabetes, and Cardiovascular Disease Risk via Short-Term Medical Trips: A Retrospective Longitudinal Study in Santo Domingo.
Topics: Aspirin; Blood Pressure; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Glycated Hemoglobin; Hu | 2022 |
Association between aspirin use during pregnancy and cardiovascular risk factors 2-7 years after delivery: The nuMoM2b Heart Health Study.
Topics: Aspirin; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Female; Heart Disease Risk Factors; Hum | 2022 |
Sjögren syndrome is a hidden contributor of macrovascular and microvascular complications in patients with type 2 diabetes.
Topics: Aspirin; Case-Control Studies; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Humans; Hydroxychlo | 2022 |
Cardiovascular Disease Prevention: Pharmacologic Prevention.
Topics: Adult; Aged; Aspirin; Cardiovascular Diseases; Cholesterol, LDL; Diabetes Mellitus, Type 2; Humans; | 2022 |
Serial assessment of thrombogenicity and hemodynamics in patients with type II diabetes in a clinical research unit: Evidence for circadian variations in clot formation.
Topics: Adenosine Diphosphate; Arachidonic Acid; Aspirin; Blood Pressure; Circadian Rhythm; Diabetes Mellitu | 2022 |
Antiplatelet agents aspirin and dipyridamole, and the risk of different carcinoma in patients with type 2 diabetes mellitus: A Taiwan retrospective cohort study.
Topics: Aspirin; Carcinoma; Diabetes Mellitus, Type 2; Dipyridamole; Humans; Liver Neoplasms; Platelet Aggre | 2022 |
Pharmacist-led medication therapy management of diabetes club patients at a primary healthcare clinic in Cape Town, South Africa: A retrospective and prospective audit.
Topics: Adult; Aspirin; Diabetes Mellitus, Type 2; Female; Humans; Male; Medication Therapy Management; Phar | 2022 |
Low-dose aspirin does not lower the risk of colorectal cancer in patients with type 2 diabetes taking metformin.
Topics: Adult; Aspirin; Cohort Studies; Colorectal Neoplasms; Diabetes Mellitus, Type 2; Humans; Hypoglycemi | 2023 |
Low-dose aspirin does not lower the risk of colorectal cancer in patients with type 2 diabetes taking metformin.
Topics: Adult; Aspirin; Cohort Studies; Colorectal Neoplasms; Diabetes Mellitus, Type 2; Humans; Hypoglycemi | 2023 |
Low-dose aspirin does not lower the risk of colorectal cancer in patients with type 2 diabetes taking metformin.
Topics: Adult; Aspirin; Cohort Studies; Colorectal Neoplasms; Diabetes Mellitus, Type 2; Humans; Hypoglycemi | 2023 |
Low-dose aspirin does not lower the risk of colorectal cancer in patients with type 2 diabetes taking metformin.
Topics: Adult; Aspirin; Cohort Studies; Colorectal Neoplasms; Diabetes Mellitus, Type 2; Humans; Hypoglycemi | 2023 |
Low-dose aspirin does not lower the risk of colorectal cancer in patients with type 2 diabetes taking metformin.
Topics: Adult; Aspirin; Cohort Studies; Colorectal Neoplasms; Diabetes Mellitus, Type 2; Humans; Hypoglycemi | 2023 |
Low-dose aspirin does not lower the risk of colorectal cancer in patients with type 2 diabetes taking metformin.
Topics: Adult; Aspirin; Cohort Studies; Colorectal Neoplasms; Diabetes Mellitus, Type 2; Humans; Hypoglycemi | 2023 |
Low-dose aspirin does not lower the risk of colorectal cancer in patients with type 2 diabetes taking metformin.
Topics: Adult; Aspirin; Cohort Studies; Colorectal Neoplasms; Diabetes Mellitus, Type 2; Humans; Hypoglycemi | 2023 |
Low-dose aspirin does not lower the risk of colorectal cancer in patients with type 2 diabetes taking metformin.
Topics: Adult; Aspirin; Cohort Studies; Colorectal Neoplasms; Diabetes Mellitus, Type 2; Humans; Hypoglycemi | 2023 |
Low-dose aspirin does not lower the risk of colorectal cancer in patients with type 2 diabetes taking metformin.
Topics: Adult; Aspirin; Cohort Studies; Colorectal Neoplasms; Diabetes Mellitus, Type 2; Humans; Hypoglycemi | 2023 |
Risk factors for in-stent restenosis after coronary stent implantation in patients with coronary artery disease: A retrospective observational study.
Topics: Aspirin; Constriction, Pathologic; Coronary Artery Disease; Coronary Restenosis; Diabetes Mellitus, | 2022 |
Risk factors for in-stent restenosis after coronary stent implantation in patients with coronary artery disease: A retrospective observational study.
Topics: Aspirin; Constriction, Pathologic; Coronary Artery Disease; Coronary Restenosis; Diabetes Mellitus, | 2022 |
Risk factors for in-stent restenosis after coronary stent implantation in patients with coronary artery disease: A retrospective observational study.
Topics: Aspirin; Constriction, Pathologic; Coronary Artery Disease; Coronary Restenosis; Diabetes Mellitus, | 2022 |
Risk factors for in-stent restenosis after coronary stent implantation in patients with coronary artery disease: A retrospective observational study.
Topics: Aspirin; Constriction, Pathologic; Coronary Artery Disease; Coronary Restenosis; Diabetes Mellitus, | 2022 |
Reduced platelet glycoprotein Ibα shedding accelerates thrombopoiesis and COX-1 recovery: implications for aspirin dosing regimen.
Topics: Aspirin; Blood Platelets; Diabetes Mellitus, Type 2; Humans; Platelet Membrane Glycoproteins; Thromb | 2023 |
Appropriateness of aspirin use among diabetic patients in primary prevention of atherosclerotic cardiovascular diseases: an analysis of the ASSOS study.
Topics: American Heart Association; Aspirin; Atherosclerosis; Cardiology; Cardiovascular Diseases; Diabetes | 2023 |
Does chronic low-dose aspirin use benefit bone health? A cross-sectional study on patients with type 2 diabetes mellitus.
Topics: Absorptiometry, Photon; Aged; Aspirin; Biomarkers; Bone Density; Cross-Sectional Studies; Diabetes M | 2023 |
The Diabetic Platelets.
Topics: Aspirin; Blood Platelets; Diabetes Mellitus; Diabetes Mellitus, Type 2; Glucose; Humans; Platelet Ag | 2023 |
Glucagon-like Peptide-1 Receptor Pathway Attenuates Platelet Activation in Aspirin-Exacerbated Respiratory Disease.
Topics: Animals; Aspirin; Asthma; Asthma, Aspirin-Induced; Diabetes Mellitus, Type 2; Glucagon-Like Peptide- | 2023 |
Inhibition of JAK-STAT and NF-κB signalling systems could be a novel therapeutic target against insulin resistance and type 2 diabetes.
Topics: Animals; Aspirin; Blood Glucose; Cytokines; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type | 2019 |
Efficacy of Aspirin in the Primary Prevention of Cardiovascular Diseases and Cancer in the Elderly: A Population-Based Cohort Study in Korea.
Topics: Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Cohort Studies; Diabetes Mellitus, Type 2 | 2020 |
Determinants of aspirin resistance in patients with type 2 diabetes.
Topics: Aged; Arachidonic Acid; Aspirin; C-Reactive Protein; Coronary Artery Disease; Diabetes Mellitus, Typ | 2020 |
Cost-effectiveness analysis of aspirin for primary prevention of cardiovascular events among patients with type 2 diabetes in China.
Topics: Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; China; Cost-Benefit Analysis; Diabetes Me | 2019 |
A Decision-Support Software to Improve the Standard Care in Chinese Type 2 Diabetes.
Topics: Antihypertensive Agents; Aspirin; Blood Glucose; Blood Pressure; Cardiovascular Diseases; China; Dec | 2019 |
Impact of risk factors of ischemic heart disease on the development of acute coronary syndrome, platelet ultrastructure, and aspirin resistance.
Topics: Acute Coronary Syndrome; Aspirin; Blood Platelets; Diabetes Mellitus, Type 2; Humans; Middle Aged; R | 2019 |
In stable CAD with type 2 diabetes, adding ticagrelor to aspirin reduced CV events but increased major bleeding.
Topics: Aspirin; Coronary Artery Disease; Diabetes Mellitus, Type 2; Hemorrhage; Humans; Ticagrelor | 2020 |
Aspirin in a diabetic retinopathy setting: Insights from NO BLIND study.
Topics: Aged; Aspirin; Cardiovascular Agents; Cardiovascular Diseases; Cross-Sectional Studies; Diabetes Mel | 2020 |
Society for Maternal-Fetal Medicine Special Statement: Updated checklist for antepartum care of pregestational diabetes mellitus.
Topics: Aspirin; Checklist; Delivery, Obstetric; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Disea | 2020 |
Recommendation of Aspirin-Guide App and Physicians Clinical Decision of Aspirin Use to Prevent CVD Among Diabetic Patients, Is there any Differences?
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Clinical Decision-Making; Cross-Se | 2021 |
Impaired intestinal barrier function in type 2 diabetic patients measured by serum LPS, Zonulin, and IFABP.
Topics: Aspirin; Diabetes Mellitus, Type 2; Fatty Acid-Binding Proteins; Glycated Hemoglobin; Glycemic Contr | 2021 |
Glycation and acetylation sites on fibrinogen in plasma fibrin clot of patients with type 2 diabetes: Effects of low-dose acetylsalicylic acid.
Topics: Acetylation; Aspirin; Diabetes Mellitus, Type 2; Fibrin; Fibrinogen; Fibrinolysis; Humans; Proteomic | 2021 |
Assessment of The High risk and unmEt Need in patients with CAD and type 2 diabetes (ATHENA): US healthcare resource use, cost, and burden of illness in a commercially insured population.
Topics: Aspirin; Coronary Artery Disease; Cost of Illness; Delivery of Health Care; Diabetes Mellitus, Type | 2021 |
[Atherosclerotic Cardiovascular Diseases and Type 2 Diabetes Mellitus - new Developments in the Treatment].
Topics: Aspirin; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Humans; Plat | 2021 |
Patient Preferences of Low-Dose Aspirin for Cardiovascular Disease and Colorectal Cancer Prevention in Italy: A Latent Class Analysis.
Topics: Aspirin; Cardiovascular Diseases; Colorectal Neoplasms; Cross-Sectional Studies; Diabetes Mellitus, | 2021 |
Dashboards to reduce inappropriate prescribing of metformin and aspirin: A quality assurance programme in a primary care sentinel network.
Topics: Aspirin; Diabetes Mellitus, Type 2; Humans; Inappropriate Prescribing; Metformin; Primary Health Car | 2021 |
Appropriateness of aspirin prescribing for primary and secondary prevention of cardiovascular disease in type 2 diabetes in different care settings.
Topics: Adult; Aspirin; Cardiovascular Diseases; Cross-Sectional Studies; Diabetes Mellitus, Type 2; Humans; | 2022 |
Metformin Targets Foxo1 to Control Glucose Homeostasis.
Topics: Animals; Aspirin; Blood Glucose; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Female; | 2021 |
Effect of diabetic kidney disease on therapeutic strategies for coronary artery disease: ten year follow-up.
Topics: Aged; Aspirin; Calcium Channel Blockers; Coronary Artery Disease; Diabetes Mellitus, Type 2; Diabeti | 2021 |
Restless legs syndrome/Willis-Ekbom disease in type 2 diabetes as the initial manifestation of Parkinson's disease and major cardiovascular disease.
Topics: Aged; Amines; Analgesics; Anticonvulsants; Antihypertensive Agents; Antiparkinson Agents; Aspirin; B | 2017 |
Impact of USPSTF recommendations for aspirin for prevention of recurrent preeclampsia.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cohort Studies; Diabetes Mellitus, Type 2; | 2017 |
Reducing CV risk in diabetes: An ADA update.
Topics: Antihypertensive Agents; Aspirin; Benzhydryl Compounds; Cardiovascular Diseases; Contraindications; | 2017 |
Letter by Ahmed et al Regarding Article, "Low-Dose Aspirin for Primary Prevention of Cardiovascular Events in Patients With Type 2 Diabetes Mellitus: 10-Year Follow-Up of a Randomized Controlled Trial".
Topics: Aspirin; Diabetes Mellitus, Type 2; Follow-Up Studies; Humans; Primary Prevention | 2017 |
Response by Saito et al to Letter Regarding Article, "Low-Dose Aspirin for Primary Prevention of Cardiovascular Events in Patients With Type 2 Diabetes Mellitus: 10-Year Follow-Up of a Randomized Controlled Trial".
Topics: Aspirin; Diabetes Mellitus, Type 2; Follow-Up Studies; Humans; Primary Prevention | 2017 |
Collapse of the Aspirin Empire: Is it Diabetic Gastroparesis or Cardioprotective Paresis?
Topics: Aspirin; Diabetes Mellitus, Type 2; Diabetic Neuropathies; Gastroparesis; Humans; Paresis | 2017 |
The effect of acetylsalicylic acid on vasopressin, serum insulin levels, insulin resistance, and biochemical parameters in rats induced with experimental diabetes type 2.
Topics: Animals; Aspirin; Blood Glucose; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Insulin | 2017 |
Computed Tomography Angiography Images of Coronary Artery Stenosis Provide a Better Prediction of Risk Than Traditional Risk Factors in Asymptomatic Individuals With Type 2 Diabetes: A Long-term Study of Clinical Outcomes.
Topics: Aged; Aspirin; Cholesterol; Computed Tomography Angiography; Coronary Angiography; Coronary Artery D | 2017 |
Aspirin Versus Clopidogrel for Type 2 Diabetic Patients with First-Ever Noncardioembolic Acute Ischemic Stroke: Ten-Year Survival Data from the Athens Stroke Outcome Project.
Topics: Aged; Aged, 80 and over; Aspirin; Brain Ischemia; Chi-Square Distribution; Clopidogrel; Diabetes Mel | 2017 |
V. Aboyans et al. in response to the article by M. Helfre et al.: Usefulness of a systematic screening of carotid atherosclerosis in asymptomatic people with type 2 diabetes for cardiovascular risk reclassification. Ann Endocrinol (Paris). 2017;78:14-19.
Topics: Aspirin; Cardiovascular Diseases; Carotid Artery Diseases; Diabetes Mellitus, Type 2; Humans; Risk F | 2017 |
Effects of aspirin in combination with EPA and DHA on HDL-C cholesterol and ApoA1 exchange in individuals with type 2 diabetes mellitus.
Topics: Adult; Aged; Apolipoprotein A-I; Aspirin; Cholesterol, HDL; Diabetes Mellitus, Type 2; Docosahexaeno | 2017 |
Antiplatelet effect of aspirin during 24h in patients with type 2 diabetes without cardiovascular disease.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Diabetes Mellitus, Type 2; Female; Humans; Male; M | 2018 |
Control of cardiovascular disease risk factors among patients with type II diabetes in a primary-care setting in Beijing.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Beijing; Blood Glucose; Cholesterol, LDL; Cross-Sectional S | 2018 |
Vitamin D diminishes the high platelet aggregation of type 2 diabetes mellitus patients.
Topics: Aged; Aspirin; Biomarkers; Blood Platelets; Diabetes Mellitus, Type 2; Female; Humans; Male; Middle | 2019 |
A foreign older diabetic woman with an acute myocardial infarction: when cognitive biases in clinical decision-making become especially important.
Topics: Aged, 80 and over; Angioplasty, Balloon, Coronary; Anticoagulants; Aspirin; Clinical Decision-Making | 2018 |
Glycaemic control and cardiovascular risk factor management in patients with diabetes with and without coronary artery disease: insights from the diabetes mellitus status in Canada survey.
Topics: Aged; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Aspirin; Blood Glu | 2016 |
Metformin and risk of hepatocellular carcinoma in patients with type 2 diabetes.
Topics: Aged; Aspirin; Carcinoma, Hepatocellular; Cohort Studies; Databases, Factual; Diabetes Mellitus, Typ | 2018 |
ASPIRIN FOR PRIMARY PREVENTION IN PATIENTS WITH TYPE 2 DIABETES.
Topics: Aspirin; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Humans; Patient | 2018 |
Comparison of nine platelet function tests used to determine responses to different aspirin dosages in people with type 2 diabetes.
Topics: Aspirin; Cross-Over Studies; Diabetes Mellitus, Type 2; Female; Humans; Male; Middle Aged; Platelet | 2019 |
The effects of cardiovascular risk factor combined anti-platelet therapy and the risk of cerebrovascular events in patients with T2DM in an urban community over 96-months follow-up: The Beijing communities diabetes study 19.
Topics: Aged; Aspirin; Beijing; Cardiovascular Diseases; Cerebrovascular Disorders; Diabetes Mellitus, Type | 2018 |
Diabetes and Platelet Response to Low-Dose Aspirin.
Topics: Adult; Aspirin; Blood Platelets; Coronary Artery Disease; Diabetes Mellitus, Type 2; Dose-Response R | 2018 |
ACOG Practice Bulletin No. 201 Summary: Pregestational Diabetes Mellitus.
Topics: Administration, Oral; Aspirin; Blood Glucose; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; | 2018 |
One quarter of total myocardial infarctions are silent manifestation in patients with type 2 diabetes mellitus.
Topics: Aged; Aspirin; Atherosclerosis; Diabetes Mellitus, Type 2; Electrocardiography; Female; Fibrinolytic | 2019 |
Aspirin Use and Cardiovascular Outcome in Patients With Type 2 Diabetes Mellitus and Heart Failure: A Population-Based Cohort Study.
Topics: Aged; Aspirin; Cardiovascular Diseases; Cohort Studies; Diabetes Mellitus, Type 2; Female; Heart Fai | 2018 |
Prediction of individual life-years gained without cardiovascular events from lipid, blood pressure, glucose, and aspirin treatment based on data of more than 500 000 patients with Type 2 diabetes mellitus.
Topics: Aged; Antihypertensive Agents; Aspirin; Cardiovascular Diseases; Cohort Studies; Diabetes Complicati | 2019 |
An Irish National Diabetes in Pregnancy Audit: aiming for best outcomes for women with diabetes.
Topics: Abortion, Spontaneous; Adult; Aspirin; Cesarean Section; Clinical Audit; Delivery of Health Care; De | 2020 |
Increased exercise-related platelet activation assessed by impedance aggregometry in diabetic patients despite aspirin therapy.
Topics: Aged; Aspirin; Blood Specimen Collection; Case-Control Studies; Diabetes Mellitus, Type 2; Electric | 2019 |
Latin American Consensus on the management of hypertension in the patient with diabetes and the metabolic syndrome.
Topics: Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Aspirin; Cardiovascular Diseases; | 2019 |
No beneficial effects of aspirin on secondary cardiovascular prevention in patients with type 2 diabetes using non-steroidal anti-inflammatory drugs.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cardiovascular Diseases; Diabetes Mellitus, | 2019 |
[The Pathways to Increase the Efficacy of Drug Therapy in Patients with Ischemic Heart Disease after Coronary Artery Bypass Grafting].
Topics: Aged; Angina Pectoris; Aspirin; Coronary Artery Bypass; Coronary Artery Disease; Diabetes Mellitus, | 2019 |
Prediction of human genes and diseases targeted by xenobiotics using predictive toxicogenomic-derived models (PTDMs).
Topics: Arrhythmias, Cardiac; Aspirin; Benzhydryl Compounds; Bradycardia; Computer Simulation; Databases, Ch | 2013 |
Association of plasma concentrations of salicylic acid and high on ASA platelet reactivity in type 2 diabetes patients.
Topics: Aged; Aspirin; Biomarkers; Blood Platelets; Chromatography, High Pressure Liquid; Coronary Artery Di | 2013 |
Primary PCI with endothelial progenitor cell-capture stent in patient with skull base fracture and aspirin allergy.
Topics: Aged; Aspirin; Contraindications; Diabetes Mellitus, Type 2; Drug Hypersensitivity; Electrocardiogra | 2013 |
Lack of effect of common single nucleotide polymorphisms in leukotriene pathway genes on platelet reactivity in patients with diabetes.
Topics: 5-Lipoxygenase-Activating Proteins; Aged; Alleles; Arachidonate 12-Lipoxygenase; Arachidonate 15-Lip | 2013 |
Aspirin resistance in patients with type II diabetes mellitus.
Topics: Aged; Aspirin; Case-Control Studies; Diabetes Mellitus, Type 2; Drug Resistance; Female; Humans; Mal | 2014 |
Assessment methods for aspirin-mediated platelet antiaggregation in type 2 diabetic patients: degree of correlation between 2 point-of-care methods.
Topics: Aspirin; Diabetes Mellitus, Type 2; Drug-Eluting Stents; Female; Humans; Male; Percutaneous Coronary | 2014 |
Clopidogrel resistance in diabetic patient with acute myocardial infarction due to stent thrombosis.
Topics: Aged, 80 and over; Aspirin; Clopidogrel; Coronary Angiography; Diabetes Mellitus, Type 2; Drug Resis | 2014 |
Differences in thrombus structure and kinetics in patients with type 2 diabetes mellitus after non ST elevation acute coronary syndrome.
Topics: Acute Coronary Syndrome; Aged; Aspirin; Clopidogrel; Diabetes Mellitus, Type 2; Female; Humans; Male | 2014 |
Non-HDL cholesterol is an independent risk factor for aspirin resistance in obese patients with type 2 diabetes.
Topics: Asian People; Aspirin; Cardiovascular Diseases; Cholesterol; Diabetes Mellitus, Type 2; Drug Resista | 2014 |
Resistance to acetylsalicylic acid in patients with type 2 diabetes mellitus is associated with lipid disorders and history of current smoking.
Topics: Aged; Aspirin; Cholesterol; Diabetes Mellitus, Type 2; Drug Resistance; Female; Hematocrit; Humans; | 2014 |
Prognostic value of bleeding after percutaneous coronary intervention in patients with diabetes.
Topics: Abciximab; Aged; Antibodies, Monoclonal; Anticoagulants; Antithrombins; Aspirin; Clopidogrel; Corona | 2014 |
Reduced antiplatelet effect of aspirin during 24 hours in patients with coronary artery disease and type 2 diabetes.
Topics: Aged; Aspirin; Biomarkers; Blood Platelets; Coronary Artery Disease; Diabetes Mellitus, Type 2; Fema | 2015 |
Myocardial infarction and gastro-intestinal bleeding risks associated with aspirin use among elderly individuals with type 2 diabetes.
Topics: Aged; Aged, 80 and over; Aspirin; Case-Control Studies; Cohort Studies; Databases, Factual; Diabetes | 2014 |
Evaluation of inflammatory conditions associated with aspirin resistance.
Topics: Aspirin; Diabetes Mellitus, Type 2; Female; Humans; Male | 2014 |
Author's reply: Predictors of aspirin resistance.
Topics: Aspirin; Diabetes Mellitus, Type 2; Female; Humans; Male | 2014 |
Circulating dickkopf-1 in diabetes mellitus: association with platelet activation and effects of improved metabolic control and low-dose aspirin.
Topics: Aged; Arginine; Aspirin; Biomarkers; Cardiovascular Diseases; Case-Control Studies; CD40 Ligand; Cro | 2014 |
The influence of type 2 diabetes on fibrin clot properties in patients with coronary artery disease.
Topics: Aged; Aspirin; Blood Coagulation Tests; C-Reactive Protein; Case-Control Studies; Complement C3; Cor | 2014 |
Impaired responsiveness to the platelet P2Y12 receptor antagonist clopidogrel in patients with type 2 diabetes and coronary artery disease.
Topics: Adult; Aged; Aspirin; Clopidogrel; Cohort Studies; Coronary Artery Disease; Diabetes Mellitus, Type | 2014 |
Evaluation of aspirin use in patients with diabetes receiving care in community health.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Data Collection; Diabe | 2015 |
Evaluation of aspirin use for primary prevention in diabetic patients.
Topics: Aspirin; Diabetes Mellitus, Type 2; Female; Humans; Male; Platelet Aggregation Inhibitors | 2015 |
Response to comment "Evaluation of aspirin use for primary prevention in diabetic patients".
Topics: Aspirin; Diabetes Mellitus, Type 2; Female; Humans; Male; Platelet Aggregation Inhibitors | 2015 |
Chocolate consumption and risk of diabetes mellitus in the Physicians' Health Study.
Topics: Aged; Aspirin; beta Carotene; Cacao; Candy; Diabetes Mellitus, Type 2; Dose-Response Relationship, D | 2015 |
Spontaneous iliopsoas haematoma: a complication of hypertensive urgency.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Blood Transfusion; Diabetes Mellitus, Type 2 | 2015 |
Metformin and salicylate synergistically activate liver AMPK, inhibit lipogenesis and improve insulin sensitivity.
Topics: AMP-Activated Protein Kinases; Animals; Aspirin; Cardiotonic Agents; Cells, Cultured; Diabetes Melli | 2015 |
[Two catheters for one coronary perforation].
Topics: Aged; Angina, Unstable; Angioplasty, Balloon, Coronary; Antihypertensive Agents; Aspirin; Cardiac Ca | 2015 |
Determinants of reduced antiplatelet effect of aspirin in patients with stable coronary artery disease.
Topics: Aged; Aspirin; Body Mass Index; Coronary Artery Disease; Cross-Sectional Studies; Diabetes Mellitus, | 2015 |
Long-Term Low-Dose Aspirin Use Reduces Gastric Cancer Incidence: A Nationwide Cohort Study.
Topics: Adult; Aged; Aspirin; Cohort Studies; Comorbidity; Diabetes Mellitus, Type 2; Female; Humans; Hypert | 2016 |
Enhanced Glucose Tolerance and Pancreatic Beta Cell Function by Low Dose Aspirin in Hyperglycemic Insulin-Resistant Type 2 Diabetic Goto-Kakizaki (GK) Rats.
Topics: Animals; Aspirin; Body Weight; Diabetes Mellitus, Type 2; Dinoprostone; Dose-Response Relationship, | 2015 |
The Therapeutic Effect of Stellate Ganglion Block on Facial Nerve Palsy in Patients with Type 2 Diabetes Mellitus.
Topics: Adult; Anesthetics, Local; Antipyrine; Aspirin; Autonomic Nerve Block; Blood Glucose; Dexamethasone; | 2015 |
Next-generation re-sequencing of genes involved in increased platelet reactivity in diabetic patients on acetylsalicylic acid.
Topics: Aged; Alleles; Aspirin; Biomarkers; Blood Platelets; Diabetes Mellitus, Type 2; Exons; Female; Gene | 2016 |
[Impact of sitagliptin on aspirin resistance in patients with Type 2 diabetes mellitus].
Topics: Aspirin; Blood Glucose; C-Reactive Protein; Diabetes Mellitus, Type 2; Drug Resistance; Glycated Hem | 2015 |
Use of cardiovascular medicines in newly treated type 2 diabetes patients: A retrospective cohort study in general practice.
Topics: Administrative Claims, Healthcare; Adult; Age Factors; Aged; Aged, 80 and over; Antihypertensive Age | 2016 |
[Correlation between the level of the urinary 11-dehydrothromboxane B2 and the clinical efficacy of aspirin in patients with type 2 diabetes and coronary artery disease].
Topics: Aspirin; Beijing; Blood Platelets; Coronary Artery Disease; Diabetes Mellitus, Type 2; Humans; Plate | 2015 |
Value of Coronary Computed Tomography Angiography in Tailoring Aspirin Therapy for Primary Prevention of Atherosclerotic Events in Patients at High Risk With Diabetes Mellitus.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Body Mass Index; Coronary Angiography; Coron | 2016 |
Increases in ambient particulate matter air pollution, acute changes in platelet function, and effect modification by aspirin and omega-3 fatty acids: A panel study.
Topics: Adult; Aged; Aged, 80 and over; Air Pollutants; Air Pollution; Aspirin; Blood Platelets; Collagen; D | 2016 |
Microparticle Shedding by Erythrocytes, Monocytes and Vascular Smooth Muscular Cells Is Reduced by Aspirin in Diabetic Patients.
Topics: Adult; Aged; Aspirin; Blood Platelets; Cardiovascular Diseases; Cell-Derived Microparticles; Diabete | 2016 |
Oral treatment with a zinc complex of acetylsalicylic acid prevents diabetic cardiomyopathy in a rat model of type-2 diabetes: activation of the Akt pathway.
Topics: Administration, Oral; Animals; Aspirin; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; | 2016 |
Topics: Aspirin; Atherosclerosis; Brazil; Cardiovascular Diseases; Coronary Artery Disease; Diabetes Mellitu | 2014 |
Medical research: Time to think differently about diabetes.
Topics: Adipose Tissue; Animals; Aspirin; Bariatric Surgery; Bile Acids and Salts; Biomedical Research; Bloo | 2016 |
The Impact of Type 2 Diabetes on the Efficacy of ADP Receptor Blockers in Patients with Acute ST Elevation Myocardial Infarction: A Pilot Prospective Study.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Case-Control Studies; Clopidogrel; Diabetes Mellitus, Type | 2016 |
Mean Daily Dosage of Aspirin and the Risk of Incident Alzheimer's Dementia in Patients with Type 2 Diabetes Mellitus: A Nationwide Retrospective Cohort Study in Taiwan.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Aspirin; Databases, Factual; Diabetes Mellitus, Type 2; | 2016 |
Prevalence of aspirin resistance in patients with type II diabetes: a descriptive-analytical study
.
Topics: Aged; Aspirin; Cross-Sectional Studies; Diabetes Mellitus, Type 2; Drug Resistance; Female; Humans; | 2017 |
Type 2 Diabetes, Obesity, and Aspirin Responsiveness.
Topics: Aspirin; Diabetes Mellitus, Type 2; Humans; Obesity; Platelet Aggregation Inhibitors; Thromboxane B2 | 2017 |
Prospective cohort study of type 2 diabetes and the risk of Parkinson's disease.
Topics: Adult; Aged; Aspirin; beta Carotene; Body Mass Index; Cardiovascular Diseases; Cohort Studies; Diabe | 2008 |
Stemming the obesity-diabetes epidemic: lifestyle changes and therapeutics.
Topics: Aspirin; Combined Modality Therapy; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Humans; Hy | 2008 |
Aspirin in type 2 diabetes: is there any evidence base?
Topics: Aspirin; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Evidence-Based Medicine; Female; Humans; | 2008 |
The presence of coronary artery disease increases platelet-dependent thrombosis in patients with type 2 diabetes mellitus.
Topics: Aged; Aspirin; Blood Platelets; Coronary Artery Disease; Diabetes Mellitus, Type 2; Female; Humans; | 2008 |
The presence of coronary artery disease increases platelet-dependent thrombosis in patients with type 2 diabetes mellitus.
Topics: Aged; Aspirin; Blood Platelets; Coronary Artery Disease; Diabetes Mellitus, Type 2; Female; Humans; | 2008 |
The presence of coronary artery disease increases platelet-dependent thrombosis in patients with type 2 diabetes mellitus.
Topics: Aged; Aspirin; Blood Platelets; Coronary Artery Disease; Diabetes Mellitus, Type 2; Female; Humans; | 2008 |
The presence of coronary artery disease increases platelet-dependent thrombosis in patients with type 2 diabetes mellitus.
Topics: Aged; Aspirin; Blood Platelets; Coronary Artery Disease; Diabetes Mellitus, Type 2; Female; Humans; | 2008 |
Aspirin for primary prevention of cardiovascular events in diabetes: still an open question.
Topics: Aspirin; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Humans; Platelet | 2008 |
Exercise status affects skin perfusion via prostaglandin, nitric oxide, and EDHF pathways in diabetes.
Topics: Aspirin; Biological Factors; Case-Control Studies; Diabetes Mellitus, Type 2; Enzyme Inhibitors; Exe | 2009 |
["Diabetes in Germany"(DIG) study. A prospective 4-year-follow-up study on the quality of treatment for type 2 diabetes in daily practice].
Topics: Adult; Aged; Aged, 80 and over; Antihypertensive Agents; Aspirin; Cardiovascular Diseases; Diabetes | 2009 |
[Acetylsalicylic acid does not prevent cardiovascular diseases in diabetic patients].
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cardiovascular Diseases; Diabetes Mellitus, Type 2 | 2009 |
Clopidogrel for preventing cardiovascular events.
Topics: Aspirin; Clopidogrel; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Evidence-Based Medicine; | 2009 |
COX-1 sensitivity and thromboxane A2 production in type 1 and type 2 diabetic patients under chronic aspirin treatment.
Topics: Adult; Aged; Aspirin; Blood Platelets; C-Reactive Protein; Case-Control Studies; Cyclooxygenase 1; D | 2009 |
Does aspirin use reduce cardiovascular risk in diabetes?
Topics: Aspirin; Atherosclerosis; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Humans; Platelet Aggre | 2009 |
A study of aspirin resistance in type 2 diabetes.
Topics: Aspirin; Cholesterol, LDL; Coronary Artery Disease; Diabetes Mellitus, Type 2; Diabetic Angiopathies | 2008 |
Should aspirin be used for the primary prevention of cardiovascular disease in people with diabetes?
Topics: Aged; Aspirin; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; | 2009 |
Aspirin: not currently for primary prevention in diabetes.
Topics: Aspirin; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Humans; Off-La | 2009 |
Diabetes: Aspirin and prevention of diabetes still a topic of debate.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Diabetes Mellitus, Type 2; Humans; Male | 2009 |
Axon-reflex cutaneous vasodilatation is impaired in type 2 diabetic patients receiving chronic low-dose aspirin.
Topics: Acetylcholine; Aspirin; Axons; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Electric | 2009 |
The effect of anti-inflammatory (aspirin and/or statin) therapy on body weight in Type 2 diabetic individuals: EAT, a retrospective study.
Topics: Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Diabetes Mellitus, | 2009 |
Diabetes mellitus is associated with increased ex vivo-platelet aggregation and decreased response to aspirin - antithrombotic potential of ACE-inhibitors and AT1-antagonists.
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Aspirin; Coronary Disease; Diabetes Mellitus, Type 2 | 2009 |
Effect of aspirin treatment in streptozotocin-induced type 2 diabetic rats.
Topics: Animals; Aspirin; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Female; I-kappa B Kina | 2009 |
Pharmacological management of type 2 diabetes in newly diagnosed older adults.
Topics: Aged; Aspirin; Blood Glucose; Blood Pressure; Diabetes Mellitus, Type 2; Humans; Lipids | 2009 |
[Use of aspirin for primary prevention of cardiovascular events in diabetic patients--is it justified?].
Topics: Aspirin; Cardiovascular Diseases; Coronary Artery Disease; Diabetes Complications; Diabetes Mellitus | 2009 |
The relation between platelet reactivity and glycemic control in diabetic patients with cardiovascular disease on maintenance aspirin and clopidogrel therapy.
Topics: Adult; Aged; Aspirin; Blood Glucose; Blood Platelets; Cardiovascular Diseases; Clopidogrel; Diabetes | 2009 |
Lack of benefits for prevention of cardiovascular disease with aspirin therapy in type 2 diabetic patients--a longitudinal observational study.
Topics: Adult; Aged; Aspirin; Cardiovascular Diseases; Cohort Studies; Diabetes Mellitus, Type 2; Female; Fo | 2009 |
Aspirin is associated with reduced cardiovascular and all-cause mortality in type 2 diabetes in a primary prevention setting: the Fremantle Diabetes study.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Australia; Body Mass Index; Cardiovascular D | 2010 |
Influence of pharmacist intervention on prescribing of angiotensin-converting-enzyme inhibitors, angiotensin II-receptor blockers, and aspirin for diabetic patients.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Con | 2010 |
Treatment of type 2 diabetes and outcomes in patients with heart failure: a nested case-control study from the U.K. General Practice Research Database.
Topics: Adrenergic beta-Antagonists; Aged; Aged, 80 and over; Angiotensin-Converting Enzyme Inhibitors; Aspi | 2010 |
Cost-effectiveness of aspirin use among persons with newly diagnosed type 2 diabetes.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Cost-Benefit Analysis; Diabetes Mellitus, Type 2; Female; H | 2010 |
Reduced platelet response to aspirin in patients with coronary artery disease and type 2 diabetes mellitus.
Topics: Aged; Aspirin; Coronary Artery Disease; Diabetes Mellitus, Type 2; Female; Humans; Male; Middle Aged | 2010 |
Aspirin as antiplatelet agent in diabetes: Cons.
Topics: Aspirin; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Hemorrhage; Humans; Platelet Aggregation | 2010 |
Impact of inflammatory state and metabolic control on responsiveness to dual antiplatelet therapy in type 2 diabetics after PCI: prognostic relevance of residual platelet aggregability in diabetics undergoing coronary interventions.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Biomarkers; Blood Glucose; C-Reactive Protein; Clopid | 2010 |
Multifactorial treatment increases endothelial progenitor cells in patients with type 2 diabetes.
Topics: Angiotensin Receptor Antagonists; Aspirin; Cell Count; Cells, Cultured; Diabetes Mellitus, Type 2; D | 2010 |
Type 2 diabetes and ASA.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cardiovascular Diseases; Diabetes Mellitus, Type 2 | 2010 |
On the unfulfilled public health potential of aspirin.
Topics: Aspirin; Cardiovascular Diseases; Diabetes Complications; Diabetes Mellitus, Type 2; Humans; Neoplas | 2010 |
Long-term effects of cilostazol on the prevention of macrovascular disease in patients with type 2 diabetes mellitus.
Topics: Aged; Aspirin; Cardiovascular Diseases; Cerebrovascular Disorders; Cilostazol; Diabetes Mellitus, Ty | 2011 |
Aspirin for the primary prevention of cardiovascular events in patients with peripheral artery disease or diabetes mellitus. Analyses from the JPAD, POPADAD and AAA trials.
Topics: Aged; Ankle Brachial Index; Aspirin; Cardiovascular Agents; Cardiovascular Diseases; Clinical Trials | 2010 |
Effect of platelet turnover on whole blood platelet aggregation in patients with coronary artery disease.
Topics: Adenosine Diphosphate; Aged; Arachidonic Acid; Aspirin; Biomarkers; Blood Platelets; Case-Control St | 2011 |
Human CD34+/KDR+ cells are generated from circulating CD34+ cells after immobilization on activated platelets.
Topics: Antigens, CD34; Aspirin; Blood Platelets; Case-Control Studies; Cell Communication; Cell Differentia | 2011 |
Automated processing of electronic medical records is a reliable method of determining aspirin use in populations at risk for cardiovascular events.
Topics: Aspirin; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Drug Utilization; Humans; Medical Recor | 2010 |
Sex-specific differences in metabolic control, cardiovascular risk, and interventions in patients with type 2 diabetes mellitus.
Topics: Aged; Angina Pectoris; Angioplasty, Balloon, Coronary; Antihypertensive Agents; Aspirin; Blood Gluco | 2010 |
Lack of correlation between platelet reactivity and glycaemic control in type 2 diabetes mellitus patients treated with aspirin and clopidogrel.
Topics: Aged; Aged, 80 and over; Angina Pectoris; Aspirin; Blood Glucose; Blood Platelets; Clopidogrel; Diab | 2011 |
[Antiplatelet agents and diabetes mellitus].
Topics: Aspirin; Cardiovascular Diseases; Clopidogrel; Diabetes Mellitus, Type 2; Humans; Platelet Aggregati | 2010 |
Genetic associations between fibrinogen and cognitive performance in three Scottish cohorts.
Topics: Aged; Aging; Aspirin; Atherosclerosis; Cognition; Cognition Disorders; Cohort Studies; Cross-Section | 2011 |
Further ex vivo evidence supporting higher aspirin dosing in patients with coronary artery disease and diabetes.
Topics: Aspirin; Coronary Artery Disease; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Dose-Response Re | 2011 |
Urinary 11-dehydro thromboxane B₂ levels in type 2 diabetic patients before and during aspirin intake.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Diabetes Mellitus, Type 2; Humans; Male; Middle Aged; Throm | 2011 |
Poor aspirin response in diabetic patients presenting with acute coronary syndromes: results using a near patient test.
Topics: Aspirin; Coronary Artery Disease; Diabetes Mellitus, Type 2; Female; Humans; Male; Platelet Activati | 2011 |
Detection of clopidogrel hyporesponsiveness using a point-of-care assay and the impact of additional cilostazol administration after coronary stent implantation in diabetic patients.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Chi-Square Distribution; Cilostazol; Clopidogrel; Cor | 2011 |
Impact of adjunctive cilostazol therapy versus high maintenance dose of clopidogrel in suboptimal responders with diabetes mellitus.
Topics: Aspirin; Blood Coagulation; Blood Platelets; Cilostazol; Clopidogrel; Diabetes Mellitus, Type 2; Hum | 2012 |
Oral administration of Bis(aspirinato)zinc(II) complex ameliorates hyperglycemia and metabolic syndrome-like disorders in spontaneously diabetic KK-A(y) mice: structure-activity relationship on zinc-salicylate complexes.
Topics: Adiponectin; Administration, Oral; Animals; Aspirin; Blood Pressure; Coordination Complexes; Diabete | 2011 |
Letter by Santos et al regarding article, "Pharmacodynamic effects of different aspirin dosing regimens in type 2 diabetes mellitus patients with coronary artery disease".
Topics: Aspirin; Coronary Artery Disease; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Humans; | 2011 |
Platelet reactivity in type 2 diabetes mellitus: a comparative analysis with survivors of myocardial infarction and the role of glycaemic control.
Topics: Adenosine Diphosphate; Adolescent; Adult; Aged; Aged, 80 and over; Arachidonic Acid; Aspirin; Blood | 2012 |
Cigarette smoking is associated with a dose-response effect in clopidogrel-treated patients with diabetes mellitus and coronary artery disease: results of a pharmacodynamic study.
Topics: Aged; Aspirin; Biomarkers; Blood Platelets; Cell Adhesion Molecules; Clopidogrel; Coronary Artery Di | 2012 |
Primary prevention with aspirin in type 2 diabetic patients. Searching for the right spot.
Topics: Aspirin; Blood Pressure; Cardiovascular Agents; Cerebrovascular Disorders; Diabetes Mellitus, Type 2 | 2012 |
Performance scores in general practice: a comparison between the clinical versus medication-based approach to identify target populations.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Diabetes Mellitus, Type 2; Diagnosis; Female; Gene | 2012 |
Aspirin twice a day keeps new COX-1 at bay.
Topics: Aspirin; Blood Platelets; Cyclooxygenase 1; Diabetes Mellitus, Type 2; Female; Humans; Male | 2012 |
Multiple cerebral infarctions related to famotidine-induced eosinophilia.
Topics: Acarbose; Adrenergic alpha-1 Receptor Antagonists; Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulc | 2012 |
The combined use of aspirin, a statin, and blood pressure-lowering agents (polypill components) in clinical practice in patients with vascular diseases or type 2 diabetes mellitus.
Topics: Adult; Aged; Antihypertensive Agents; Aspirin; Diabetes Mellitus, Type 2; Drug Combinations; Drug Th | 2013 |
Long-term successful percutaneous coronary intervention in factor VII deficiency.
Topics: Angina Pectoris; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Stenosis; Diabetes M | 2012 |
Effect of hypoglycemic drugs on aspirin resistance in patients with diabetes mellitus.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Angioplasty, Balloon, Coronary; Aspirin; Chi-S | 2012 |
Tighter aspirin control urged for patients with diabetes. Taking aspirin increases bleeding risk that is not always outweighed by the potential benefits for patients with low cardiovascular disease risk.
Topics: Aspirin; Diabetes Mellitus, Type 2; Diabetic Cardiomyopathies; Dose-Response Relationship, Drug; Gas | 2010 |
EV-077 in vitro inhibits platelet aggregation in type-2 diabetics on aspirin.
Topics: Aged; Aged, 80 and over; Anticoagulants; Arachidonic Acid; Aspirin; Coronary Artery Disease; Diabete | 2012 |
Secondary prevention therapies for coronary heart disease in patients with type 2 diabetes: an audit.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme I | 2012 |
Body mass index predicts failure of surgical management in benign prostatic hyperplasia.
Topics: Aged; Aspirin; Body Mass Index; Cardiovascular Diseases; Cohort Studies; Diabetes Mellitus, Type 2; | 2013 |
Circulating microRNAs as novel biomarkers for platelet activation.
Topics: Adult; Aspirin; Biomarkers; Blood Platelets; Blood Specimen Collection; Carotid Artery Diseases; Cas | 2013 |
Aspirin treatment hampers the use of plasma microRNA-126 as a biomarker for the progression of vascular disease.
Topics: Analysis of Variance; Arachidonic Acid; Aspirin; Biomarkers; Contraindications; Diabetes Mellitus, T | 2013 |
Platelets, endothelium, and circulating microRNA-126 as a prognostic biomarker in cardiovascular diseases: per aspirin ad astra.
Topics: Aspirin; Contraindications; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Humans; Male; | 2013 |
Comparison of secondary prevention of heart disease in Europe: lifestyle getting worse, therapy getting better in Ireland.
Topics: Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Aspirin; Diabetes Mellitus, T | 2002 |
Heart attack and stroke prevention guidelines emphasize lifestyle factors.
Topics: Adult; Age Factors; American Heart Association; Aspirin; Diabetes Mellitus, Type 2; Diet; Exercise; | 2002 |
Under-prescribing of cardiovascular therapies for diabetes in primary care.
Topics: Adrenergic beta-Antagonists; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibit | 2003 |
Management of hyperglycaemia in the patient with acute myocardial infarction.
Topics: Aspirin; Diabetes Mellitus, Type 2; Humans; Hyperglycemia; Hypoglycemic Agents; Insulin; Metformin; | 2003 |
[Stroke is not equal to stroke. Keep track of the causes].
Topics: Adult; Antihypertensive Agents; Aspirin; Carotid Artery, Common; Carotid Artery, External; Carotid S | 2003 |
C-reactive protein, antiinflammatory drugs, and quality of life in diabetes.
Topics: Analysis of Variance; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; C-Reactive Protein; Diabetes | 2003 |
Retinopathy in diabetes.
Topics: Aspirin; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Diabetic Retinopathy; Humans; Laser C | 2004 |
Dietary magnesium intake in relation to plasma insulin levels and risk of type 2 diabetes in women.
Topics: Aspirin; Diabetes Mellitus, Type 2; Diet; Double-Blind Method; Exercise; Female; Humans; Insulin; Ma | 2004 |
Aspirin therapy in type 2 diabetes in a general practice in Italy.
Topics: Adult; Aged; Aspirin; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Family Practice; Female; H | 2003 |
Does cardiovascular therapy affect the onset and recurrence of preretinal and vitreous haemorrhage in diabetic eye disease?
Topics: Adult; Aged; Angiotensin-Converting Enzyme Inhibitors; Aspirin; Cardiovascular Agents; Cardiovascula | 2004 |
Association of type 2 diabetes with cyclooxygenase-mediated inflammation and oxidative stress in an elderly population.
Topics: Aged; alpha-Tocopherol; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Biomarkers; Blood Glucose; | 2004 |
[Therapeutic use of acetylsalicylic acid in diabetics].
Topics: Aspirin; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Fibrinolytic Agents; Humans; Platelet Agg | 2003 |
Effect of Bacopa monniera and Azadirachta indica on gastric ulceration and healing in experimental NIDDM rats.
Topics: Acetic Acid; Animals; Anti-Ulcer Agents; Aspirin; Azadirachta; Bacopa; Cold Temperature; Diabetes Me | 2004 |
Underuse of aspirin in type 2 diabetes mellitus: prevalence and correlates of therapy in rural Canada.
Topics: Adult; Aged; Aged, 80 and over; Alberta; Aspirin; Cardiovascular Diseases; Cohort Studies; Diabetes | 2004 |
Aspirin resistance in diabetic patients.
Topics: Aspirin; Diabetes Mellitus; Diabetes Mellitus, Type 2; Drug Resistance; Humans; Platelet Aggregation | 2004 |
Is aspirin resistance a real problem in people with type 2 diabetes?
Topics: Aspirin; Blood Platelets; Diabetes Mellitus, Type 2; Drug Resistance; Humans; Platelet Aggregation I | 2004 |
Reduced sensitivity of platelets from type 2 diabetic patients to acetylsalicylic acid (aspirin)-its relation to metabolic control.
Topics: Adult; Aspirin; Blood Platelets; Cross-Over Studies; Diabetes Mellitus, Type 2; Drug Resistance; Fem | 2004 |
[Risk intervention in persons with diabetes mellitus in general practice].
Topics: Adult; Aged; Anticholesteremic Agents; Antihypertensive Agents; Aspirin; Cardiovascular Diseases; Di | 2004 |
Today's guidance.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Coronary Disease; Diabetes Mellitus, Type 2; Guide | 2004 |
A prospective study of red meat consumption and type 2 diabetes in middle-aged and elderly women: the women's health study.
Topics: Ascorbic Acid; Aspirin; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Energy Intake; Feeding B | 2004 |
[Acetylsalicylic acid in patients with diabetes for the primary prevention of cardiovascular disease].
Topics: Aspirin; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Humans; Platelet Aggregation Inhibitors | 2004 |
Underuse of aspirin therapy among patients with type 2 diabetes mellitus attending primary care in Greece.
Topics: Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Diabetes Mellitus, | 2004 |
Changing aspirin use in patients with Type 2 diabetes in the UKPDS.
Topics: Age Distribution; Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cardiovascular Diseases; D | 2004 |
Plasma leptin concentration in patients with Type 2 diabetes: relationship to cardiovascular disease risk factors and insulin resistance.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Body Mass Index; C-Reactive Protein; Cardiov | 2005 |
[Practical prevention and treatment of cardiovascular diseases in patients with diabetes mellitus type 2 in an endocrinological department].
Topics: Angiotensin-Converting Enzyme Inhibitors; Aspirin; Cardiovascular Diseases; Diabetes Mellitus, Type | 2004 |
[Characteristic features of the pathogenesis and treatment of coronary heart diseases, heart failure and arterial hypertension in patients with diabetes mellitus].
Topics: Adrenergic beta-Antagonists; Adult; Aspirin; Blood Glucose; Calcium Channel Blockers; Clinical Trial | 2005 |
[Revascularization of multiple coronary vascular disease in diabetes mellitus--a case report].
Topics: Angioplasty, Balloon, Coronary; Aspirin; Coronary Disease; Diabetes Mellitus, Type 2; Humans; Male; | 2005 |
Use of antiplatelet therapy in a diabetic outpatient service of a large urban public hospital.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Female; | 2005 |
Prevalence of aspirin resistance in patients with type 2 diabetes.
Topics: Aspirin; Blood Platelets; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; | 2005 |
Basal production of nitric oxide (NO) and non-NO vasodilators in the forearm microcirculation in Type 2 diabetes: associations with blood pressure and HDL cholesterol.
Topics: Acetylcholine; Aspirin; Blood Pressure; Case-Control Studies; Cholesterol, HDL; Diabetes Mellitus, T | 2006 |
Platelet function profiles in patients with type 2 diabetes and coronary artery disease on combined aspirin and clopidogrel treatment.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Blood Platelets; Clopidogrel; Coronary Disea | 2005 |
Platelet function profiles in patients with type 2 diabetes and coronary artery disease on combined aspirin and clopidogrel treatment.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Blood Platelets; Clopidogrel; Coronary Disea | 2005 |
Platelet function profiles in patients with type 2 diabetes and coronary artery disease on combined aspirin and clopidogrel treatment.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Blood Platelets; Clopidogrel; Coronary Disea | 2005 |
Platelet function profiles in patients with type 2 diabetes and coronary artery disease on combined aspirin and clopidogrel treatment.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Blood Platelets; Clopidogrel; Coronary Disea | 2005 |
Platelet function profiles in patients with type 2 diabetes and coronary artery disease on combined aspirin and clopidogrel treatment.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Blood Platelets; Clopidogrel; Coronary Disea | 2005 |
Platelet function profiles in patients with type 2 diabetes and coronary artery disease on combined aspirin and clopidogrel treatment.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Blood Platelets; Clopidogrel; Coronary Disea | 2005 |
Platelet function profiles in patients with type 2 diabetes and coronary artery disease on combined aspirin and clopidogrel treatment.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Blood Platelets; Clopidogrel; Coronary Disea | 2005 |
Platelet function profiles in patients with type 2 diabetes and coronary artery disease on combined aspirin and clopidogrel treatment.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Blood Platelets; Clopidogrel; Coronary Disea | 2005 |
Platelet function profiles in patients with type 2 diabetes and coronary artery disease on combined aspirin and clopidogrel treatment.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Blood Platelets; Clopidogrel; Coronary Disea | 2005 |
A case of type 2 diabetes mellitus developing hypothyroidism discovered as a result of a discrepancy between glycated hemoglobin and glycated albumin values.
Topics: Aged; Antihypertensive Agents; Aspirin; Blood Cell Count; Diabetes Mellitus, Type 2; Diet; Female; G | 2006 |
Effect of increasing doses of aspirin on platelet function as measured by PFA-100 in patients with diabetes.
Topics: Adult; Aspirin; Blood Coagulation Tests; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug | 2005 |
[Assessment of the budgetary impact of treatment guidelines in type II diabetes mellitus in France].
Topics: Adolescent; Adult; Aged; Aspirin; Biguanides; Cerebrovascular Disorders; Coronary Disease; Cost-Bene | 2005 |
Treatment disparities in the care of patients with and without diabetes presenting with non-ST-segment elevation acute coronary syndromes.
Topics: Acute Disease; Adrenergic beta-Antagonists; Adult; Aspirin; Cardiac Catheterization; Clopidogrel; Co | 2006 |
Increased blood plasma hydrolysis of acetylsalicylic acid in type 2 diabetic patients: a role of plasma esterases.
Topics: Adult; Aspirin; Blood Platelets; Butyrylcholinesterase; Carboxylic Ester Hydrolases; Cholesterol; Di | 2006 |
Comparison of aspirin resistance in type 1 versus type 2 diabetes mellitus.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Cholesterol, HDL; Diabetes Mellitu | 2006 |
Safety of coronary sirolimus-eluting stents in daily clinical practice: one-year follow-up of the e-Cypher registry.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Cause of Death; Clopidogrel; Comorbidity; Coronary Di | 2006 |
Safety of coronary sirolimus-eluting stents in daily clinical practice: one-year follow-up of the e-Cypher registry.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Cause of Death; Clopidogrel; Comorbidity; Coronary Di | 2006 |
Safety of coronary sirolimus-eluting stents in daily clinical practice: one-year follow-up of the e-Cypher registry.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Cause of Death; Clopidogrel; Comorbidity; Coronary Di | 2006 |
Safety of coronary sirolimus-eluting stents in daily clinical practice: one-year follow-up of the e-Cypher registry.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Cause of Death; Clopidogrel; Comorbidity; Coronary Di | 2006 |
The rate of checking urine microalbumin and aspirin primary prevention in type 2 DM.
Topics: Albuminuria; Aspirin; Atherosclerosis; Diabetes Mellitus, Type 2; Dyslipidemias; Female; Humans; Hyp | 2006 |
Plasma lycopene, other carotenoids, and the risk of type 2 diabetes in women.
Topics: Aged; Aspirin; beta Carotene; Carotenoids; Case-Control Studies; Cryptoxanthins; Diabetes Mellitus, | 2006 |
Insulin therapy is associated with platelet dysfunction in patients with type 2 diabetes mellitus on dual oral antiplatelet treatment.
Topics: Aged; Aspirin; Clopidogrel; Coronary Disease; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Drug | 2006 |
Aspirin and clopidogrel resistance in patients with diabetes mellitus.
Topics: Aspirin; Clopidogrel; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Diabetic Angiopathies; D | 2006 |
[Finding the right platelet anti-aggregant prescription for type-2 diabetes patients, according to the ADA 2003 criteria].
Topics: Adult; Aged; Aspirin; Body Mass Index; Cardiovascular Diseases; Confidence Intervals; Diabetes Melli | 2006 |
Platelet non-responsiveness to dual antiplatelet therapy and relation to coronary disease among diabetes patients.
Topics: Adult; Aspirin; Blood Platelets; Case-Control Studies; Clopidogrel; Coronary Disease; Diabetes Melli | 2007 |
Elevated platelet microparticle levels in nonvalvular atrial fibrillation: relationship to p-selectin and antithrombotic therapy.
Topics: Aged; Aspirin; Atrial Fibrillation; Blood Coagulation Factors; Blood Platelets; Cardiovascular Disea | 2007 |
[Primary prevention with aspirin for cardiovascular diseases in diabetic patients. What evidence supports the criteria of the ADA?].
Topics: Adult; Age Factors; Aspirin; Cardiovascular Diseases; Clinical Trials as Topic; Confidence Intervals | 2007 |
High levels of low-density lipoprotein cholesterol and triglycerides and suboptimal glycemic control predict diminished ex vivo aspirin responsiveness in patients with Type 2 diabetes.
Topics: Aged; Aspirin; Blood Glucose; Cholesterol, LDL; Diabetes Mellitus, Type 2; Drug Resistance; Female; | 2007 |
TNF-alpha -308G>A polymorphism modulates cytokine serum concentrations and macrovascular complications in diabetic patients on aspirin.
Topics: Aged; Aspirin; Cerebrovascular Disorders; Coronary Disease; Cytokines; Diabetes Mellitus, Type 2; Di | 2007 |
Management outcomes of patients with type 2 diabetes: targeting the 10-year absolute risk of coronary heart disease.
Topics: Angiotensin-Converting Enzyme Inhibitors; Aspirin; Blood Pressure; Cholesterol; Cohort Studies; Coro | 2007 |
Adherence to clinical guidelines in the prevention of coronary heart disease in type II diabetes mellitus.
Topics: Adult; Aged; Aspirin; Clinical Protocols; Coronary Disease; Diabetes Mellitus, Type 2; Female; Guide | 2008 |
Impact of platelet reactivity on cardiovascular outcomes in patients with type 2 diabetes mellitus and coronary artery disease.
Topics: Aged; Angina, Unstable; Aspirin; Blood Platelets; Clopidogrel; Coronary Artery Disease; Death, Sudde | 2007 |
Impact of platelet reactivity on cardiovascular outcomes in patients with type 2 diabetes mellitus and coronary artery disease.
Topics: Aged; Angina, Unstable; Aspirin; Blood Platelets; Clopidogrel; Coronary Artery Disease; Death, Sudde | 2007 |
Impact of platelet reactivity on cardiovascular outcomes in patients with type 2 diabetes mellitus and coronary artery disease.
Topics: Aged; Angina, Unstable; Aspirin; Blood Platelets; Clopidogrel; Coronary Artery Disease; Death, Sudde | 2007 |
Impact of platelet reactivity on cardiovascular outcomes in patients with type 2 diabetes mellitus and coronary artery disease.
Topics: Aged; Angina, Unstable; Aspirin; Blood Platelets; Clopidogrel; Coronary Artery Disease; Death, Sudde | 2007 |
Sweet and sticky: diabetic platelets, enhanced reactivity, and cardiovascular risk.
Topics: Angina, Unstable; Aspirin; Blood Platelets; Clopidogrel; Coronary Artery Disease; Death, Sudden, Car | 2007 |
Clinical decisions. Management of stable coronary disease.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Coronary Artery Bypass; Coronary Disease; Diabetes Me | 2007 |
The assessment and management of albuminuria in primary care.
Topics: Aged; Albuminuria; Aspirin; Blood Glucose; Cardiovascular Diseases; Chronic Disease; Diabetes Mellit | 2008 |
Chronic kidney disease--a disease domain complex.
Topics: Aged; Alendronate; Amlodipine; Anti-Inflammatory Agents, Non-Steroidal; Antihypertensive Agents; Asp | 2008 |
Effects of diabetes mellitus on platelet reactivity after dual antiplatelet therapy with aspirin and clopidogrel.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Cohort Studies; Coronary Artery Disease; | 2008 |
Control of cardiovascular risk factors and use of aspirin in diabetic patients remain elusive.
Topics: Academic Medical Centers; Adult; Aged; Aged, 80 and over; Albuminuria; Aspirin; Blood Pressure; Chol | 2008 |
Plasma 8-epi-PGF2 alpha levels are elevated in individuals with non-insulin dependent diabetes mellitus.
Topics: Adult; Aspirin; Chromatography, Gas; Diabetes Mellitus, Type 2; Dinoprost; Esterification; Humans; I | 1995 |
From the Food and Drug Administration.
Topics: Aspirin; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Drug Labeling; Drugs, Investigational; | 1993 |
Effects of acetyl salicylic acid and cilostazol administration on serum thrombomodulin concentration in diabetic patients.
Topics: Aged; Aspirin; Cilostazol; Diabetes Mellitus, Type 2; Endothelium, Vascular; Female; Humans; Male; M | 1993 |
Progression of distal symmetric polyneuropathy during diabetes mellitus: clinical, neurophysiological, haemorheological changes and self-rating scales of patients.
Topics: Adolescent; Adult; Aged; Aspirin; Blood Glucose; Blood Viscosity; Diabetes Mellitus, Type 1; Diabete | 1997 |
Aspirin therapy in diabetes mellitus.
Topics: Aspirin; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Gastrointestin | 1997 |
Diabetes and coronary heart disease.
Topics: Aspirin; Coronary Disease; Diabetes Mellitus, Type 2; Humans; Platelet Aggregation Inhibitors | 1998 |
Effects of aspirin treatment on survival in non-insulin-dependent diabetic patients with coronary artery disease. Israeli Bezafibrate Infarction Prevention Study Group.
Topics: Aged; Aspirin; Cerebrovascular Disorders; Confounding Factors, Epidemiologic; Coronary Disease; Diab | 1998 |
The 14-year incidence of lower-extremity amputations in a diabetic population. The Wisconsin Epidemiologic Study of Diabetic Retinopathy.
Topics: Adolescent; Adult; Age Factors; Age of Onset; Aged; Amputation, Surgical; Aspirin; Blood Pressure; D | 1999 |
Aspirin usage in a large teaching hospital diabetes clinic setting.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Australia; Diabetes Mellitus, Type 1; Diabetes Mellitus, Ty | 1999 |
Aspirin in the treatment of type 2 diabetes.
Topics: Adult; Aspirin; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Humans; Lipids; Platelet Aggrega | 2000 |
Diabetes mellitus with left transverse sinus thrombosis and right transverse sinus aplasia.
Topics: Aged; Aspirin; Cerebral Angiography; Cranial Sinuses; Diabetes Mellitus, Type 2; Diabetic Angiopathi | 2001 |
Individual dosing of ASA prophylaxis by controlling platelet aggregation.
Topics: Aged; Aged, 80 and over; Arachidonic Acid; Aspirin; Diabetes Mellitus, Type 2; Dose-Response Relatio | 2001 |
Mechanism by which high-dose aspirin improves glucose metabolism in type 2 diabetes.
Topics: Adult; Aspirin; Blood Glucose; Cyclooxygenase Inhibitors; Diabetes Mellitus, Type 2; Female; Glucose | 2002 |
Thromboxane biosynthesis and platelet function in type II diabetes mellitus.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Blood Platelets; Diabetes Mellitus, Type 2; Female; Humans; | 1990 |
Abnormality in prostacyclin-stimulatory activity in sera from diabetics.
Topics: 6-Ketoprostaglandin F1 alpha; Adult; Animals; Arachidonic Acid; Arachidonic Acids; Aspirin; Cells, C | 1989 |
Clinical evaluation of acetylsalicylic acid to improve glycemia in type II diabetic patients.
Topics: Adult; Aged; Aspirin; Blood Glucose; Body Weight; Diabetes Mellitus, Type 2; Female; Humans; Insulin | 1989 |
Insulin receptors and glucose homeostasis in type 2 diabetics influenced by acetyl-salicylic acid treatment.
Topics: Aged; Aspirin; Diabetes Mellitus, Type 2; Glucose; Homeostasis; Humans; Male; Middle Aged; Receptor, | 1988 |
Acetyl-salicylic acid impairs insulin-mediated glucose utilization and reduces insulin clearance in healthy and non-insulin-dependent diabetic man.
Topics: Aspirin; Blood Glucose; Diabetes Mellitus, Type 2; Homeostasis; Humans; Insulin; Reference Values | 1987 |
Acetylsalicylic acid and glucose metabolism in man: is there a role for prostaglandins?
Topics: Aspirin; Diabetes Mellitus, Type 2; Glucose; Humans; Prostaglandins E | 1986 |
Acetyl-salicylic acid impairs insulin-mediated glucose utilization and reduces insulin clearance in healthy and non-insulin-dependent diabetic man.
Topics: Adult; Aspirin; Blood Glucose; C-Peptide; Diabetes Mellitus, Type 2; Female; Humans; Hyperglycemia; | 1985 |
Effect of aspirin on glucose tolerance and insulin levels in patients with type 2 diabetes mellitus.
Topics: Aspirin; Blood Glucose; Diabetes Mellitus, Type 2; Humans; Insulin | 1985 |
Effects of salicylate, tolbutamide, and prostaglandin E2 on insulin responses to glucose in noninsulin-dependent diabetes mellitus.
Topics: Adult; Aspirin; Blood Glucose; Diabetes Mellitus, Type 2; Dinoprostone; Drug Interactions; Glucose; | 1985 |
Impaired insulin secretion in human diabetes mellitus. Interactions between naloxone, phentolamine and lysine acetylsalicylate upon glucose induced insulin release.
Topics: Adult; Analgesics; Aspirin; Blood Glucose; Diabetes Mellitus, Type 2; Drug Interactions; Glucose; Hu | 1985 |